Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors

Abstract

The present invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, the present invention provides a pharmaceutical composition comprising the said compound.

Description

TECHNICAL FIELD

This invention relates to certain novel heterocyclic derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

BACKGROUND ART

SHP2 (The Src Homolgy-2 phosphatease) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene that harbors a classical tyrosine phosphatase domain and two N-terminal Src homology 2 (SH2) domains and a C-terminal tail. The two SH₂ domains control the subcellular localization and functional regulation of SHP2. In its inactive state, the N-terminal SH₂ domain blocks the PTP domain and this autoinhibition is relieved by binding of the SH₂ domains to specific phosphotyrosine sites on receptors or receptor-associated adaptor proteins. The stimulation, for example, by cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.

SHP2 is widely expressed and participated in multiple cell signaling processes, such as the Ras-Erk, PI3K-Akt, Jak-Stat, Met, FGFR, EGFR, and insulin receptors and NF-kB pathways, in which plays an important role in proliferation, differentiation, cell cycle maintenance and migration.

The hyperactivation of SHP2 catalytic activity caused by either germline or somatic mutations in PTPN11 have been identified in patients with Noonan syndrome, Leopard syndrome, juvenile myelomonocytic leukemias, myelodysplastic syndrome, B cell acute lymphoblastic leukemia/lymphoma, and acute myeloid leukemia. In addition, activating mutation s of PTPN11 have been found in solid tumors as well, such as lung cancer, colon cancer, melanoma, neuroblastoma, and hepatocellular carcinoma. Therefore, the presence of activated or up-regulated SHP2 protein in human cancers and other disease make SHP2 an excellent target for development of novel therapies. The compounds of the present invention fulfill the need of small molecules in order to inhibit the activity of SHP2.

SUMMARY OF INVENTION

The present invention relates to certain novel heterocyclic compounds useful as SHP2 inhibitors and their use for treating a SHP2 mediated disorder. The compounds of the invention have the general structure as Formula I or a pharmaceutically acceptable salt:

ring A is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—;

each of R_G is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted or unsubstituted;

ring B is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring, a 3-10 membered carbocyclic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

T is absent, O, NR₁ or CR₁R₂;

each of R₁ and R₂ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl; or

R₁ and R₂ together with the carbon atom to which they are both attached form CO or C═NR₅;

p is 0, 1, 2, 3 or 4;

each of R₃ and R₄ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl; or

R₃ and R₄ together with the carbon atom to which they are both attached form a 3-12 membered heterocyclic ring or a 5-12 membered heteroaromatic ring or C═NR₅, and each of the ring systems is independently optionally substituted or unsubstituted;

each of R₅ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy;

q is 0, 1, 2, 3 or 4;

W is absent, O, S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-6alkyl, —CO—OC_1-6alkyl, —C_1-6alkylene-O—C_1-6alkoxy, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

when ring C is absent, Y₅ is CR_5aR_5b, NR_5a or O, and Y₆ is CR_6aR_6b, NR_6a or O;

when ring C is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring;

• • i) Y₅ is CR_5a or N, and Y₆ is CR_6a or N, when the “” in the term “Y₅Y₆” represents a single bond; or
  • ii) Y₅ is C, and Y₆ is C, when the “” in the term “Y₅Y₆” represents a double bond;

each of R_5a and R_5b is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

each of R_6a and R_6b is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

each of R_a is independently selected from hydrogen, deuterium, halogen, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, —C_1-6alkoxy, —C_1-6alkyl, —C_3-8cycloalkyl,-C_1-6alkylene—NR_a1R_a2, —C_1-6alkylene-O—C_1-6alkyl, —C_1-6alkylene—CO—OR_a1, —C_1-6alkylene-(3-10 membered heterocyclic), —C_1-6alkylene-(5-10 membered heteroaryl), —C_1-6alkylene—CO—NR_a1R_a2, —C_1-6alkylene—NR_a1—CO—NR_a1R_a2, —C_1-6alkylene—NR_a1—CO—C_1-6alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, _locarbocyclic, −5-10 membered heteroaryl, −3-10 membered heterocyclic, —CO—C_1-6alkyl, —COO—C_1-6alkyl, —CO—C_1-6alkylene—NR_a1R_a2, —CO—NR_al-(3-10 membered heterocyclic), —CO—NR_a1-(3-10 membered heterocyclic), —CO—(3-10 membered heterocyclic), —O—C_1-6alkylene—CO—OR_a1, —O—C_1-6alkylene-C —NR_a1R_a2, —O—C_1-6alkylene—NR_a1R_a2, —O—C_3-10carbocyclic, —O—(3-10 membered heterocyclic), —NR_a1—CO—C_1-6alkyl, —NR_a1—CO—NR_a1R_a2, —NR_al—CO—(5-10 membered heteroaryl), —NR_a1—CO—C_3-8cycloalkyl,—NR_a1—C_1-6alkylene—NR_a1R_a2, —NR_al —C_1-6alkylene-(3-10 membered heterocyclic), —NR_al —C_1-6alkylene-(5-10 membered heteroaryl), —NR_ar S 0₂C_1-6alkyl, —S—C_1-6alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-6alkyl, —SO₂—C_1-6alkyl, —PO(C_1-6alkyl)₂, —PO(C_1-6alkoxy)₂, −3-10 membered heterocyclic or −5-10 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6; or

two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted; or

R_a and R_w with the atom to which they are both attached form a 3-10 membered aromatic ring, 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted;

each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, ring A is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring A is a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring A is a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring A is

represents a single bond or a double bond;

X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1;

each of R_X1 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl,

X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO;

each of R_X2 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —SF_S, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO—(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X1and R_X2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3;

each of R_X3 is independently selected from hydrogen, deuterium, halogen, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl, —O—C_1-6alkylene—C_1-6alkoxy, —O—C_5-8aryl or —O—C_1-6alkylene—C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X2 and R_X3together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted ;

X₄ is N, S, NR_X4, C(R_x4)₂ or CR_X4;

each of R_X4 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl, —C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or a 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X3 and R_X4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5;

each of R_X5 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X4 and R_X5 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₆ is O, S, CO or NR_X6, or C(R_X6)₂;

each of R_X6 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy, or

R_X5 and R_X6together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_Xlis independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —SF₅, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —SF₅, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₂ is N, S, NR_X2, C(R_X2)₂,CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-4alkyl, —C_1-3alkoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHC 0-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl or 3-6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₂ is N, S, NR_X2, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF_S, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_X1and R_X2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X1and R_X2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X1and R_X2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl, —O—C_1-6alkylene—C_1-6alkoxy, —O—C_5-8aryl or —O—C_1-6alkylene—C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl,—O—C_1-6alkylene-C_1-6alkyl, —O—C_5-8aryl or —O—C_1-6alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-3alkyl, —C_1-3alkoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl, —O—C_1-3alkylene—C_h3alkyl, —O—C_5-6aryl or —O—C_1-3alkylene-C_5-6aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl, —O—C_1-3alkylene—C_1-3alkyl, —O—C_5-6aryl or —O—C_1-3alkylene-C_5-6aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl, —O—C_1-3alkylene—C_1-3alkyl, —O—C_5-6aryl or —O—C_1-3alkylene—C_5-6aryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_X2 and R_X3 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X2 and R_X3 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X2 and R_X3 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, an 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl, —C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl, —C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl, —C_1-3alkoxy, —NHCO-(5-10 membered heterocyclyl) or 5-10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_X3 and R_X4 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X3 and R_X4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X3 and R_X4 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_X4 and R_X5together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X4 and R_X5together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X4 and R_X5together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, X₆ is O, S, CO or NR_X6, or C(R_X6)₂; each of R_X6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, X₆ is O, S, CO or NR_X6, or C(R_X6)₂; each of R_X6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₆ is O, S, CO or NR_X6, or C(R_X6)₂; each of R_X6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, X₆ is O, S, CO or NR_X6, or C(R_X6)₂; each of R_X6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, X₆ is O, S, CO or NR_X6, or C(R_X6)₂; each of R_X6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_X5 and R_X6 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X5 and R_X6 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered. heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_X5 and R_X6 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring A is selected from

In some embodiments of Formula I, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring B is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring, a 3-10 membered carbocyclic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2,3, 4, 5 or 6 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2, 3, 4, 5 or 6heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, wherein ring B is a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring, a 3-10 membered carbocyclic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2,3, 4, 5 or 6 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring B is a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, a 7 membered carbocyclic ring, a 8 membered carbocyclic ring, a 9 membered carbocyclic ring, a 10 membered carbocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, a 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2, 3 or 4 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2, 3 or 4 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring B is

Y₁ is N or CR_Y1,

R_Y1 is selected from hydrogen, deuterium, halogen, —NH₂, —OH, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_s-loaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl;

Y₂ is N or CR_Y2;

R_Y2 is selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_Y1and R_Y2together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

when the “” in the term “^Y3 Y₄” represents a single bond, Y₃ is NR_Y3 or C(R_Y3)₂, and Y₄ is

CO, C(R_Y4)₂ or NR_Y4;

when the “” in the term “^Y3 Y₄” represents a double bond, Y₃ is N or CR_Y3, and Y₄ is N or

CR_Y4;

R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, halogen, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH , —C_1-6alkylene—OH, —CO—C_3-8heterocyclic ring, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl, —C_1-6alkyl substituted with —OH, or —C_1-6alkoxy; or

R_Y3 and R_Y4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH₂, —OH, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH₂, —OH, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH₂, —OH, —CN, —C_1-3alkyl, —C_1-3alkoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH₂, —OH, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl, —C_1-3alkoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_Y1and R_Y2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, wherein R_Y1and R_Y2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_Y1and R_Y2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH, —CO—C_3-8heterocyclic ring, —C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl, —C_1-6alkyl substituted with —OH, or —C_1-6alkoxy.

In some embodiments of Formula I, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH, —C_1-6alkylene—OH, —CO—C_3-8heterocyclic ring, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-3alkyl, carboxyl, —COO—C_1-3alkyl, —NH—C_1-3alkylene—OH, —C_1-3alkylene—OH, —CO—C_3-8heterocyclic ring, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl, —C_1-3alkyl substituted with —OH or —C_1-3alkoxy.

In some embodiments of Formula I, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, methyl, ethyl, propyl, isopropyl, carboxyl, —COO—C_1-3alkyl, —NH—C_1-3alkylene—OH, —C_1-3alkylene—OH, —CO—C_3-8heterocyclic ring, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, ethyl substituted with —OH, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R_Y3 and R_Y4 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_Y3 and R_Y4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R_Y3 and R_Y4together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring B is selected from

In some embodiments of Formula I, each of R₁ and R₂ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, each of R₁ and R₂ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-3alkyl, —N(C_1-3alkyl)₂, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula I, each of R₁ and R₂ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, each of R₁ and R₂ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R₁ and R₂ together with the carbon atom to which they are both attached form CO or C═NR₅.

In some embodiments of Formula I, R₁ and R₂ together with the carbon atom to which they are both attached form CO.

In some embodiments of Formula I, R₁ and R₂ together with the carbon atom to which they are both attached form C═NR₅.

In some embodiments of Formula I, each of R₃ and R₄ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, each of R₃ and R₄ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-3alkyl, —N(C_1-3alkyl)₂, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula I, each of R₃ and R₄ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, each of R₃ and R₄ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, R₃ and R₄ together with the carbon atom to which they are both attached form 3-12 membered heterocyclic ring or 5-12 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R₃ and R₄ together with the carbon atom to which they are both attached form 3-10 membered heterocyclic ring or 5-10 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, R₃ and R₄ together with the carbon atom to which they are both attached form 3 membered heterocyclic ring, 4 membered heterocyclic ring, 5 membered heterocyclic ring, 6 membered heterocyclic ring, 7 membered heterocyclic ring, 8 membered heterocyclic ring, 9 membered heterocyclic ring, 10 membered heterocyclic ring, 5 membered heteroaromatic ring, 6 membered heteroaromatic ring, 7 membered heteroaromatic ring, 8 membered heteroaromatic ring, 9 membered heteroaromatic ring, 10 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, each of R₅ is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, each of R₅ is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, each of R₅ is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-6alkyl, —CO—OC_1-6alkyl, —C_1-6alkylene-O—C_1-6alkoxy, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-3alkyl, —CO—OC_1-3alkyl, —C_1-3alkylene-O—C_1-3alkoxy, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula I, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN;—OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkylene-O—C_1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkylene-O—C_1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN;—OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkylene-O—C_1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring C is absent, a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring C is absent, a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula I, ring C is selected from

In some embodiments of Formula I, each of R_5a and R_5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, each of R_5a and R_5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula I, each of R_5a and R_5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, each of R_5a and R_5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, each of R_6a and R_6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, each of R_6a and R_6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula I, each of R_6a and R_6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, each of R_6a and R_6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula I, each of R_a is independently hydrogen, deuterium, F, Cl, Br, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, —C_1-3alkoxy, —C_1-4alkyl, —C_3-6cycloalkyl,-C_1-3alkylene—NRA_a2, —C_1-3alkylene-O—C_1-6alkyl, —C_1-3alkylene —CO—OR_a′, —C_1-3alkylene -(3-8 membered heterocyclic), —C_1-3alkylene -(5-8 membered heteroaryl), —C_1-3alkylene—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—C —NR_a1R_a2, —C_1-3alkylene —NR_a1—C —C_1-3alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C_3-8carbocyclic, −5-8 membered heteroaryl, −3-8 membered heterocyclic, —CO—C_1-3alkyl, —COO—C_1-3alkyl, —CO—C_1-3alkylene—NR_a1R_a2, —CO—NR_a1-(3-8 membered heterocyclic), —CO—NR_a1-(3-8 membered heterocyclic), —CO—(3-8 membered heterocyclic), —O—C_1-3alkylene—CO—OR_a1, —O—C_1-3alkylene-C —NR_a1R_a2, —O—C_1-3alkylene —NR_al R_a2, —O—C_3-8carbocyclic, —O-(3-8 membered heterocyclic), —NR_a1—CO—C_1-3alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-8 membered heteroaryl), —NR_al—CO—C_3-6cycloalkyl, —NR_a1—C_1-3alkylene —NR_a1R_a2, —NR_al—C_1-3alkylene -(3-8 membered heterocyclic), —NR_al—C_1-3alkylene -(5-8 membered heteroaryl), —NR_al—SO₂C_1-3alkyl, -S —C_1-3alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-3alkyl, —SO₂—C_1-3alkyl, —PO(C_1-3alkyl)₂, —PO(C_1-3alkoxy)₂, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

In some embodiments of Formula I, each of R_a is independently hydrogen, deuterium, F, Cl, Br, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, methoxy, ethoxy, propoxy, isopropoxy methyl, ethyl, propyl, isopropyl, butyl, isobutyl, —C_3-6cycloalkyl,-C_1-3alkylene—NR_a1R_a2, —C_1-3alkylene-O—C_1-6alkyl, —C_1-3alkylene—CO—OR_a1, —C_1-3alkylene-(3-8 membered heterocyclic), —C_1-3alkylene-(5-8 membered heteroaryl), —C_1-3alkylene—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—C_1-3alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C_3-8carbocyclic, −5-8 membered heteroaryl, −3-8 membered heterocyclic, —CO—C_1-3alkyl, —COO—C_1-3alkyl, —CO—C_1-3alkylene—NR_a1R_a2, —CO—NR_ar(3-8 membered heterocyclic), —CO—NR_a1-(3-8 membered heterocyclic), —O—C-(3-8 membered heterocyclic), —O—C_1-3alkylene—CO—OR_a1, —O—C_1-3alkylene—CO—NR_a1R_a2, —O—C_1-3alkylene—NR_a1R_a2, —O—C_3-8carbocyclic, —O-(3-8 membered heterocyclic), —NR_a1—CO—C_1-3alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-8 membered heteroaryl), —NR_a1—CO—C_3-6cycloalkyl,—NR_a1—C_1-3alkylene—NR_a1R_a2, —NR_al —C_1-3alkylene-(3-8 membered heterocyclic), —NR_al—C_1-3alkylene-(5-8 membered heteroaryl), —NR_a1—SO₂C_1-3alkyl, —S—C_1-3alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-3alkyl, —SO₂—C_1-3alkyl, —PO(C_1-3alkyl)₂, —PO(C_1-3alkoxy)₂, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

In some embodiments of Formula I, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 3 membered carbocyclic ring, a 4 membered carbocyclic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, wherein each of the heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, R_a and R_w with the atom to which they are both attached form a 3-10 membered aromatic ring, 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula I, R_a and R_w with the atom to which they are both attached form a 3-10 membered aromatic ring, 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, R_a and R_w with the atom to which they are both attached form a 3-10 membered aromatic ring, 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, R_a and R_w with the atom to which they are both attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 5 membered heteroaryl ring, a 6 membered heteroaryl ring, a 5 membered heterocyclic ring or a 6 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula I, each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula I, each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula I, each of R_a1 and R_w is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula I, each of R_a1 and R_a2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

The present invention further provides the compound of Formula II or a pharmaceutically acceptable salt thereof:

X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1;

each of R_X1 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl,

X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO;

each of R_X2 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —SF_S, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X1and R_X2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₃ is N, S, NR_X3, C(R_X3)₂ or CR_X3;

each of R_X3 is independently selected from hydrogen, deuterium, halogen, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl, —O—C_1-6alkylene—C_1-6alkoxy, —O—C_5-8aryl or —O—C_1-6alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X2 and R_X3together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₄ is N, S, NR_X4, C(R)_X4, C(R_X4)₂ or CR_X4;

each of R_X4 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl,-C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X3 and R_X4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5;

each of R_X5 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X4 and R_X5together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

represents a single bond or a double bond;

G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—;

each of R_G is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted or unsubstituted;

Y₁ is N or CR_Y1,

R_Y1 is selected from hydrogen, deuterium, halogen, —NH₂, —OH, —CN, —C_1-6alkyl, —C_1-6alkoxyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_s-loaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl;

Y₂ is N or CR_Y2;

R_Y2 is selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_1-6aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_Y1and R_Y2together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

when the “” in the term “Y₃Y₄” represents a single bond, Y₃ is NR_Y3 or C(R_Y3)₂, and Y₄ is CO, C(R_Y4)₂ or NR_Y4;

when the “” in the term “Y₃Y₄” represents a double bond, Y₃ is N or CR_Y3, and Y₄ is N or CR_Y4;

R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, halogen, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH ,—C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_Y3 and R_Y4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

T is absent, O, NR₁ or CR₁R₂;

each of R₁ and R₂ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl; or

R₁ and R₂ together with the carbon atom to which they are both attached form CO or C═NR₅;

p is 0, 1, 2 or 3;

each of R₃ and R₄ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl; or

R₃ and R₄ together with the carbon atom to which they are both attached form a 3-12 membered heterocyclic ring or a 5-12 membered heteroaromatic ring or C═NR₅, and each of the ring systems is independently optionally substituted or unsubstituted;

each of R₅ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxyl;

q is 0, 1, 2, 3 or 4;

W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-6alkyl, —CO—OC_I-6alkyl, —C_1-6alkyl-O— C_1-6alkoxy, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

when ring C is absent, Y₅ is CR_5aR_5b, NR_5a or O, and Y₆ is CR_6aR_6b, NR_6a or O;

when ring C is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring;

• • i) Y₅ is CR_5a or N, and Y₆ is CR_6a or N, when the “” in the term “Y₅Y₆” represents a single bond; or
  • ii) Y₅ is C, and Y₆ is C, when the “” in the term “Y₅Y₆” represents a double bond;

each of R_Ya and R_5b is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

each of R_6a and R_6b is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

each of R_a is independently hydrogen, deuterium, halogen, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, —C_1-6alkoxy, —C_1-6alkyl, —C_3-8cycloalkyl, —C_1-6alkylene—NR_a1R_a2, —C_1-6alkylene-O—C_1-6alkyl, —C_1-6alkylene—CO—OR_a1, —C_1-6alkylene-(3-10 membered heterocyclic), —C_1-6alkylene-(5-10 membered heteroaryl), —C_1-6alkylene—CO—NR_a1R_a2, —C_1-6alkylene—NR_a1—CO—NRA_a2, —C_1-6alkylene—NR_a1—CO—C_1-6alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C₃₄₀carbocyclic, −5-10 membered heteroaryl, −3-10 membered heterocyclic, —CO—C_1-6alkyl, —CO—C_1-6alkyl, —CO—C_1-6alkylene—NRA_a2, —CO—NR_a1-(3-10 membered heterocyclic), —CO—NR_a1-(3-10 membered heterocyclic), —CO-(3-10 membered heterocyclic), —O—C_1-6alkylene—CO—OR_a1, —O—C_1-6alkylene—CO—NR_a1R_a2, —O—C_1-6alkylene—NR_a1R_a2, —O—C₃₄₀carbocyclic, —O-(3-10 membered heterocyclic), —NR_a1—CO—C_1-6alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-10 membered heteroaryl), —NR_a1—CO—C_3-8cycloalkyl,—NR_a1—C_1-6alkylene—NR_a1R_a2, —NR_a1—C_1-6alkylene-(3-10 membered heterocyclic), —NR_a1—C_1-6alkylene-(5-10 membered heteroaryl), —NR_a1—SO₂C_1-6alkyl, —S—C_1-6alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-6alkyl, —SO₂—C_1-6alkyl, —PO(C_1-6alkyl)₂, —PO(C_1-6alkoxy)₂, −3-10 membered heterocyclic or −5-10 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6; or

two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaomatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted;

each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl. C(R_X1)₂,

In some embodiments of Formula II, X₁ is N, S, NR_X1, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy. C(R_X1)₂,

In some embodiments of Formula II, X₁ is N, S, NR_X1, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy. C(R_X1)₂,

In some embodiments of Formula II, X₁ is N, S, NR_X1, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy. C(R_X1)₂,

In some embodiments of Formula II, X₁ is N, S, NR_X1, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy. C(R_X1)₂,

In some embodiments of Formula II, X₁ is N, S, NR_X1, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxyl, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, -S F₅, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, -S F₅, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl, —C_1-3alkoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, -S F₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl or 3-6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R_mand R_X2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X1and R_X2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X1and R_X2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, X₃ is N, S, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl, —O—C_1-6alkylene-C_1-6alkoxy, —O—C_5-8aryl or —O—C_1-6alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, X₃ is N, S, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl, —O—C_1-6alkylene—C_1-6alkoxy, —O—C_5-8aryl or —O—C_1-6alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₃ is N, S, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-3alkyl, —C_1-3alkoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl, —O—C_1-3alkylene—C_1-3alkoxy, —O—C_5-8aryl or —O—C_1-6alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₃ is N, S, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl or —O—C_1-3alkylene—C_1-3alkoxy, —O—C_5-8aryl or —O—C_1-3alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, X₃ is N, S, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl or —O—C_1-3alkylene—C_1-3alkoxy, —O—C_5-8aryl or —O—C_1-3alkylene-C_5-8aryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R_X2 and R_X3together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X2 and R_X3together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X2 and R_X3together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl, —C_1-6alkoxyl, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl, —C_1-6alkoxyl, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl, —C_1-3alkoxy, —NHCO-(5-10 membered heterocyclyl) or 5-10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R_X3 and R_X4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X3 and R_X4together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X3 and R_X4together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, X₅ is N, S, NR_X5, C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R_X4 and R_X5together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X4 and R_X5together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_X4 and R_X5together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, ring A is selected from

In some embodiments of Formula II, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or −50₂—NR_G—; each of R_G is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-3alkyl, —C_1-3alkoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl, —C_1-3alkoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R_Y1and R_Y2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_Y1and R_Y2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_Y1and R_Y2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH, —C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH, —C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-3alkyl, carboxyl, —COO—C_1-3alkyl, —NH—C_1-3alkylene—OH, —C_1-3alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, methyl, ethyl, propyl, isopropyl, carboxyl, —COO—C_1-3alkyl, —NH—C_1-3alkylene—OH, —C_1-3alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R_Y3 and R_Y4 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_Y3 and R_Y4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R_Y3 and R_Y4 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, ring B is selected from

In some embodiments of Formula II, each of R₁ and R₂ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula II, each of R₁ and R₂ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-3alkyl, —N(C_1-3alkyl)₂, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula II, each of R₁ and R₂ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, each of R₁ and R₂ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R₁ and R₂ together with the carbon atom to which they are both attached form CO or C═NR₅.

In some embodiments of Formula II, R₁ and R₂ together with the carbon atom to which they are both attached form CO.

In some embodiments of Formula II, R₁ and R₂ together with the carbon atom to which they are both attached form C═NR₅.

In some embodiments of Formula II, each of R₃ and R₄ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula II, each of R₃ and R₄ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-3alkyl, —N(C_1-3alkyl)₂, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula II, each of R₃ and R₄ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, each of R₃ and R₄ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, R₃ and R₄ together with the carbon atom to which they are both attached form a 3-12 membered heterocyclic ring or a 5-12 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R₃ and R₄ together with the carbon atom to which they are both attached form a 3-10 membered heterocyclic ring or a 5-10 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, R₃ and R₄ together with the carbon atom to which they are both attached form a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, each of R₅ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, each of R₅ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, each of R₅ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-6alkyl, —CO—OC_I-6alkyl, —C_1-6alkyl-O—C_1-6alkoxy, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula II, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-3alkyl, —CO—OC_1-3alkyl, —C_1-3alkyl-O—C_h3alkoxy, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula II, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkyl-O—C_h3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkyl-O—C_h3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN;—OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkyl-O—C_h3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, ring C is absent, a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, ring C is absent, a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, a 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula II, ring C is selected from

In some embodiments of Formula II, each of R_5a and R_5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula II, each of R_5a and R_5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula II, each of R_5a and R_5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, each of R_5a and R_5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, each of R_6a and R_6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula II, each of R_6a and R_6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula II, each of R_6a and R_6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, each of R_6a and R_6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, each of R_a is independently selected from hydrogen, deuterium, F, Cl, Br, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, —C_1-3alkoxy, —C_1-3alkyl, —C_3-6cycloalkyl,-C_1-3alkylene—NR_a1R_a2, —C_1-3alkylene-O—C_1-6alkyl, —C_1-3alkylene—CO—OR_a1, —C_1-3alkylene-(3-8 membered heterocyclic), —C_1-3alkylene-(5-8 membered heteroaryl), —C_1-3alkylene—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—C_1-3alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C_3-8carbocyclic, −5-10 membered heteroaryl, −3-8 membered heterocyclic, —CO—C_1-3alkyl, —COO—C_1-3alkyl, —CO—C_1-3alkylene—NR_a1R_a2, —CO—NR_a1-(3-8 membered heterocyclic), —CO—NR_a1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C_1-3alkylene—CO—NR_a1R_a2, —O—C_1-3alkylene—NR_a1R_a2, —O—C_3-8carbocyclic, —O-(3-8 membered heterocyclic), —NR_a1—CO—C_1-3alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-8 membered heteroaryl), —NR_a1—CO—C_3-6cycloalkyl,—NR_a1—C_1-3alkylene—NR_a1R_a2, —NR_a1—C_1-3alkylene-(3-8 membered heterocyclic), —NR_a1—C_1-3alkylene-(5-8 membered heteroaryl), —NR_a1—SO₂C_1-3alkyl, —S—C_1-3alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-3alkyl, —SO₂C_1-3alkyl, —PO(C_1-3alkyl)₂, —PO(C_1-3alkoxy)₂, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

In some embodiments of Formula II, each of R_a is independently selected from hydrogen, deuterium, F, Cl, Br, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, methoxy, ethoxy, propoxy, isopropoxy methyl, ethyl, propyl, isopropyl, —C_3-6cycloalkyl,-C_1-3alkylene—NR_a1R_a2, —C_1-3alkylene-O—C_1-6alkyl, —C_1-3alkylene—CO—OR_a1, —C_1-3alkylene-(3-8 membered heterocyclic), —C_1-3alkylene-(5-8 membered heteroaryl), —C_1-3alkylene—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—C_1-3alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C_3-8carbocyclic, −3-8 membered heterocyclic, —CO—C_1-3alkyl, —COO—C_1-3alkyl, —CO—C_1-3alkylene—NR_a1R_a2, —CO—NR_a1-(3-8 membered heterocyclic), —CO—NR_a1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C_1-3alkylene—CO—OR_a1, —O—C_1-3alkylene—CO—NR_a1R_a2, —O—C_1-3alkylene—NR_a1R_a2, —O—C_3-8carbocyclic, -O-(3-8 membered heterocyclic), —NR_a1—CO—C_1-3alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-8 membered heteroaryl), —NR_a1—CO—C_3-6cycloalkyl,—NR_a1—C_1-3alkylene—NR_a1R_a2, —NR_a1—C_1-3alkylene-(3-8 membered heterocyclic), —NR_a1—C_1-3alkylene-(5-8 membered heteroaryl), —NR_al—SO₂C_1-3alkyl, -S-C_1-3alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-3alkyl, —SO₂C_1-3alkyl, —PO(C_1-3alkyl)₂, —PO(C_1-3alkoxy)₂, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

In some embodiments of Formula II, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula II, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 3 membered carbocyclic ring, a 4 membered carbocyclic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, wherein each of the heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula II, each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula II, each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula II, each of R_a1 and R_a2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula II, each of R_a1 and R_a2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula II, the compound is of Formula II-a:

X₁, X₂, X₃, X₄, X₅, G, R_Y1, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

In some embodiments of Formula II, the compound is of Formula II-b

X₁, X₂, X₃, X₄, X₅, G, R_Y1, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

In some embodiments of Formula II, the compound is of Formula II-c

Wherein X₁, X₂, X₃, X₄, X₅, G, R_Y1, R_Y2, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

The present invention further provides the compound of Formula III or a pharmaceutically

acceptable salt thereof:

X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1;

each of R_X1 is selected from hydrogen, deuterium, halogen, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl;

X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO;

each of R_X2 is selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —SF_S, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X1and R_X2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, halogen, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl,-C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl or —O—C_1-6alkylene-C_1-6alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X2 and R_X3together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted ;

X₄ is N, S, NR_X4, C(R_X4)₂or CR_X4;

each of R_X4 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl, —C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X3 and R_X4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

X₅ is N, NR_X5 C(R_X5)₂ or CR_X5;

each of R_X5 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy; or

R_X4 and R_X5together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

represents a single bond or a double bond;

G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—, —NR_G—SO₂—,

—C(R_G)₂— or -5 0₂—NR_G—;

each of R_G is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted or unsubstituted;

Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl;

Y₂ is N or CR_Y2;

R_Y2 is selected from hydrogen, deuterium, halogen, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl;

when the “” in the term “Y₃Y₄” represents a single bond, Y₃ is NR_Y3; and Y₄ is CO;

when the “” in the term “Y₃Y₄” represents a double bond, Y₃ is N or CR_Y3, and Y₄ is N or CR_Y4;

R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, halogen, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH ,—C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxyl;

T is absent, O, NR₁ or CR₁R₂;

each of R₁ and R₂ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl; or

R₁ and R₂ together with the carbon atom to which they are both attached form CO or C═NR₅;

p is 0, 1, 2 or 3;

each of R₃ and R₄ is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl; or

R₃ and R₄ together with the carbon atom to which they are both attached form a 3-12 membered heterocyclic ring or 5-12 membered heteroaromatic ring or C═NR₅, and each of the ring systems is independently optionally substituted or unsubstituted;

each of R₅ is selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxyl;

q is 0, 1, 2, 3 or 4;

W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-6alkyl, —CO—OC_I-6alkyl, —C_1-6alkyl-O—C_1-6alkoxy, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the ring systems is independently optionally substituted or unsubstituted;

when ring C is absent, Y₅ is CR_5aR_5b, NR_5a or O, and Y₆ is CR_6aR_6b, NR_6a or O;

when ring C is 5-12 membered aromatic ring, 5-12 membered heteroaromatic ring or 5-12 membered heterocyclic ring;

• • i) Y₅ is CR_5a or N, and Y₆ is CR_6a or N, when the “” in the term “Y₅Y₆” represents a single bond; or
  • ii) Y₅ is C, and Y₆ is C, when the “” in the term “Y₅Y₆” represents a double bond;

each of R_Ya and R_5b is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

each of R_6a and R_6b is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl;

each of R_a is independently hydrogen, deuterium, halogen, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, —C_1-6alkoxy, —C_3-8cycloalkyl, —C_1-6alkylene—NR_a1R_a2, —C_1-6alkylene-O—C_1-6alkyl, —C_1-6alkylene-C —C_1-6alkylene-(3-10 membered heterocyclic), —C_1-6alkylene-(5-10 membered heteroaryl), —C_1-6alkylene—CO—NR_a1R_a2, —C_1-6alkylene—NR_arCO—NR_a1R_a2, —C_1-6alkylene—NR_arCO—C_1-6alkyl, —CO—NR_a1R_a2, —COO—C_1-6alkyl, —CO—CO—NR_a1R_a2, —C₃₄₀carbocyclic, −5-10 membered heteroaryl, −3-10 membered heterocyclic, —CO—C_1-6alkyl, —CO—C_1-6alkylene—NR_a1R_a2, —CO—NR_ar(3-10 membered heterocyclic), —CO—NR_ar(3-10 membered heterocyclic), —CO-(3-10 membered heterocyclic), —O—C_1-6alkylene—CO—OR_a1, —O—C_1-6alkylene—CO—NR_a1R_a2, —O—C_1-6alkylene—NR_a1R_a2, —O—C₃₄₀carbocyclic, —O-(3-10 membered heterocyclic), —NR_arCO—C_1-6alkyl, —NR_a1—CO—NR_a1R_a2, —NR_arC 045-10 membered heteroaryl), —NR_arCO—C_3-8cycloalkyl,—NR_arC_1-6alkylene—NR_a1R_a2, —NR_a1—C_1-6alkylene-(3-10 membered heterocyclic), —NR_a1—C_1-6alkylene-(5-10 membered heteroaryl), —NR_ar S 0₂C_1-6alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO₂C_1-6alkyl, —PO(C_1-6alkyl)₂, —PO(C_1-6alkoxy)₂, −3-10 membered heterocyclic or −5-10 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6; or

two adjacent R_a can be joined together to form a 6-membered aromatic ring, 5-membered heteroaromatic ring, 6-membered heteroaromatic ring, −3-6 membered heterocyclic ring or −3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted; or

R_a and R_w with the atom to which they are both attached form a 3-10 membered aromatic ring, 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted;

each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted

In some embodiments of Formula III, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X, is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, X₁ is N, S, NR_X1, C(R_X1)₂, or CR_X1; each of R_X1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CONH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —SF₅, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —CO—C_1-6alkyl, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —SF₅, —NHCO—C_3-8cycloalkyl, —NH—C_3-8cycloalkyl, —C_1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C_1-6alkylene—C_3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-4alkyl, —C_1-3alkoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHC 0-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl or 3-6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, X₂ is N, S, NR_X2, C(R_X2)₂, CR_X2 or CO; each of R_X2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C_1-3alkyl, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —SF₅, —NHCO—C_3-6cycloalkyl, —NH—C_3-6cycloalkyl, —C_1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C_1-3alkylene—C_3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, -oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R_X1and R_X2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X1and R_X2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X1and R_X2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl or —O—C_1-6alkylene-C_1-6alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-6alkyl, —C_1-6alkoxy, C_3-8cycloalkyl, C_5-8aryl, —S—C_1-6alkyl, 3-12 membered heterocyclyl, —O—C_3-8cycloalkyl or —O—C_1-6alkylene-C_1-6alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, —C_1-3alkyl,-C_1-3alkoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl or —O—C_1-3alkylene—C_h3alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl or —O—C_1-3alkylene—C_h3alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, X₃ is N, S, O, NR_X3, C(R_X3)₂ or CR_X3; each of R_X3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO₂, —NH₂, —CN, —CONH₂, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C_3-6cycloalkyl, C_5-8aryl, —S—C_1-3alkyl, 3-10 membered heterocyclyl, —O—C_3-6cycloalkyl or —O—C_1-3alkylene—C_h3alkyl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R_X2 and R_X3together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X2 and R_X3together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X2 and R_X3 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl,-C_1-3alkoxy, —NHCO-(5-10 membered heterocyclyl) or 5-10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, X₄ is N, S, NR_X4, C(R_X4)₂ or CR_X4; each of R_X4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, oxo, ═O, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R_X3 and R_X4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X3 and R_X4together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X3 and R_X4together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, X₅ is N, S, NR_X5 C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, X₅ is N, S, NR_X5 C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₅ is N, S, NR_X5 C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, X₅ is N, S, NR_X5 C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, X₅ is N, S, NR_X5 C(R_X5)₂ or CR_X5; each of R_X5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R_X4 and R_X5 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X4 and R_X5 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R_X4 and R_X5 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, ring A is selected from

In some embodiments of Formula III, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independent selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—,

—C(R_G)₂— or −50₂—NR_G—; each of R_G is independent selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl or —C_1-3alkoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, G is selected from absent, S, —SO—, —SO₂—, O, —CO—, —NR_G—,

—C(R_G)₂— or —SO₂—NR_G—; each of R_G is independent selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or -C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6alkenyl, —C_3-8cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl, —C_1-3alkoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, Y₁ is N or CR_Y1; R_Y1 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-6alkyl, —C_1-6alkoxy, —NH—C_1-6alkyl, —N—(C_1-6alkyl)₂, —C_1-6 alkenyl, —C_3-8cycloalkyl or —C_5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —C_1-3alkyl, —C_1-3alkoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, Y₂ is N or CR_Y2; R_Y2 is selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C_1-3alkyl, —N—(C_1-3alkyl)₂, —C_1-3alkenyl, —C_3-6cycloalkyl or —C_5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH ,—C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-6alkyl, carboxyl, —COO—C_1-6alkyl, —NH—C_1-6alkylene—OH ,—C_1-6alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, —C_1-3alkyl, carboxyl, —C —C_1-3alkyl, —NH—C_1-3alkylene—OH ,—C_1-3alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, R_Y3 and R_Y4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —OH, —CN, methyl, ethyl, propyl, isopropyl, carboxyl, —COO—C_1-3alkyl, —NH—C_1-3alkylene—OH ,—C_1-3alkylene—OH, —CONH₂ or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH₂, —CN, —OH, —NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, ring B is selected from

In some embodiments of Formula III, each of R₁ and R₂ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula III, each of R₁ and R₂ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-3alkyl, —N(C_1-3alkyl)₂, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula III, each of R₁ and R₂ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, each of R₁ and R₂ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R₁ and R₂ together with the carbon atom to which they are both attached form CO or C═NR₅.

In some embodiments of Formula III, R₁ and R₂ together with the carbon atom to which they are both attached form CO.

In some embodiments of Formula III, R₁ and R₂ together with the carbon atom to which they are both attached form C═NR₅.

In some embodiments of Formula III, each of R₃ and R₄ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-6alkyl, —N(C_1-6alkyl)₂, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula III, each of R₃ and R₄ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —NH—C_1-3alkyl, —N(C_1-3alkyl)₂, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula III, each of R₃ and R₄ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, each of R₃ and R₄ is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; —NH—C_1-3alkyl; —N(C_1-3alkyl)₂; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, R₃ and R₄ together with the carbon atom to which they are both attached form 3-12 membered heterocyclic ring or 5-12 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R₃ and R₄ together with the carbon atom to which they are both attached form 3-10 membered heterocyclic ring or 5-10 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, R₃ and R₄ together with the carbon atom to which they are both attached form 3 membered heterocyclic ring, 4 membered heterocyclic ring, 5 membered heterocyclic ring, 6 membered heterocyclic ring, 7 membered heterocyclic ring, 8 membered heterocyclic ring, 9 membered heterocyclic ring, 10 membered heterocyclic ring, 5 membered heteroaromatic ring, 6 membered heteroaromatic ring, 7 membered heteroaromatic ring, 8 membered heteroaromatic ring, 9 membered heteroaromatic ring, 10 membered heteroaromatic ring or C═NR₅, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, each of R₅ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, each of R₅ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, each of R₅ is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-6alkyl, —CO—OC_I-6alkyl, —C_1-6alkyl-O—C_1-6alkoxy, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula III, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —CO—C_1-3alkyl, —CO—OC_1-3alkyl, —C_1-3alkyl-O—C_h3alkoxy, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula III, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN;—OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkyl-O—C_h3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN;—OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkyl-O—C_h3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, W is absent, —O, —S or —C(R_W)₂—; and each of R_W is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN;—OH; —NO₂; carboxyl; —CO—C_1-3alkyl; —CO—OC_1-3alkyl; —C_1-3alkyl-O—C_h3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, ring C is absent, a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, ring C is absent, a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, a 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

In some embodiments of Formula III, ring C is selected from

In some embodiments of Formula III, each of R_5a and R_5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula III, each of R_5a and R_5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula III, each of R_5a and R_5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, each of R_5a and R_5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, each of R_6a and R_6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula III, each of R_6a and R_6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula III, each of R_6a and R_6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, each of R_6a and R_6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, each of R_a is independently selected from hydrogen, deuterium, F, Cl, Br, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, —C_1-3alkoxy, —C_1-4alkyl, —C_3-6cycloalkyl,-C_1-3alkylene—NRA_a2, —C_1-3alkylene-O—C_1-6alkyl, —C_1-3alkylene —CO-0R_a′, —C_1-3alkylene -(3-8 membered heterocyclic), —C_1-3alkylene -(5-8 membered heteroaryl), —C_1-3alkylene—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—C—NR_a1R_a2, —C_1-3alkylene —NR_a1—C —C_1-3alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C_3-8carbocyclic, −3-8 membered heterocyclic, —C—C_1-3alkyl, —COO—C_1-3alkyl, —CO—C_1-3alkylene—NR_a1R_a2, —CO—NR_a1-(3-8 membered heterocyclic), —CO—NR_a1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C_1-3alkylene —C—OR_a1, —O—C_1-3alkylene —C —NR_a1R_a2, —O—C_1-3alkylene —NR_al R_a2,—O—C_3-8carbocyclic, —O-(3-8 membered heterocyclic), —NR_a1—CO—C_1-3alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-8 membered heteroaryl), —NR_al—CO—C_3-6cycloalkyl, —NR_a1—C_1-3alkylene —NR_a1R_a2, —NR_al—C_1-3alkylene -(3-8 membered heterocyclic), —NR_al—C_1-3alkylene -(5-8 membered heteroaryl), —NR_al—SO₂C_1-3alkyl, -S —C_1-3alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-3alkyl, —SO₂C_1-3alkyl, —PO(C_1-3alkyl)₂, —PO(C_1-3alkoxy)₂, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

In some embodiments of Formula III, each of R_a is independently selected from hydrogen, deuterium, F, Cl, Br, —NR_a1R_a2, —CN, —OH, —NO₂, oxo, ═O, carboxyl, methoxy, ethoxy, propoxy, isopropoxy methyl, ethyl, propyl, isopropyl, butyl, isobutyl, —C_3-6cycloalkyl,-C_1-3alkylene—NR_a1R_a2, —C_1-3alkylene-O—C_1-6alkyl, —C_1-3alkylene—CO—OR_a1, —C_1-3alkylene -(3-8 membered heterocyclic), —C_1-3alkylene -(5-8 membered heteroaryl), —C_1-3alkylene—CO—NR_a1R_a2, —C_1-3alkylene—NR_a1—CO—NR_a1R_a2, —C_1-3alkylene —NR_a1—C—C_1-3alkyl, —CO—NR_a1R_a2, —CO—CO—NR_a1R_a2, —C_3-8carbocyclic, −3-8 membered heterocyclic, —C—C_1-3alkyl, —COO—C_1-3alkyl, —CO—C_1-3alkylene—NR_a1R_a2, —CO—NR_a1-(3-8 membered heterocyclic), —CO—NR_a1-(3-8 membered heterocyclic), —C-(3-8 membered heterocyclic), —O—C_1-3alkylene -C -0R_a1, —O—C_1-3alkylene —C—NR_a1R_a2, —O—C_1-3alkylene —NR_al R_a2,—O—C_3-8carbocyclic, —O-(3-8 membered heterocyclic), —NR_a1—CO—C_1-3alkyl, —NR_a1—CO—NR_a1R_a2, —NR_a1—CO-(5-8 membered heteroaryl), —NR_al—CO—C_3-6cycloalkyl, —NR_a1—C_1-3alkylene —NR_a1R_a2, —NR_al—C_1-3alkylene -(3-8 membered heterocyclic), —NR_al—C_1-3alkylene -(5-8 membered heteroaryl), —NR_al—SO₂C_1-3alkyl, -S —C_1-3alkyl, —SONR_a1R_a2, —SO₂NR_a1R_a2, —SO—C_1-3alkyl, —SO₂C_1-3alkyl, —PO(C_1-3alkyl)₂, —PO(C_1-3alkoxy)₂, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

In some embodiments of Formula III, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, two adjacent R_a can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 3 membered carbocyclic ring, a 4 membered carbocyclic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, wherein each of the heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, R_a and R, with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, halogen, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-6alkyl or —C_1-6alkoxy.

In some embodiments of Formula III, R_a and R, with the atom to which they are both attached form a 3-10 membered aromatic ring, 3-10 membered heteroaromatic ring or 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, R_a and R, with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, R_a and R, with the atom to which they are both attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 5 membered heteroaryl ring, a 6 membered heteroaryl ring, a 5 membered heterocyclic ring or a 6 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, —C_1-3alkyl or —C_1-3alkoxy.

In some embodiments of Formula III, each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-6alkoxy, or substituted or unsubstituted —C_1-6alkyl.

In some embodiments of Formula III, each of R_a1 and R_a2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH₂, —CN, —OH, —NO₂, carboxyl, substituted or unsubstituted —C_1-3alkoxy, or substituted or unsubstituted —C_1-3alkyl.

In some embodiments of Formula III, each of R_a1 and _Rae is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with halogen, NH₂, CN, OH, NO₂, carboxyl, C_1-3alkyl or C_1-3alkoxy.

In some embodiments of Formula III, each of R_a1 and R_a2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH₂; —CN; —OH; —NO₂; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C_1-3alkoxy substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C_1-3alkyl substituted with F, Cl, Br, NH₂, CN, OH, NO₂, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

In some embodiments of Formula III, the compound is of Formula III-a:

Wherein X₁, X₂, X₃, X₄, X₅, G, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

In some embodiments of Formula II, the compound is of Formula III-b:

Wherein X₁, X₂, X₃, X₄, X₅, G, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

In some embodiments of Formula III, the compound is of Formula III-c:

Wherein X₁, X₂, X₃, X₄, X₅, G, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

In some embodiments of Formula III, the compound is of Formula III-d:

Wherein X₁, X₂, X₃, X₄, X₅, G, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein.

In some embodiments of Formula III, the compound is of Formula III-e:

Wherein X₁, X₂, X₃, X₄, X₅, G, R_Y3, T, R₃, R₄, W, Y₅, Y₆, R_a, p, q and n are as defined herein. In some embodiments, the present invention provides a compound selected from the group consisting of:

1   ethyl (S)-3-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-(2,3-dichlorophenyl)-5--2-
    carboxylate
2   (S)-1′-(5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-
    6,4′-piperidin]-5-amine
3   (S)-3-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-(2,3-dichlorophenyl)-5-
    methylpyrazine-2-carboxylic acid
4   (S)-3-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-(2,3-dichlorophenyl)-5-
    methylpyrazine-2-carboxamide
5   ethyl (S)-3-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-((2-amino-3-chloropyridin-
    4-yl)thio)-5-methylpyrazine-2-carboxylate
6   (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)-6-methylpyrazin-2-yl)-1,3-dihydrospiro[indene-2
    4′-piperidin]-1-amine
7   (S)-1′-(6-amino-5-((2,3-dichlorophenyl)thio)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
8   (S)-1′-(4-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrimidin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
9   (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)pyridin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
10  (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)-6-(methylamino)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
11  (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)-6-(dimethylamino)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
12  (S)-1′-(6-amino-5-(thiazol-4-ylthio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-
    piperidin]-5-amine
13  (S)-1′-(6-amino-5-(thiazol-2-ylthio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-
    piperidin]-5-amine
14  (S)-1′-(6-amino-5-(quinolin-3-ylthio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-
    piperidin]-5-amine
15  (S)-5-amino-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)pyridin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidine]-3-carbonitrile
16  (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-N-methyl-1,3-dihydrospiro[indene-
    2,4′-piperidin]-1-amine
17  (S)-1′-(5-((3,5-dichloropyridin-4-yl)thio)pyrazin-2-yl)-5,6,7-trifluoro-1,3-dihydrospiro[indene-
    2,4′-piperidin]-1-amine
18  (S)-1-amino-1′-(2-((2-cyanopyridin-3-yl)thio)pyrimidin-5-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidine]-4-carbonitrile
19  (S)-1′-(5-((3-chloro-2-methoxypyridin-4-yl)thio)pyrazin-2-yl)-6-(methylthio)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
20  (S)-1-(5-((5-(4-amino-2-(tert-butyl)-4,6-dihydrospiro[cyclopenta[b]thiophene-5,4′-piperidin]-1′-
    yl)pyrazin-2-yl)thio)-2-chlorophenyl)ethan-1-one
21  (S)-1′-(5-((3-chloro-2-(isopropylamino)pyridin-4-yl)thio)pyrazin-2-yl)-6-(methylsulfonyl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
22  (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-7,7-d2-5-amine
23  (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-(2,3-dichlorophenyl)-5-
    methylpyrazin-2-yl)methanol
24  (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-((2-amino-3-chloropyridin-4-
    yl)thio)-5-methylpyrazin-2-yl)methanol
25  (S)-1′-(3-bromo-5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
26  (S)-3-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(2,3-
    dichlorophenyl)-5-methylpyrazine-2-carbonitrile
27  (S)-3-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(2,3-
    dichlorophenyl)-5-methylpyrazine-2-carboxamide
28  (S)-3-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(2,3-
    dichlorophenyl)-5-methylpyrazin-2-ol
29  (S)-1′-(6-amino-3-bromo-5-((2,3-dichlorophenyl)thio)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
30  (S)-5-amino-3-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-((2,3-
    dichlorophenyl)thio)pyrazine-2-carbonitrile
31  (S)-5-amino-3-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-((2,3-
    dichlorophenyl)thio)pyrazine-2-carboxamide
32  (S)-1′-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyridin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
33  (S)-1′-(6-((2-amino-3-chloropyridin-4-yl)thio)pyridin-3-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
34  (S)-1′-(4-((2-amino-3-chloropyridin-4-yl)thio)phenyl)-5,7-dihydrospiro[cyclopenta[b]pyridine-
    6,4′-piperidin]-5-amine
35  (S)-1′-(4-((2-amino-3-chloropyridin-4-yl)thio)isoquinolin-1-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidin]-1-amine
36  (S)-6-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-3-(2,3-
    dichlorophenyl)-5-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
37  (S)-6-(1-amino-6-fluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-(2,3-dichlorophenyl)-
    5-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
38  (S)-6-(1-amino-5,6,7-trifluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-methyl-3-(5-
    methylthiophen-2-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
39  (S)-2-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-5-(2,3-
    dichlorophenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
40  (S)-6-amino-2-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-((2-amino-3-
    chloropyridin-4-yl)thio)-3-methylpyrimidin-4(3H)-one
41  (S)-1′-(6-amino-5-((4-chlorothiazol-2-yl)thio)pyrazin-2-yl)-4,6-
    dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-4-amine
42  (S)-1-amino-1′-(5-((4-amino-5-bromopyrimidin-2-yl)thio)-1-methyl-6-oxo-1,6-dihydropyridin-2-
    yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-6-carbonitrile
43  (S)-6-(1-amino-6-bromo-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-((3-chloro-2-
    methoxypyridin-4-yl)thio)-1-methyipyridin-2(1H)-one
44  (S)-1-amino-1′-(4-(6-bromonaphthalen-2-yl)thiazol-2-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidine]-6-carbonitrile
45  (S)-1′-(6-amino-5-(2-chloro-3-methylphenyl)pyrazin-2-yl)-6-bromo-1,3-dihydrospiro[indene-2,4′-
    piperidin]-1-amine
46  (S)-1′-(5-(3-amino-2-(trifluoromethyl)phenyl)pyrimidin-2-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidine]-1,6-diamine
47  (S)-1′-(6-amino-5-(2-chloro-3-methylphenyl)pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidine]-1,6-diamine
48  (S)-1′-(6-(5-chlorothiophen-2-yl)pyridazin-3-yl)-5-methyl-1,3-dihydrospiro[indene-2,4′-
    piperidin]-1-amine
49  (S)-1′-(6′-chloro-[3,3′-bipyridazin]-6-yl)-5-methyl-1,3-dihydrospiro[indene-2,4′-piperidin]-1-
    amine
50  (S)-1′-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
51  (R)-1′-(5-(2,3-dichloro-5-methoxyphenyl)pyridin-2-yl)-2,3-dihydrospiro[indene-1,4′-piperidin]-
    2-amine
52  (S)-6′-(1-amino-4-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1′-methyl-2′-oxo-1′,2′-
    dihydro-[3,3′-bipyridine]-2-carbonitrile
53  (S)-6′-(1-amino-4-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1′-methyl-2′-oxo-1′,2′-
    dihydro-[3,3′-bipyridine]-2-carboxamide
54  (S)-1′-(4-(3-methoxyphenyl)cyclohexyl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-
    5-amine
55  (S)-1-amino-1′-(6-((3-amino-2-chlorophenyl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidine]-6-carbonitrile
56  1-(5-((5-((1S)-1-amino-6-(methylsulfinyl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)pyrazin-
    2-yl)thio)-2-chlorophenyl)ethan-1-one
57  (S)-1′-(5-(pyrimidin-2-ylthio)pyrazin-2-yl)-6-(trifluoromethyl)-1,3-dihydrospiro[indene-2,4′-
    piperidin]-1-amine
58  (S)-6-bromo-5-fluoro-1′-(5-(quinolin-4-ylthio)pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidin]-1-amine
59  (S)-6-(4-amino-4,6-dihydrospiro[cyclopenta[b]thiophene-5,4′-piperidin]-1′-yl)-3-(3-
    (trifluoromethyl)pyridin-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
60  (S)-2-(1-amino-6-chloro-5-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-(3,5-
    dichloropyridin-4-yl)-3-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
61  (S)-1′-(7-(5-chloropyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-3-yl)-1,3-
    dihydrospiro[cyclopenta[a]naphthalene-2,4′-piperidin]-3-amine
62  (S)-1′-(7-(3-chloropyridin-2-yl)-5H-pyrrolo[2,3-b]pyrazin-3-yl)-1H,3H-spiro[phenalene-2,4′-
    piperidin]-1-amine
63  (R)-1′-(3-(2-methylpyridin-3-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3,4-dihydro-1H-
    spiro[naphthalene-2,4′-piperidin]-3-amine
64  (S)-6-amino-2-(1-amino-7-bromo-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-methyl-5-
    phenylpyrimidin-4(3H)-one
65  (S)-1-amino-1′-(4-amino-6-oxo-5-(pyridazin-3-ylthio)-1,6-dihydropyrimidin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidine]-7-carbonitrile
66  (S)-1-amino-1′-(1-methyl-6-oxo-5-(pyrazin-2-yl)-1,6-dihydropyrimidin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidine]-7-carbonitrile
67  (S)-2-(1-amino-6-chloro-5-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-((4-
    isopropylphenyl)thio)pyrimidin-4(3H)-one
68  (S)-4-amino-6-(1-amino-6-bromo-5-fluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-(2-
    chloro-3-methylphenyl)-1-methylpyridin-2(1H)-one
69  (S)-6-(4-acetyl-1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-4-amino-3-(4-
    (trifluoromethyl)phenyl)pyridin-2(1H)-one
70  (S)-6′-(1-amino-4-hydroxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-2′-oxo-1′,2′-dihydro-
    [3,3′-bipyridine]-2-carbonitrile
71  (S)-1′-(3-bromo-5-(1H-indol-6-yl)-6-methylpyrazin-2-yl)-4,6-
    dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-4-amine
72  (S)-3-(4-amino-4,6-dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-1′-yl)-5-methyl-6-(2-
    oxoindolin-7-yl)pyrazine-2-carbonitrile
73  (S)-1′-(5-amino-6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
74  (S)-1′-(5-amino-6-((2-amino-3-chloropyridin-4-yl)thio)pyridin-3-yl)-6-chloro-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
75  (S)-1′-(4-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyridin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
76  (S)-1′-(5-((2,3-dichlorophenyl)thio)thiazol-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-
    piperidin]-7-amine
77  (R)-1′-(4-((3-chloropyridin-4-yl)thio)thiazol-2-yl)spiro[indoline-2,4′-piperidin]-3-amine
78  (R)-1′-(2-(7-chloro-1H-indol-1-yl)thiazol-4-yl)-2,3-dihydrospiro[indene-1,4′-piperidin]-2-amine
79  (R)-1′-(2-((2-(trifluoromethyl)phenyl)thio)thiazol-5-yl)-3H-spiro[benzofuran-2,4′-piperidin]-3-
    amine
80  (S)-(5-(1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)pyrazin-2-yl)(2,3-
    dichlorophenyl)methanone
81  (S)-2-(1-amino-6-fluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-(indolin-1-yl)-3-methyl-
    3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
82  (S)-1′-(5-((1,2,3,4-tetrahydroquinolin-8-yl)thio)pyrazin-2-yl)-1,3-
    dihydrospiro[cyclopenta[b]naphthalene-2,4′-piperidin]-1-amine
83  (S)-1′-(5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-1,3-
    dihydrospiro[cyclopenta[a]naphthalene-2,4′-piperidin]-1-amine
84  1′-(5-((3-amino-2-chlorophenyl)thio)-6-methylpyrazin-2-yl)-1-methyl-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
85  (R)-1′-(7-((2-amino-3-chloropyridin-4-yl)thio)-1H-indol-4-yl)-3H-spiro[benzofuran-2,4′-
    piperidin]-3-amine
86  (S)-1′-(7-((2-amino-3-chloropyridin-4-yl)thio)isoquinolin-3-yl)-5,6-dibromo-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
87  (S)-4-((5-(5-acetyl-1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-aminopyrazin-2-
    yl)thio)-3-chloro-1-methylpyridin-2(1H)-one
88  (S)-5-(1-amino-6-bromo-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-2-((2,3-
    dichlorophenyl)thio)-6-(hydroxymethyl)pyridin-3-ol
89  (S)-6-bromo-1′-(5-(2,3-dichlorophenyl)-6-methylimidazo[1,5-a]pyrazin-8-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
90  (S)-1′-(7-((2-amino-3-chloropyridin-4-yl)thio)-[1,2,5]thiadiazolo[3,4-c]pyridin-4-yl)-6-bromo-
    1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine
91  (S)-1′-(8-((2-amino-3-chloropyridin-4-yl)thio)pyrido[4,3-d]pyrimidin-5-yl)-6-bromo-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
92  (S)-3-(5-(1-amino-6-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)pyridin-2-yl)-4,5-
    dichlorophenol
93  (S)-1-amino-1′-(5-(5-methylthiophen-2-yl)pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-
    6-ol
94  (S)-1′-(5-(1H-indol-7-yl)pyrazin-2-yl)-5-ethyl-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine
95  (S)-1′-(5-(cyclohex-1-en-1-yl)pyrazin-2-yl)-5-isopropyl-1,3-dihydrospiro[indene-2,4′-piperidin]-
    1-amine
96  (S)-N-(1-amino-1′-(5-(2-(trifluoromethyl)phenyl)pyrimidin-2-yl)-1,3-dihydrospiro[indene-2,4′-
    piperidin]-6-yl)methanesulfonamide
97  (S)-1′-(5-((4-(trifluoromethyl)pyrimidin-5-yl)thio)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[c]pyridine-6,4′-piperidin]-7-amine
98  (S)-1′-(5-((2-chloropyridin-3-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[c]pyridine-6,4′-
    piperidin]-5-amine
99  (S)-4-((5-(5-amino-5,7-dihydrospiro[cyclopenta[d]pyrimidine-6,4′-piperidin]-1′-yl)pyrazin-2-
    yl)thio)-3-chlorobenzoic acid
100 (S)-1′-(5-((3-(trifluoromethyl)pyrazin-2-yl)thio)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-7-amine
101 (S)-1′-(5-((3-chloropyridazin-4-yl)thio)pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[d]pyrimidine-
    6,4′-piperidin]-7-amine
102 (S)-4-((5-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyrazine-6,4′-piperidin]-1′-yl)pyrazin-2-
    yl)thio)-3-chlorobenzamide
103 (S)-(1-amino-1′-(5-((3-chloro-2-(methylamino)pyridin-4-yl)thio)pyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-6-yl)dimethylphosphine oxide
104 (S)-1-amino-1′-(6-amino-5-((3-chloro-2-(dimethylamino)pyridin-4-yl)thio)pyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidine]-5-carboxylic acid
105 ethyl (S)-1-amino-1′-(5-((3-chloro-2-(methylamino)pyridin-4-yl)thio)pyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidine]-5-carboxylate
106 (S)-1′-(5-((3-(morpholinomethyl)phenyl)thio)pyrazin-2-yl)-6-(trifluoromethyl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
107 (S)-6-bromo-5-fluoro-1′-(5-((3-(pentafluoro-16-sulfanyl)phenyl)thio)pyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
108 (S)-N-(3-((5-(1-amino-6-(methylthio)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)pyrazin-2-
    yl)thio)phenyl)cyclopropanecarboxamide
109 (S)-6-(6-amino-1-bromo-4H,6H-spiro[cyclopenta[c]thiophene-5,4′-piperidin]-1′-yl)-3-(m-tolyl)-
    1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
110 (S)-2-(1-amino-5,6,7-trifluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-(3-ethylphenyl)-3-
    methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
111 (R)-1′-(3-(3-(tert-butyl)phenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3,4-dihydro-1H-
    spiro[naphthalene-2,4′-piperidin]-3-amine
112 (S)-2-(3-amino-1,3-dihydrospiro[cyclopenta[a]naphthalene-2,4′-piperidin]-1′-yl)-5-
    (3-isopropylphenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
113 (S)-1-amino-1′-(3-(3-chloro-2-morpholinopyridin-4-yl)-4-oxo-4,5-dihydro-1H-
    pyrrolo[3,2-c]pyridin-6-yl)-5-fluoro-1,3-dihydrospiro[indene-2,4′-piperidine]-6-carbonitrile
114 (S)-1′-(7-(3-chloro-2-(cyclobutylamino)pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazin-3-yl)-1,3-
    dihydrospiro[cyclopenta[a]naphthalene-2,4′-piperidin]-3-amine
115 (S)-1′-(3-(3-chloro-2-(cyclopropylamino)pyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-N6-
    methyl-1,3-dihydrospiro[indene-2,4′-piperidine]-1,6-diamine
116 (S)-5-amino-1′-(3-(3-chloro-2-(pyrrolidin-1-yl)pyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-2-
    fluoro-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidine]-3-carboxamide
117 1-(4-(6-((S)-4-amino-2-chloro-4,6-dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-3-chloropyridin-2-yl)pyrrolidin-3-ol
118 (S)-1′-(3-(3-chloro-2-((cyclopropylmethyl)amino)pyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-
    N6,N6-dimethyl-1,3-dihydrospiro[indene-2,4′-piperidine]-1,6-diamine
119 (S)-1′-(3-(2-amino-6-chloropyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-2-(tert-butyl)-4,6-
    dihydrospiro[cyclopenta[b]thiophene-5,4′-piperidin]-4-amine
120 (S)-2-chloro-1′-(3-(1,3-dihydroisobenzofuran-5-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-4,6-
    dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-6-amine
121 (S)-3-chloro-1′-(3-((2-chlorophenyl)thio)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
122 (S)-1′-(3-(3-chloro-2-(ethylamino)pyridin-4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-4,6-
    dihydrospiro[cyclopenta[b]thiophene-5,4′-piperidin]-4-amine
123 (R)-1′-(7-(methyl(pyridin-4-yl)amino)-5H-pyrrolo[2,3-b]pyrazin-3-yl)-3H-
    spiro[furo[2,3-b]pyridine-2,4′-piperidin]-3-amine
124 (R)-1′-(3-((3-chloropyridin-4-yl)amino)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6,7-
    dihydrospiro[cyclopenta[b]pyridine-5,4′-piperidin]-6-amine
125 (S)-2-methoxy-1′-(3-(1-phenylvinyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-4,6-
    dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-4-amine
126 (R)-1-(3-benzyl-1H-pyrazolo[3,4-b]pyrazin-6-yl)-1′,3′-dihydrospiro[piperidine-4,2′-
    pyrrolo[2,3-b]pyridin]-3′-amine
127 (S)-(6-(6-amino-4,6-dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)(phenyl)methanone
128 (4S)-1′-(3-(1-phenylethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-4,6-
    dihydrospiro[cyclopenta[d]thiazole-5,4′-piperidin]-4-amine
129 1-(6-((S)-5-amino-2-methoxy-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-1-phenylethan-1-ol
130 (S)-1′-(3-((2,3-dichloropyridin-4-yl)oxy)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
131 (S)-6-bromo-1′-(3-(5-(3,4-difluorophenyl)-3,4-dihydroquinolin-1(2H)-yl)-1H-pyrazolo[3,4-
    b]pyrazin-6-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine
132 (S)-6-amino-2-(1-amino-6-bromo-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-(4-
    cyclopropoxyphenyl)-3-methylpyrimidin-4(3H)-one
133 (S)-N-(1-amino-1′-(4-amino-5-((4-(methylthio)phenyl)thio)-6-oxo-1,6-dihydropyrimidin-2-yl)-
    1,3-dihydrospiro[indene-2,4′-piperidin]-6-yl)acetamide
134 (S)-2-(1-amino-6-(methylamino)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-(4-
    (benzyloxy)phenyl)-3-methylpyrimidin-4(3H)-one
135 (S)-2-(7-acetyl-1-amino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-(benzo[d][1,3]dioxol-
    4-ylthio)pyrimidin-4(3H)-one
136 4-amino-6-((1S)-1-amino-7-(1-hydroxyethyl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-
    (4-(difluoromethoxy)phenyl)-1-methyipyridin-2(1H)-one
137 (S)-1-amino-1′-(4-amino-6-oxo-5-(4-phenoxyphenyl)-1,6-dihydropyridin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidine]-4-carbonitrile
138 (S)-6-(1-amino-4-hydroxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-(4-
    cyclohexylphenyl)-1-methylpyridin-2(1H)-one
139 (S)-3-([1,1′-biphenyl]-4-yl)-6-(1-amino-4-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-
    yl)pyridin-2(1H)-one
140 (S)-6-amino-2-(1-amino-6-(2-oxopiperidin-1-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-
    methyl-5-(4-(trifluoromethoxy)phenyl)pyrimidin-4(3H)-one
141 (S)-1-(1-amino-1′-(4-amino-5-((4-cyanophenyl)thio)-1-methyl-6-oxo-1,6-dihydropyrimidin-2-
    yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-6-yl)urea
142 (S)-4-amino-6-(1-amino-6-chloro-5-fluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1-
    methyl-3-(4-(tetrahydro-2H-pyran-4-yl)phenyl)pyridin-2(1H)-one
143 (S)-6-(1-amino-6-(trifluoromethyl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-(4-(2-
    methoxyethoxy)phenyl)-1-methylpyridin-2(1H)-one
144 (S)-6-amino-2-(1-amino-6-(piperidine-1-carbonyl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-
    3-methyl-5-(quinolin-8-ylthio)pyrimidin-4(3H)-one
145 (S)-6-amino-2-(1-amino-6-morpholino-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-methyl-
    5-((4-nitrophenyl)thio)pyrimidin-4(3H)-one
146 (S)-6-amino-2-(5-amino-3-nitro-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-3-
    methyl-5-(quinolin-8-ylthio)pyrimidin-4(3H)-one
147 (S)-6-(5-amino-3-(4-methylpiperazin-1-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-
    piperidin]-1′-yl)-1-methyl-3-(naphthalen-1-ylthio)pyridin-2(1H)-one
148 (S)-2-(1-amino-6-(1H-pyrrol-1-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-((2,2-
    difluorobenzo[d][1,3]dioxol-4-yl)thio)pyrimidin-4(3H)-one
149 (S)-7-(5-(1-amino-6-(1H-imidazol-1-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-
    (hydroxymethyl)-3-methylpyrazin-2-yl)isoindolin-1-one
150 (S)-3-(1-amino-6-(ethylamino)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-(1H-indol-5-yl)-
    5-methylpyrazine-2-carboxamide
151 (S)-N-(1-amino-1′-(3-bromo-5-(1H-indol-6-yl)-6-methylpyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-6-yl)cyclopropanecarboxamide
152 (S)-4-(6-amino-5-(1-amino-4-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-3-
    methylpyrazin-2-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
153 (S)-3-(1-amino-5-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-5-methyl-6-(2-
    oxoindolin-7-yl)pyrazine-2-carbonitrile
154 (S)-N-(5-(1-amino-7-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-((2-
    hydroxyethyl)amino)-3-methylpyrazin-2-yl)benzenesulfonamide
155 (S)-1′-(6-methyl-3-(1H-pyrazol-5-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
156 (S)-2-(3-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-6-(8-
    chlorochroman-7-yl)-5-methylpyrazin-2-yl)propan-2-ol
157 (S)-6-chloro-1′-(5-(7-chloro-2,3-dihydrobenzofuran-6-yl)pyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
158 (S)-4-bromo-1′-(5-(3-(1-methyl-1H-pyrazol-5-yl)phenyl)pyrazin-2-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
159 (S)-1-amino-1′-(6-cyano-5-(1H-indazol-7-yl)pyrazin-2-yl)-5-fluoro-1,3-dihydrospiro[indene-2,4′-
    piperidine]-6-carboxamide
160 (S)-1′-(5-(1H-indol-3-yl)-6-iodopyrazin-2-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-
    piperidin]-5-amine
161 (R)-6-(5-(7′-amino-7′,8′-dihydro-5′H-spiro[piperidine-4,6′-quinolin]-1-yl)-3-vinylpyrazin-2-
    yl)isoindolin-1-one
162 (R)-1-(4-(5-(6-amino-6,7-dihydrospiro[cyclopenta[b]pyridine-5,4′-piperidin]-1′-yl)-3-
    ethylpyrazin-2-yl)-3,3-difluoroindolin-1-yl)ethan-1-one
163 (S)-1′-(5-(3-methyl-1H-indazol-6-yl)-6-phenylpyrazin-2-yl)-5,7-
    dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-5-amine
164 (S)-1′-(5-(1H-benzo[d][1,2,3]triazol-6-yl)-6-cyclopropylpyrazin-2-yl)-6-((tetrahydro-2H-pyran-
    4-yl)oxy)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine
165 (S)-1-amino-1′-(3-((1-methyl-1H-imidazol-2-yl)thio)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidine]-6-carbonitrile
166 (S)-1′-(3-(1H-benzo[d]imidazol-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-6-bromo-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
167 (S)-1-(6-(1-amino-5-chloro-6-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-3,4-dihydro-1,5-naphthyridin-2(1H)-one
168 (1-(6-((S)-1-amino-6-(methylthio)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-1,2,3,4-tetrahydro-1,5-naphthyridin-4-yl)methanol
169 1-(6-((1S)-1-amino-6-(methylsulfmyl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-5-fluoro-1,2,3,4-tetrahydroquinoline-6-carbonitrile
170 (S)-6-chloro-1′-(3-(2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-
    5-methyl-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine
171 (S)-5-(6-(1-amino-4-methoxy-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1H-pyrazolo[3,4-
    b]pyrazin-3-yl)-N-(2-methoxyethyl)-5,6,7,8-tetrahydro-1,5-naphthyridine-2-carboxamide
172 (S)-1-amino-5-fluoro-1′-(3-(6-(piperazin-1-yl)-3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-
    pyrazolo[3,4-b]pyrazin-6-yl)-1,3-dihydrospiro[indene-2,4′-piperidine]-6-carbonitrile
173 (S)-2-(1-(6-(1-amino-6-(methylthio)-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-1,2,3,4-tetrahydroquinolin-5-yl)thiazole-4-carboxylic acid
174 (S)-1′-(6-(aminomethyl)-5-(2,3-dichloropyridin-4-yl)pyrazin-2-yl)-6-(1H-imidazol-1-yl)-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
175 (1S)-1-amino-1′-(5-(2,3-dichloropyridin-4-yl)-3-(2-(hydroxymethyl)pyrrolidine-1-carbonyl)-6-
    methylpyrazin-2-yl)-N,N-dimethyl-1,3-dihydrospiro[indene-2,4′-piperidine]-6-carboxamide
176 (S)-1′-(8-(2-amino-3-chloropyridin-4-yl)-7-methylimidazo[1,2-c]pyrimidin-5-yl)-5-fluoro-1,3-
    dihydrospiro[indene-2,4′-piperidin]-1-amine
177 (S)-1′-(5-(1-methyl-1H-indol-2-yl)pyrazin-2-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-3,3-d2-
    1-amine
178 (S)-1-(6-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridine-6,4′-piperidin]-1′-yl)-1H-
    pyrazolo[3,4-b]pyrazin-3-yl)-1,2,3,4-tetrahydro-6H-pyrido[1,2-a]pyrimidin-6-one
179 (S)-1′-(3-(2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-5,7-
    dihydrospiro[cyclopenta[c]pyridine-6,4′-piperidin]-5-amine
180 (3-((S)-1-amino-6-fluoro-1,3-dihydrospiro[indene-2,4′-piperidin]-1′-yl)-6-((R)-1-
    methylisoindolin-2-yl)pyrazin-2-yl)methanol
181 (S)-1′-(3-(6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-5,7-
    dihydrospiro[cyclopenta[c]pyridine-6,4′-piperidin]-5,5-d2-7-amine
182 (S)-4-(difluoromethyl)-1′-(5-methyl-6-((R)-2-methyl-3,4-dihydro-1,5-naphthyridin-1(2H)-
    yl)pyridin-3-yl)-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine
183 (S)-1′-(8-(2-chloro-3-(isopropyl(methyl)amino)phenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-yl)-
    2,3,6,8-tetrahydrospiro[indeno[5,6-b][1,4]dioxine-7,4′-piperidin]-6-amine
184 (S)-1-(5-amino-1′-(8-((5-chloro-1-methylindolin-6-yl)thio)imidazo[1,5-a]pyridin-5-yl)-2,3,5,7-
    tetrahydro-1H-spiro[cyclopenta[b]pyrrolo[3,2-e]pyridine-6,4′-piperidin]-1-yl)ethan-1-one

The present invention further provides a pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof as defined herein and at least one pharmaceutically acceptable excipient.

In some embodiments, the compound in a weight ratio to the said excipient within the range from about 0.0001 to about 10.

The present invention additionally provides a combination pharmaceutical product comprising the compound or a pharmaceutically acceptable salt thereof mentioned above, together with one or more other therapeutically active agents.

The present invention further provides use of the above-mentioned compound or a pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product for the preparation of a medicament.

In some embodiments, the medicament is used for the treatment or prevention of cancer, cancer metastasis , cardiovascular disease, an immunological disorder or an ocular disorder.

The present invention additionally provides use, in the manufacture of a medicament for use as an inhibitor of SHP2, of at least one above-mentioned compound or a pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product.

The present invention further provides use of the above-mentioned compound or a pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product for the preparation of a medicament in the treatment of diseases or conditions mediated by the activity of SHP2.

In some embodiments, wherein the diseases or conditions mediated by the activity of SHP2 is cancer.

In some embodiments, the diseases or conditions mediated by the activity of SHP2 is selected from Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.

The present invention additionally provides a method for preventing or treating a disease, lessening a disease symptoms, delaying the progression or onset of a disease, comprising administering to the patient in need thereof a therapeutically effective amount of the above-mentioned compound or the pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product, and the disease is cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.

The present invention further provides a method for inhibiting the activity of SHP2 level, comprising administering to the patient in need thereof a therapeutically effective amount of the above-mentioned compound or the pharmaceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product.

The present invention additionally provides a method for preventing or treating a disease, lessening a disease symptoms, delaying the progression or onset of a disease, comprising administering to the patient in need thereof a therapeutically effective amount of the above-mentioned compound or the pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product, and the disease is mediated by the activity of SHP2.

In some embodiments, the disease mediated by the activity of SHP2 is cancer.

In some embodiments, the disease mediated by the activity of SHP2 is selected from Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.

The present invention further provides the above-mentioned compound or the pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product for use in preventing or treating a disease, lessening a disease symptom, delaying the progression or onset of a disease, wherein the disease is cancer, cancer metastasis , cardiovascular disease, an immunological disorder or an ocular disorder.

The present invention additionally provides the above-mentioned compound or the pharmaceutically acceptable slat thereof, the above-mentioned pharmaceutical composition , or the above-mentioned combination pharmaceutical product, for use in inhibiting the activity of SHP2.

The present invention further provides the above-mentioned compound or the pharmaceutically acceptable salt thereof, the above-mentioned pharmaceutical composition, or the above-mentioned combination pharmaceutical product for use in preventing or treating a disease, lessening a disease symptom, delaying the progression or onset of a disease, and the disease is mediated by the activity of SHP2.

In some embodiments, the disease mediated by the activity of SHP2 is cancer.

In some embodiments, the disease mediated by the activity of SHP2 is selected from Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.

Definition

As used herein, the singular form “a”, “an”, and “the” include plural references unless indicated otherwise. For example, “a” substituent includes one or more substituents.

As used herein, the term “alkyl” is defined to include saturated aliphatic hydrocarbons including straight chains and branched chains. In some embodiments, the alkyl group has 1 to 20 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. For example, the term “C_1-6 alkyl,” as well as the alkyl moieties of other groups referred to herein (e.g., C_1-6 alkoxy) refers to linear or branched radicals of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, or n-hexyl). For yet another example, the term “C_1-4 alkyl” refers to linear or branched aliphatic hydrocarbon chains of 1 to 4 carbon atoms; the term “C_1-3 alkyl” refers to linear or branched aliphatic hydrocarbon chains of 1 to 3 carbon atoms; the term “C_1-2 alkyl” refers to methyl and/or ethyl; and the term “C1 alkyl” refers to methyl. An alkyl group optionally can be substituted by one or more (e.g., 1 to 5) suitable substituents.

As used herein, the term “alkoxy” or “alkyloxy” refers to an -0-alkyl group. For example, the term “C_h6 alkoxy” or “C_1-6 alkyloxy” refers to an -0-(C_1-6 alkyl) group; and the term “C_1-4 alkoxy” or “C₁-₄ alkyloxy” refers to an -0-(C_1-4 alkyl) group; For another example, the term “C₁,₂ alkoxy” or “C_1-2 alkyloxy” refers to an -0-(C_1-2 alkyl) group. Examples of alkoxy include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, and the like. The alkoxy or alkyloxy group optionally can be substituted by 1 or more (e.g., 1 to 5) suitable substituents.

As used herein, the term “Alkylene” refers to a divalent hydrocarbyl group having the specified number of carbon atoms which can link two other groups together. Sometimes it refers to a group -(CH₂)_t— where is 1-8, and preferably t is 1-4. Where specified, an alkylene can also be substituted by other groups and may include one or more degrees of unsaturation (i.e., an alkenylene or alkynlene moiety) or rings. The open valences of an alkylene need not be at opposite ends of the chain. Thus branched alkylene groups such as —CH(Me)—, —CH₂CH(Me)— and —C(Me)₂— are also included within the scope of the term “alkylenes” as are cyclic groups such as cyclopropan-1,1-diyl and unsaturated groups such as ethylene (—CH═CH—) or propylene (—CH₂—CH═CH—). Where an alkylene group is described as optionally substituted, the substituents include those typically present on alkyl groups as described herein.

As used herein, the term “halo” or “halogen” refers to fluoro (which may be depicted as —F), chloro (which may be depicted as —Cl), bromo (which may be depicted as —Br), or iodo (which may be depicted as —I). The preferred halogen groups include F, Cl and Br. The terms “haloC_1-6alkyl”, “haloC_2-6alkenyl”, “haloC_2-6alkynyl” and “haloC_1-6alkoxy” mean a C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl or C_1-6alkoxy in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. In some embiment, preferred are fluoroC_1-6alkyl, fluoroC_2-6alkenyl, fluoroC_2-6alkynyl and fluoroC_1-6alkoxy groups, in particular fluoroC_1-3alkyl, for example, CF₃, CHF₂, CH₂F, CH₂CH₂F, CH₂CHF₂, CH₂CF₃ and fluoroC_1-3alkoxy groups, for example, OCF₃, OCHF₂, OCH₂F, OCH₂CH₂F, OCH₂CHF₂ or OCH₂CF₃, and most especially CF₃, OCF₃ and OCHF₂.

As used herein, the term “n-membered”, where n is an integer, typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, pyridine is an example of a 6-membered heteroaryl ring and thiophene is an example of a 5-membered heteroaryl group.

At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual sub-combination of the members of such groups and ranges. For example, the term “C_1-6 alkyl” is specifically intended to include C₁ alkyl (methyl), C₂ alkyl (ethyl), C₃ alkyl, C₄ alkyl, C₅ alkyl, and C₆ alkyl. For another example, the term “a 5- to 12-membered heteroaryl group” is specifically intended to include any 5—, 6—, 7—, 8—, 9—, 10—, 11- or 12-membered heteroaryl group.

As used herein, the term “oxo” refers to ═O. When an oxo is substituted on a carbon atom, they together form a carbonyl moiety [—C(═O)—]. When an oxo is substituted on a sulfur atom, they together form a sulfinyl moiety [—S(═O)—]; when two oxo groups are substituted on a sulfur atom, they together form a sulfonyl moiety [—S(═O)₂—].

As used herein, the term “aryl” or “aromatic” refers to an optionally substituted monocyclic or fused bicyclic or polycyclic ring system having the well-known characteristics of aromaticity, wherein at least one ring contains a completely conjugated pi-electron system. Typically, aryl groups contain 6 to 20 carbon atoms (“C₆—C₂₀ aryl”) as ring members, preferably 6 to 14 carbon atoms (“C₆—C₁₄ aryl”) or more preferably, 6 to 12 carbon atoms (“C₆—C₁₂ aryl”). Fused aryl groups may include an aryl ring (e.g., a phenyl ring) fused to another aryl or heteroaryl ring, or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring, provided the point of attachment to the base molecule on such fused ring systems is an atom of the aromatic portion of the ring system. Examples, without limitation, of aryl groups include phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and tetrahydronaphthyl. The aryl group is unsubstituted or substituted as further described herein.

As used herein, the term “heteroaryl” or “heteroaromatic” refers to monocyclic or fused bicyclic or polycyclic ring systems having the well-known characteristics of aromaticity that contain the specified number of ring atoms and include at least one heteroatom selected from N, O and S as a ring member in an aromatic ring. The inclusion of a heteroatom permits aromaticity in 5-membered rings as well as 6-membered rings. Typically, heteroaryl groups contain 5 to 20 ring atoms (“5-20 membered heteroaryl”), preferably 5 to 14 ring atoms (“5-14 membered heteroaryl”), and more preferably 5 to 12 ring atoms (“5-12 membered heteroaryl”). Heteroaryl rings are attached to the base molecule via a ring atom of the heteroaromatic ring, such that aromaticity is maintained. Thus, 6-membered heteroaryl rings may be attached to the base molecule via a ring C atom, while 5-membered heteroaryl rings may be attached to the base molecule via a ring C or N atom. Heteroaryl groups may also be fused to another aryl or heteroaryl ring, or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring, provided the point of attachment to the base molecule on such fused ring systems is an atom of the heteroaromatic portion of the ring system. Examples of unsubstituted heteroaryl groups often include, but are not limited to, pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, triazole, oxadiazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, benzofuran, benzothiophene, indole, benzimidazole, indazole, indazole,

quinoline, isoquinoline, purine, triazine, naphthryidine and carbazole. In frequent preferred embodiments, 5- or 6-membered heteroaryl groups are selected from the group consisting of pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, pyridinyl and pyrimidinyl, pyrazinyl or pyridazinyl rings. The heteroaryl group is unsubstituted or substituted as further described herein.

As used herein, the term “heterocyclyl”, “heterocyclic” or “heteroalicyclic” used interchangeably herein refers to a non-aromatic, saturated or partially unsaturated ring system containing the specified number of ring atoms, including at least one heteroatom selected from N, O and S as a ring member, where ring S atoms are optionally substituted by one or two oxo groups (i.e., S(O)_x, where x is 0, 1 or 2) and where the heterocyclic ring is connected to the base molecule via a ring atom, which may be C or N. Heterocyclic rings include rings which are spirocyclic, bridged, or fused to one or more other heterocyclic or carbocyclic rings, where such spirocyclic, bridged, or fused rings may themselves be saturated, partially unsaturated or aromatic to the extent unsaturation or aromaticity makes chemical sense, provided the point of attachment to the base molecule is an atom of the heterocyclic portion of the ring system. Preferably, heterocyclic rings contain 1 to 4 heteroatoms selected from N, O, and S(O)_q as ring members, and more preferably 1 to 2 ring heteroatoms, provided that such heterocyclic rings do not contain two contiguous oxygen atoms. Heterocyclyl groups are unsubstituted or substituted by suitable substituent groups, for example the same groups that are described herein as suitable for alkyl, aryl or heteroaryl. Such substituents may be present on the heterocycylic ring attached to the base molecule, or on a spirocyclic, bridged or fused ring attached thereto. In addition, ring N atoms are optionally substituted by groups suitable for an amine, e.g., alkyl, acyl, carbamoyl, sulfonyl substituents, and the like.

As used herein, the term “cycloalkyl” refers to a non-aromatic, saturated or partially unsaturated carbocyclic ring system containing the specified number of carbon atoms, which may be a monocyclic, spirocyclic, bridged or fused bicyclic or polycyclic ring system that is connected to the base molecule through a carbon atom of the cycloalkyl ring. Typically, the cycloalkyl groups of the invention contain 3 to 12 carbon atoms (“C₃—C₁₂ cycloalkyl”), preferably 3 to 8 carbon atoms (“C₃—C₈ cycloalkyl”). Representative examples include, e.g., cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, adamantane, and the like. Cycloalkyl groups are unsubstituted or substituted by the same groups that are described herein as suitable for alkyl.

Compounds described herein can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ³²P, ³⁵S, ¹⁸F, ³⁶Cl, and ¹²⁵I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention. In some embodiments, one or more hydrogen atoms of any of the compounds described herein can be substituted with deuterium to provide the corresponding deuterium-labeled or -enriched compounds.

The term “composition”, as used herein, is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts. Accordingly, pharmaceutical compositions containing the compounds of the present invention as the active ingredient as well as methods of preparing the instant compounds are also part of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents and such solvates are also intended to be encompassed within the scope of this invention.

“SHP2” means “Src Homolgy-2 phosphatase” and is also known as SH-PTP2, SH-PTP3, Syp, PTP1D, PTP2C, SAP-2 or PTPN11.

Cancers harboring “PTPNll mutations” include but are not limited to: N58Y, D61Y, V; E69K; A72V, T, D; E76G, Q, K (ALL); G60A: D61Y; E69V; F71K; A72V; T731; E76G, K; R₂₈₉G; G503V (AML); G6OR, D61Y, V, N; Y₆₂D; E69K; A72T, V; T731; E76K, V, G, A, Q; E139D; G503A, R; Q506P (JMML); G60V; D61V; E69K; F71L; A72V; E76A (MDS), Y₆₃C (CMML); Y₆₂C; E69K; T507K (neuroblastoma); V46L; N58S; E76V (Lung cancer), R₁₃₈Q (melanoma); E76G (colon cancer).

The term “subject” (alternatively referred to herein as “patient”) as used herein refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.

The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds of Formula I, II, III or IV are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure, especially at least 98% pure (% are on a weight for weight basis).

The compounds of the present invention may also be present in the form of pharmaceutically acceptable salts. For use in medicine, the salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts”. The pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts. The pharmaceutically acceptable acidic/anionic salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, hydriodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic. Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium and zinc.

The present invention includes within its scope the prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds that are readily converted in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.

It is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques know in the art as well as those methods set forth herein.

The present invention includes compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof.

The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

When a tautomer of the compound of Formula (I) exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically stated otherwise.

When the compound of Formula (I) and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. A type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.

The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure, especially at least 98% pure (% are on a weight for weight basis).

The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

In practice, the compounds represented by Formula I, or a prodrug, or a metabolite, or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound represented by Formula I, or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound, or a pharmaceutically acceptable salt, of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen. In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05 mg to about 5 g of the active ingredient and each cachet or capsule preferably containing from about 0.05 mg to about 5 g of the active ingredient. For example, a formulation intended for the oral administration to humans may contain from about 0.5 mg to about 5 g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about lmg to about 2 g of the active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing hydrophilic material and water, together with about 5wt % to about 1 Owt % of the compound, to produce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.

In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including antioxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

Generally, dosage levels on the order of from about 0.01 mg/kg to about 150 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation, cancer, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system (CNS), may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.

It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

These and other aspects will become apparent from the following written description of the invention.

EXAMPLES

The following Examples are provided to better illustrate the present invention. All parts and percentages are by weight and all temperatures are degrees Celsius, unless explicitly stated otherwise. The following abbreviations have been used in the examples:

DMF                N,N-Dimethylformamide
EA                 Ethyl acetate
Hex                Hexane
MeOH               Methanol
DCM                Dichloromethane
DCE                1,2-Dichloroethane
EtOH               Ethanol
t-BuOH             tert-Butanol
iPrOH              Propan-2-ol
CD3I               Iodomethane-d3
LiHMDS             Lithium bis(trimethylsilyl)amide
THF                Tetrahydrofuran
Ti(OEt)4           Titanium ethoxide
NMP                1-Methyl-2-pyrrolidinone
DIPEA              N,N-Diisopropylethylamine
(Boc)2O            Di-tert-butyl dicarbonate
LDA                Lithium diisopropylamide
LiHMDS             Lithium bis(trimethylsilyl)amide
PPA                Polyphosphoric acids
TEA                Triethylamine
PPh3               Triphenylphosphane
Pd(PPh3)4          Tetrakis(triphenylphosphine)palladium
DBU                1,8-Diazabicyclo[5.4.0]undec-7-ene
XantPhos           4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene
BINAP              2,2′-Bis(diphenylphosphanyl)-1,1′-binaphthalene
DavePhos           2′-(dicyclohexylphosphanyl)-N,N-dimethyl-[1,1′-biphenyl]-2-amine
Pd(OAc)2           Palladium diacetate
Pd2(dba)3          Tris(dibenzylideneacetone)dipalladium(0)
Pd(dppf)Cl2        [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
Pd(dppf)Cl2•CH2Cl2 [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
                   dichloromethane complex
BOP                Benzotriazol-1-yloxytris(dimethylamino)-phosphonium
                   hexafluorophosphate
PyBOP              Benzotriazole-1-yl-oxytripyrrolidinophosphonium
                   hexafluorophosphate
K4Fe(CN)6•3H2O     Potassium ferrocyanide trihyrate
Cy3PH•BF4          Tricyclohexylphosphonium tetrafluoroborate
t-BuOK             Potassium tert-butoxide
NaOEt              Sodium ethoxide
NCS                N-Chlorosuccinimide
NBS                N-Bromosuccinimide
NIS                N-Iodosuccinimide
TFA                2,2,2-Trifluoroacetic acid
RT                 Room temperature
min                minute(s)
h                  hour(s)
aq                 aqueous
sat                saturated
TLC                Thin layer chromatography
Prep - TLC         Preparative thin layer chromatography

Intermediate A1

A mixture of 3-chloro-4-iodopyridin-2-amine (25.55 g, 100.41 mmol), methyl 3-mercaptopropanoate (12.72 g, 105.85 mmol), Pd₂(dba)₃ (0.96 g, 1.05 mmol), XantPhos (1.21 g, 2.09 mmol) and DIPEA (26.01 g, 201.25 mmol) in 1,4-dioxane (80 mL) was stirred for 18 h at 100° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with EA (80 mL), filtered and concentrated under reduced pressure. The residue was diluted with EA (50 mL) and Hex (250 mL), the resulting suspension was stirred for 10 min and filtered. The filter cake was collected. The filtration was concentrated under reduced pressure and the residue was purified by silica gel chromatography (eluting with EA:Hex=1:1, v/v). The product was combined with the filter cake to give compound A1-1 (21.62 g). MS: 247 [M+1]⁺.

Sodium (2.48 g, 107.83 mmol) was dissolved in EtOH (200 mL) and added to a suspension of compound A1-1 (21.62 g, 87.63 mmol) in EtOH (100 mL) dropwise at 0° C. The resulting mixture was allowed to warm to RT and stirred for 2 h. The mixture was diluted with EtOH (20 mL) and DCM (200 mL), stirred for another 20 min, filtered and washed with DCM (30 mL). The filter cake was collected and dried in an high vacuum oven to afford intermediate A1 (12.72 g). MS: 161 [M−Na+2H]⁺.

The following compounds were synthesized using the above procedure with the corresponding starting materials.

Intermediate A2

To a −80° C. solution of 2,6-dibromonaphthalene (994 mg, 3.48 mmol) in THF (20 mL) under nitrogen atmosphere was added n-BuLi (2.5 M, 1.60 mL, 4.00 mmol) dropwise. The resulting mixture was stirred for 50 min at −80° C. Then triisopropyl borate (789 mg, 4.20 mmol) was added and the resulting mixture was allowed to warm to RT and stirred for 16 h. Hydrochloric acid (1 M, 10.00 mL) was added and stirred for 1 h. The reaction mixture was diluted with brine. The layers were separated and the organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give intermediate A2 (922 mg) as an off—white solid.

The following compound was synthesized using the above procedure with 2-bromo-5-chlorothiophene.

Intermediate B1

To a 0° C. mixture of 3-bromo-6-chloropyrazin-2-amine (511 mg, 2.45 mmol) in DMF (5 mL) under nitrogen atmosphere was added NaH (60%, 153 mg, 3.83 mmol). The resulting mixture was allowed to warm to RT and stirred for 30 min. Then CH₃I (453 mg, 3.19 mmol) was added and the resulting mixture was stirred for 1 h at RT. The reaction mixture was quenched with brine (50 mL) and extracted with EA (80 mL). The organic layer was washed with brine (3×50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give intermediate B1 (503 mg) as a brown solid which was used in next step without further purification. MS: 222 [M+1]⁺.

The following compounds were synthesized using with corresponding starting materials.

Intermediate B2

A mixture of 6-chloropyridin-2(1H)-one (5.03 g, 38.83 mmol), CH₃I (8.49 g, 66.86 mmol), K₂CO₃ (8.99 g, 65.05 mmol) and EtOH (25 mL) in a sealed tube was stirred for 17 h at 70° C. After cooling to RT, the reaction mixture was poured into water (200 mL) and extracted with EA (2 A 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound B2-1 (4.35 g) as a yellow solid. MS: 144 [M+1]⁺. Following procedures of WO 2007146824, intermediate B2 was prepared from compound B2-1.

Intermediate C1

To a −70° C. solution of 1-(tert-butyl) 4-ethyl piperidine-1,4-dicarboxylate (26.02 g, 101.18 mmol) in THF (100 mL) under nitrogen atmosphere was added LDA (2 M, 65.00 mL, 130.00 mmol) dropwise. The resulting mixture was stirred for 1 h at -70° C. Then (bromomethyl)benzene (17.98 g, 105.12 mmol) was added and the resulting mixture was stirred for 30 min. The reaction mixture was quenched by the addition of brine (100 mL) dropwise. The layers were separated and the organic layer was washed with brine (1×80 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound C1-1 (38.05 g, crude) as a yellow oil. MS: 348 [M+1]⁺.

A mixture of compound C1-1 (38.05 g, 0.11 mol) and PPA (50.00 g) was stirred for 1.5 hat 130° C. After cooling to RT, the reaction mixture was poured into ice/water and the pH value of the resulting mixture was adjusted to 9 with NaOH. (Boc)₂O (40.12 g, 0.18 mol) was added and the resulting mixture was stirred for 16 h at RT. The reaction mixture was extracted with EA (3×150 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:10, v/v) to give compound C1-2 (10.00 g). MS: 302 [M+1]⁺.

A mixture of compound C1-2 (10.00 g, 0.033 mol) and (R)-(+)-2-methyl-2-propanesulfinamide (8.33 g, 0.069 mol) in Ti(OEt)₄ (50 mL) was stirred for 2 h at 120° C. The reaction mixture was poured into water (100 mL) and diluted with EA (300 mL). The resulting mixture was filtered through a pad of Celite, the filtrate was separated and the organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound C_1-3 (18.49 g, crude) as a yellow oil. MS: 405 [M+1]⁺.

To a −50° C. solution of compound C_1-3 (18.49 g, 0.046 mol) in THF (100 mL) was added BH₃ /THF (1 M, 125.00 mL, 0.13 mol) dropwise. The resulting mixture was allowed to warm to RT and stirred for 16 h. The reaction mixture was quenched by the addition of brine dropwise. The layers were separated and the organic layer was washed with brine (1×100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:2, v/v) to give compound C1-4 (8.06 g) as a yellow oil. MS: 407 [M+1]⁺.

A mixture of compound C1-4 (8.06 g, 0.020 mol) and HCl/EA (4 M, 20.00 mL, 80.00 mmol) in DCM (120 mL) was stirred for 1 h at RT. Another portion of HCl/EA (4 M, 10.00 mL, 40.00 mmol) was added and stirred for 1.5 h at RT. The reaction mixture was filtered followed by EA (50 mL) wash. The filter cake was collected, dried under high vacuum to give intermediate C1 (4.57 g) as a white solid. MS: 203 [M+1]⁺.

The following compounds were synthesized using the above procedure or modified procedure with the corresponding starting materials.

Intermediate C2

A solution of 2,2′-azanediylbis(ethan-l-ol) (198.15 g, 1.88 mol), K₂CO₃ (520.95 g, 3.77 mol) and (bromomethyl)benzene (386.79 g, 2.26 mol) in acetonitrile (2000 mL) was stirred at 90° C. for 2.5 h. After cooling to RT, the reaction mixture was filtered followed by EA (2×100mL) wash. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:10, v/v) to give compound C2-1 (89.44 g) as a colorless oil. MS: 196 [M+H]⁺.

To a 0° C. solution of compound C2-1 (30.66 g, 0.16 mol) in toluene (300 mL) was added tribromophosphane (69.13 g, 0.26 mol) dropwise. The resulting mixture was stirred at 105° C. for 16 h. After cooling to RT, the volatiles were removed under reduce pressure. The residue was diluted with water (300 mL), and the pH value was adjusted to 9 with NaOH. The resulting mixture was extracted with EA (3×150 mL), the organic layers combined, dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentrated under reduced pressure to give compound C2-2 (41.58 g) which was used in next step without any further purification. MS: 320 [M+H]⁺.

To a 0° C. solution of compound C2-2 (1.70 g, 12.77 mmol) in DMF (20 mL) under nitrogen atmosphere was added NaH (60% dispersion in mineral oil, 982 mg, 24.55 mmol) in three portions, and the mixture was heated to 60° C., stirred for 1 h at this temperature. Then N-benzyl-2-bromo-N-(2-bromoethypethan-l-amine (4.54 g, 14.14 mmol) was added and stirred at 60° C. for another 1 h. After cooling to RT, the reaction mixture was quenched with water (80 mL), extracted with EA (3×80 mL). The combined organic layers were washed with water (3×80 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA) to give compound C2-3 (1.14 g). MS: 293 [M+H]⁺.

To a 0° C. solution of compound C2-3 (1.05 g, 3.59 mmol) in DCE (10 mL) was added 1-chloroethyl carbonochloridate (903 mg, 6.32 mmol) dropwise. The resulting mixture was stirred at RT for 1.5 h. The volatiles were removed under reduced pressure and the residue was dissolved in MeOH (20 mL), stirred at 80° C. for 4 h. The volatiles were removed under reduced pressure and dissolved in DCM (20 mL). DIPEA (1.33 g, 10.32 mmol) and (Boc)₂O (1.38 g, 6.32 mmol) were added. The resulting solution was stirred for 16 h at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:1, v/v) to give compound C2-4 (438 mg). MS: 303 [M+H]⁺.

Intermediate C2 was synthesized in the manner similar to intermediate C1, except compound C1-2 was replaced with compound C2-4.

Intermediate C3

To a -78° C. solution of 1-(tert-butyl) 4-ethyl piperidine-1,4-dicarboxylate (2.83 g, 11.00 mmol) in THF (50 mL) was added LDA (2 M, 6.00 mL, 12.00 mmol) dropwise under nitrogen atmosphere. The resulting mixture was stirred for 1 h at this temperature. Then 2-chloro-5-(chloromethyl)thiazole (in 3 mL THF, 1.69 g, 10.06 mmol) was added dropwise and stirred for 1 h. The reaction mixture was quenched with brine (50 mL), extracted with EA (2×30 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:20, v/v) to give compound C3-1 (1.15 g). MS: 389 [M+H]⁺.

To a −78° C. solution of compound C3-1 (900 mg, 2.31 mmol) in THF (50 mL) was added LDA (2 M, 3.00 mL, 6.00 mmol) dropwise under nitrogen atmosphere. The resulting mixture was stirred for 30 min at this temperature, and quenched with brine (30 mL). The resulting mixture was extracted with EA (2×30 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound C3-2 (832 mg). MS: 343 [M+1]⁺.

Compound C3-4 was synthesized in the manner similar to intermediate C1-4, except compound C1-2 was replaced with compound C3-2.

A suspension of compound C3-4 (2.50 g, 5.58 mmol), TEA (2 mL) and Pd/C (10%, 690 mg) in MeOH (50 mL) was stirred for 24 h at 40° C. under hydrogen atmosphere. The resulting mixture was filtered, and an additional portion of Pd/C (10%, 1.32 g) was added to the filtration. The resulting mixture was stirred for another 16 h at 50° C. under hydrogen atmosphere. The resulting mixture was filtered, the filtration was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:1, v/v) to give intermediate C3 (1.28 g). MS: 414 [M+H]⁺.

Intermediate C4

To a −30° C. solution of compound C1-4 (695 mg, 1.71 mmol) in DMF (6 mL) was added LiHMDS (1 M, 2.10 mL, 2.10 mmol) dropwise. The resulting mixture was stirred for 1.5 h at this temperature. Then CH₃I (496 mg, 3.49 mmol) was added dropwise. The resulting mixture was allowed to warm to RT and stirred for 2 h. The reaction mixture was quenched with water and extracted with EA. The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (EA:Hex=2:5, v/v) to give compound C4-1 (232 mg) as a yellow solid. MS: 421 [M+1]⁺.

A mixture of compound C4-1 (232 mg, 0.55 mmol) and HCl/EA (4 M, 2.00 mL, 8.00 mmol) in EA (5 mL) was stirred for 1.5 h at RT. The reaction mixture was filtered. The filter cake was collected, dried under high vacuum to give intermediate C4 (50 mg) as a white solid. MS: 217 [M+1]⁺.

Following procedures of WO2018172984, the following intermediates were prepared with corresponding starting materials.

Intermediate C5

To a solution of 2,3-dibromopyridine (47.38 g, 0.20 mol) in THF (300 ml) was added isopropylmagnesium chloride (2 M solution in THF, 110 mL) dropwise at RT under nitrogen atmosphere. The reaction mixture was stirred for 1.5 h, and C5-1 (46.93 g in 130 mL THF, 0.22 mol) was added at RT. The reaction mixture was stirred for 1 h and quenched with brine (300 mL), and then the mixture was filtered. The filtrate was separated and the organic layer was collected. The aqueous layer was extracted with EA (1×200 mL).The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give C5-2 (87.67 g) which was used without any further purification. MS: 371 (M+H)⁺.

To a solution of C5-2 (64.77 g, 17.45 mmol) in DCM (500 mL) was added Dess-Martin (90.12 g, 21.25 mmol) below 30° C. The resulting mixture was stirred for 4 h, and then saturated sodium bicarbonate solution (500 mL) and saturated sodium carbonate solution (300 mL) were added. The organic layer was collected and washed with brine (500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was added to the solution of EA (60 mL) and Hex (300 mL) and stirred for 27 h. The mixture was filtered, and the filter cake was collected to give C5-3 (30.57 g) as an off-white solid. MS: 369 (M+H) +.

To a −30° C. solution of C5-3 (10.16 g, 27.52 mmol) in THF (80 mL) were added LiHMDS (1 M solution in THF, 31.00 mL) and CD₃I under nitrogen atmosphere. The resulting mixture was allowed to warm to RT and stirred for 20 h. The reaction mixture was quenched with brine (80 mL), and the organic layer was collected. The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica chromatography (eluting with EA:Hex=1:5, v/v) to give C5-4 (8.40 g). MS: 386 (M+H)⁺.

A mixture of C5-4 (8.40 g, 21.74 mmol), Cs₂CO₃ (7.04 g, 21.61 mmol), pivalic_.ucid (672 mg, 6.58 mmol), Pd(OAc)₂ (248 mg, 1.10 mmol) and Cy₃PHBF₄ (809 mg, 2.20 mmol) in 1,3,5-mesitylene (40 mL) was stirred for 16 h at 140° C. under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica chromatography (eluting with EA:Hex=1:1, v/v) to give C5-5 (3.80 g). MS:305 (M+H) +.

A mixture of C5-5 (3.80 g, 12.48 mmol) and (R)-(+)-2-Methyl-2-propanesulfinamide (3.03 g, 25.00 mmol) in Ti(OEt)₄ (38 mL) was stirred for 2 h at 100° C. After cooling to RT, the reaction mixture was diluted with EA (200 mL) and water (40 mL). The resulting mixture was filtered through a pad of Celite followed by EA (40 mL) wash. The organic layer was separated, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give C5-6 (5.50 g). MS: 408 (M+H) +.

To a −40° C. solution of C5-6 (5.40 g, 13.25 mmol) in THF (50 mL) was added BH₃ (1 M solution in THF, 40.00 mL). The resulting mixture was allowed to warm to RT and stirred for 3 h. The reaction mixture was quenched with MeOH (150 mL) and stirred at 80° C. for 20 h. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica chromatography (eluting with EA:Hex=1:1, v/v) to give C5-7 (3.78 g). MS: 410 (M+H) +.

To solution of C5-7 (3.70 g, 9.03 mmol) in EA (40 mL) was added HCl (4 M solution in EA, 15 mL), and stirred at RT for 17 h. The resulting mixture was filtered followed by EA (10 *2 mL) wash, and then the filter cake was concentrated under reduced pressure to give C5 (3.30 g) as a white solid. MS: 206 (M+H)⁺.

Examnle 1

A solution of propane-1,2-diamine (11.00 mL, 129.11 mmol) in EtOH (220 mL) was cooled to 0° C. Diethyl 2-oxomalonate (20.00 mL, 131.15 mmol) was added to the solution dropwise. Then the cooling bath was removed. The solution was allowed to warmed to RT and stirred for 1 h. The clear solution had become a thick mixture. The mixture was warmed to reflux temperature and stirred for 24 h. After cooling to RT, the reaction mixture was concentrated under reduced pressure to give compound 1-1 (27.12 g, crude) as a solid. MS: 183 [M+1]⁺.

To a 0° C. solution of compound 1-1 (27.12 g, crude) in DMF (100 mL) under nitrogen atmosphere was added NBS (21.30 g, 0.12 mol). The resulting mixture was allowed to warm to RT and stirred for 2 h. The reaction mixture was diluted with brine (100 mL) and EA (400 mL). The organic layer was separated, washed with water (2×100 mL) and brine (3×100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:100, v/v) to give compound 1-2 (7.75 g) as a yellow solid. MS: 261 [M+1]⁺. ¹HNMR (400 MHz, DMSO-d₆) δ12.72 (brs, 1H), 4.29 (q, J=7.1 Hz, 2H), 2.44 (s, 3H), 1.28 (t, J=7.1 Hz, 1H).

To a solution of PPh₃ (31.03 g, 80.18 mmol) in 1,4-dioxane (280 mL) was added NCS (10.77 g, 80.66 mmol). The resulting mixture was stirred for 30 min at RT. Compound 1-2 (6.96 g, 26.66 mmol) was added, the resulting mixture was warmed to 100° C. and stirred for 1 h. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:5, v/v) to give compound 1-3 (6.66 g) as a yellow oil. MS: 279 [M+1]⁺.

A mixture of compound 1-3 (1.19 g, 4.26 mmol), (2,3-dichlorophenyl)boronic acid (1.21 g, 6.34 K₂CO₃ (2.42 g, 17.51 mmol), Pd(dppf)Cl₂.CH₂Cl₂ (0.44 g, 0.54 mmol) in CH₃CN/H₂O (15 mL/1 mL) was stirred for 2.5 h at 100° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with EA (50 mL) and washed with brine (2×50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:30, v/v) to give compound 1-4 (0.67 g). MS: 345 [M+1]⁺.

A mixture of compound 1-4 (0.67 g, 1.94 mmol), intermediate Cl (0.64 g, 2.33 mmol) and K₂CO₃ (2.70 g, 19.54 mmol) in CH₃CN (15 mL) was stirred for 24 h at 100° C. After cooling to RT, the reaction mixture was diluted with EA (60 mL) and water (100 mL). The organic layer was separated, the aqueous layer was extracted with EA (1×50 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:50, v/v) to give example 1 (468 mg) as a yellow solid. MS: 511 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ7.65 (dd, J=7.9, 1.6 Hz, 1H), 7.47-7.34 (m, 3H), 7.29-7.14 (m, 3H), 4.40 (q, J=7.1 Hz, 2H), 4.02-3.91 (m, 3H), 3.41-3.37 (m, 1H), 3.32-3.30 (m, 1H), 3.19-3.15 (m, 1H), 2.85-2.81 (m, 1H), 2.27 (s, 3H), 1.94-1.82 (m, 2H), 1.62-1.55 (m, 1H), 1.46 (m, 1H), 1.39 (t, J=7.1 Hz, 3H).

The following example was synthesized using the above procedure or modified procedure with the corresponding starting materials.

Ex No.	Chemical Name	Structure	MS & 1HNMR
2	(S)-1′-(5-(2,3- dichlorophenyl)-6- methylpyrazin-2-yl)-5,7- dihydrospiro[cyclo- penta[b]pyridine-6,4′- piperidin]-5-amine		MS: 440 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.34 (d, J = 4.6 Hz, 1H), 8.05 (s, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.61 (dd, J = 8.0, 1.5 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.32-7.25 (m, 2H), 4.38-4.33 (m, 2H), 4.03 (s, 1H), 3.29-3.22 (m, 3H), 2.96-2.90 (m, 1H), 2.19 (s, 3H), 1.96- 1.80 (m, 2H), 1.68-1.62 (m, 1H), 1.46-
			1.39 (m, 1H).

Example 3

A mixture of example 1 (302 mg, 0.59 mmol) and LiOH (81 mg, 3.38 mmol) in MeOH/H₂(20 mL/3 mL) was stirred for 4 h at 60° C. After cooling to RT, MeOH was removed under reduced pressure. The residue was dissolved in brine (50 mL), extracted with EA (3×40 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give example 3 (258 mg) as a light yellow solid. MS: 483 [M+1]⁺.

Example 4

A solution of example 3 (60 mg, 0.12 mmol), (Boc)₂O (0.50 mL, 2.18 mmol) and DIPEA (1.00 mL, 6.05 mmol) in DCM was stirred for 1 h at 40° C. The reaction solution was concentrated under reduced pressure to give compound 4-1 (0.39 g, crude), which was used in next step without further purification. MS: 583 [M+1]⁺.

A solution of compound 4-1 (0.39 g, crude), NH₄Cl (466 mg, 8.71 mmol), PyBOP (194 mg, 0.37 mmol) and DIPEA (0.50 mL, 3.03 mmol) in NMP (8 mL) was stirred for 2 h at 80° C. The reaction solution was diluted with EA (40 mL) and washed with brine (3×30 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 4-2 (0.37 g, crude) as a yellow oil, which was used in next step without further purification. MS: 582 [M+1]⁺.

A mixture of compound 4-2 (0.37 g, crude) and HCl/EA (4 M, 3.00 mL, 12.00 mmol) in DCM (20 mL) was stirred for 2.5 h at RT. The reaction mixture was diluted with brine (50 mL) and the pH value was taken to 9 with NH₃H₂O (25%). The resulting mixture was extracted with DCM (1×50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:10, v/v) to give example 4 (9 mg) as a light yellow solid. MS: 482 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ7.66 (d, J=9.4 Hz, 1H), 7.52 (d, J=7.3 Hz, 1H), 7.48-7.29 (m, 5H), 4.39 (s, 1H), 4.13-4.00 (m, 2H), 3.39-3.35 (m, 1H), 3.31-3.28 (m, 1H), 3.24-3.12 (m, 2H), 2.29 (s, 3H), 2.03-1.88 (m, 2H), 1.73-1.62 (m, 2H).

Example 5

A mixture of intermediate A1 (504 mg, 2.76 mmol), compound 1-3 (769 mg, 2.75 mmol), Pd₂(dba)₃ (127 mg, 0.14 mmol), XantPhos (144 mg, 0.25 mmol) and DIPEA (1.10 g, 8.51 mmol) in 1,4-dioxane (20 mL) was stirred for 3 h at 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was quenched with brine (100 mL), extracted with EA (1×60 mL), the organic layer dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:2, v/v) to give compound 5-1 (489 mg) as a yellow solid. MS: 359 [M+1]⁺.

Example 5 was synthesized in the manner similar to example 1, except compound 1-4 was replaced with compound 5-1. MS: 525 1M+11⁺. ¹HNMR (400 MHz, methanol-d₄) δ7.63 (d, J=5.5 Hz, 1H), 7.47-7.34 (m, 1H), 7.26-7.19 (m, 3H), 5.91 (d, J=5.5 Hz, 1H), 4.40 (q, J=7.1 Hz, 2H), 4.06-3.98 (m, 2H), 3.97 (s, 1H), 3.43-3.35 (m, 2H), 3.18-3.14 (m, 1H), 2.85-2.81 (m, 1H), 2.49 (s, 3H), 1.96-1.76 (m, 2H), 1.64-1.57 (m, 1H), 1.48-1.42 (m, 1H), 1.39 (t, J=8.0 Hz, 3H).

The following examples were synthesized using the above procedure or modified procedure with the corresponding starting materials.

EX
No	Chemical Name	Structure	MS & 1HNMR
6	(S)-1′-(5-((2-amino- 3-chloropyridin-4- yl)thio)-6-methyl- pyrazin-2-yl)-1,3-di- hydrospiro[indene-2,4′- piperidin]-1-amine		MS: 453 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.16 (s, 1H), 7.60- 7.32 (m, 5H), 5.80 (s, 1H), 4.46-4.25 (m, 3H), 3.46-3.35 (m, 2H), 3.23- 3.08 (m, 2H), 2.45 (s, 3H), 1.89-1.57 (m, 4H).
7	(S)-1′-(6-amino-5- ((2,3-dichlorophenyl) thio)pyrazin-2-yl)- 5,7-dihydrospiro [cyclopenta[b]pyridine- 6,4′-piperidin]-5- amine		MS: 473 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.36 (d, J = 4.7 Hz, 1H), 7.84 (d, J = 7.4 Hz, 1H), 7.62 (s, 1H), 7.37-7.22 (m, 2H), 7.13 (t, J = 8.0 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 4.33 (d, J = 13.4 Hz, 2H), 4.05 (s, 1H), 3.29-3.17 (m, 3H), 2.94 (d, J = 16.5 Hz, 1H), 1.98-1.75 (m, 2H), 1.70- 1.57 (m, 1H), 1.48-1.37 (m, 1H).
8	(S)-1′-(4-amino-5- ((2-amino-3-chloro- pyridin-4-yl)thio) pyrimidin-2-yl)-5,7-di- hydrospiro[cyclopenta [b]pyridine-6,4′- piperidin]-5-amine		MS: 455 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.41 (d, J = 4.4 Hz, 1H), 7.96 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 5.5 Hz, 1H), 7.31 (dd, J = 7.6, 5.2 Hz, 1H), 6.03 (d, J = 5.5 Hz, 1H), 4.62 (t, J = 13.3 Hz, 2H), 4.19 (s, 1H), 3.24 (m, 3H), 3.09-2.95 (m, 1H), 1.92-1.63 (m, 2H), 1.63- 1.42 (m, 2H).
9	(S)-1′-(5-((2-amino- 3-chloropyridin-4- yl)thio)pyridin-2-yl)- 5,7-dihydrospiro [cyclopenta[b]pyridine- 6,4′-piperidin]-5- amine		MS: 439 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.38 (d, J = 4.5 Hz, 1H), 8.21 (s, 1H), 7.87 (d, J = 7.5 Hz, 1H), 7.72-7.55 (m, 2H), 7.38-7.26 (m, 1H), 6.97 (d, J = 9.0 Hz, 1H), 5.92 (d, J = 5.5 Hz, 1H), 4.43-4.26 (m, 2H), 4.10 (s, 1H), 3.32-3.19 (m, 3H), 3.03-2.91 (m, 1H), 1.98-1.79 (m, 2H), 1.70-1.60 (m, 1H), 1.54-1.44
			(m, 1H).
10	(S)-1′-(5-((2-amino- 3-chloropyridin-4- yl)thio)-6-(methyl- amino)pyrazin-2-yl)- 5,7-dihydrospiro [cyclopenta[b]pyridine- 6,4′-piperidin]-5- amine		MS: 469 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.36 (d, J = 4.3 Hz, 1H), 7.83 (d, J = 10.6 Hz, 1H), 7.73- 7.71,7.51-7.49 (m, 1H), 7.59 (dd, J = 9.9, 4.4 Hz, 1H), 7.29 (dd, J = 7.4, 5.2 Hz, 1H), 5.89-5.84 (m, 1H), 4.45- 4.13 (m, 2H), 4.06 (s, 1H), 3.31-3.13 (m, 3H), 3.07 (s, 1H), 2.88 (s, 3H), 2.00-1.77 (m, 2H), 1.67-1.63 (m, 1H), 1.47-1.43 (m, 1H).
11	(S)-1′-(5-((2-amino- 3-chloropyridin-4- yl)thio)-6-(dimethyl- amino)pyrazin-2-yl)- 5,7-dihydrospiro [cyclopenta[b]pyri- dine-6,4′-piperidin]- 5-amine		MS: 483 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.36 (d, J = 4.5 Hz, 1H), 7.85 (d, J = 7.5 Hz, 1H), 7.72- 7.50 (m, 1H), 7.64-7.57 (m, 1H), 7.29 (dd, J = 7.5, 5.2 Hz, 1H), 5.89- 5.84 (m, 1H), 4.36 (t, J = 15.0 Hz, 2H), 4.07 (s, 1H), 3.31-3.16 (m, 3H), 3.10 (s, 3H), 3.06 (s, 1H), 2.88 (s, 3H), 1.98-1.77 (m, 2H), 1.71-1.57 (m, 1H), 1.71-1.44 (m, 1H).
12	(S)-1′-(6-amino-5- (thiazol-4-ylthio)pyr- azin-2-yl)-5,7-dihy- drospiro[cyclopenta [b]pyridine-6,4′-pi- peridin]-5-amine		MS: 412 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 9.00 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 4.3 Hz, 1H), 7.94 (d, J = 7.5 Hz, 1H), 7.53 (s, 1H), 7.40- 7.34 (m, 1H), 7.20 (d, J = 2.0 Hz, 1H), 4.40-4.23 (m, 3H), 3.28-3.06 (m, 4H), 1.90-1.79 (m, 2H), 1.68-1.56 (m, 2H).
13	(S)-1′-(6-amino-5- (thiazol-2-ylthio)pyr- azin-2-yl)-5,7-di- hydrospiro[cyclopenta [b]pyridine-6,4′-pi- peridin]-5-amine		MS: 412 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.41 (d, J = 4.7 Hz, 1H), 7.89 (d, J = 7.6 Hz, 1H), 7.67 (d, J = 3.4 Hz, 1H), 7.60 (s, 1H), 7.45 (d, J = 3.4 Hz, 1H), 7.32 (dd, J = 7.5, 5.2 Hz, 1H), 4.45-4.29 (m, 2H), 4.17 (s, 1H), 3.31-3.20 (m, 3H), 3.08-2.96 (m, 1H), 1.97-1.78 (m, 2H), 1.70- 1.59 (m, 1H), 1.55-1.44 (m, 1H).
14	(S)-1′-(6-amino-5- (quinolin-3-ylthio) pyrazin-2-yl)-5,7-di- hydrospiro[cyclopenta [b]pyridine-6,4′- piperidin]-5-amine		MS: 456 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.69 (d, J = 2.1 Hz, 1H), 8.42 (d, J = 4.6 Hz, 1H), 8.09 (d, J = 1.6 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 7.5 Hz, 1H), 7.84 (d, J = 8.1 Hz, 1H), 7.74 (t, J = 7.2 Hz, 1H), 7.62 (t, J = 7.1 Hz, 2H), 7.33 (dd, J = 7.4, 5.2 Hz, 1H), 4.34 (t, J = 11.8 Hz, 2H), 4.17 (s, 1H), 3.30-3.19 (m, 3H), 3.08-2.95 (m, 1H), 1.92-1.82 (m, 2H) , 1.64 (d, J = 12.5 Hz, 1H),
			1.51 (d, J = 12.2 Hz, 1H).
15	(S)-5-amino-1′-(5- ((2-amino-3-chloro- pyridin-4-yl)thio)pyr- idin-2-yl)-5,7-di- hydrospiro[cyclopenta [b]pyridine-6,4′-pi- peridine]-3-carboni- trile		MS: 464 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.20 (d, J = 2.3 Hz, 1H), 7.74 (s, 1H), 7.67-7.56 (m, 2H), 7.45 (d, J = 7.8 Hz, 1H), 6.96 (d, J = 9.0 Hz, 1H), 5.91 (d, J = 5.6 Hz, 1H), 4.37-4.27 (m, 2H), 4.07 (s, 1H), 3.29- 3.19 (m, 3H), 2.98-2.93 (m, 1H), 1.95-1.85 (m, 2H), 1.79-1.74 (m, 1H), 1.63-1.60 (m, 1H).
16	(S)-1′-(5-((2-amino- 3-chloropyridin-4- yl)thio)pyrazin-2-yl)- N-methyl-1,3-di- hydrospiro[indene- 2,4′-piperidin]-1- amine		MS: 453 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.36 (s, 1H), 8.31 (s, 1H), 7.63 (d, J = 5.6 Hz, 1H), 7.46 (d, J = 7.3 Hz, 1H), 7.38-7.21 (m, 3H), 5.96 (d, J = 5.6 Hz, 1H), 4.37-4.27 (m, 1H), 4.25-4.16 (m, 1H), 3.86 (s, 1H), 3.53-3.39 (m, 2H), 3.09 (dd, J = 38.1, 15.9 Hz, 2H), 2.56 (s, 3H), 2.00-
			1.92 (m, 1H),1.60-1.51 (m, 2H),
			1.37-1.29 (m, 1H).
17	(S)-1′-(5-((3,5-dichloro- pyridin-4-yl)thio) pyrazin-2-yl)-5,6, 7-trifluoro-1,3-di- hydrospiro[indene-2, 4′-piperidin]-1-amine		MS: 512 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.54 (s, 2H), 8.19- 8.05 (m, 2H), 7.06-6.97 (m, 1H), 4.33-3.97 (m, 3H), 3.46-3.34 (m, 2H), 3.09 (d, J = 16.3 Hz, 1H), 2.90 (d, J = 16.2 Hz, 1H), 1.95-1.84 (m, 1H), 1.76-1.60 (m, 2H), 1.59-1.46 (m, 1H).
18	(S)-1-amino-1′-(2- ((2-cyanopyridin-3- yl)thio)pyrimidin-5- yl)-1,3-dihydrospiro [indene-2,4′-piper- idine]-4-carbonitrile		MS: 440 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.52 (s, 2H), 7.87- 7.82 (m, 2H), 7.80-7.76 (m, 2H), 7.56-7.52 (m, 2H), 3.91-3.68 (m, 3H), 3.28-3.08 (m, 4H), 1.86-1.78 (m, 2H), 1.76-1.63 (m, 2H).
19	(S)-1′-(5-((3-chloro- 2-methoxypyridin- 4-yl)thio)pyrazin-2- yl)-6-(methylthio)- 1,3-dihydrospiro [indene-2,4′-piperidin]- 1-amine		MS: 500 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.30 (s, 1H), 8.26 (s, 1H), 7.50 (s, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 6.85 (s, 1H), 4.43 (d, J = 13.8 Hz, 1H), 4.31 (d, J = 13.9 Hz, 1H), 4.13 (s, 1H), 3.28- 3.21 (m, 1H), 3.11 (dd, J = 33.5, 15.9 Hz, 3H), 2.60 (s, 3H), 1.94-1.74
			(m, 4H), 1.40 (s, 9H).
20	(S)-1-(5-((5-(4-amino- 2-(tert-butyl)-4, 6-dihydrospiro[cyclo- penta[b]thiophene- 5,4′-piperidin]-1′- yl)pyrazin-2-yl)thio)- 2-chlorophenyl) ethan-1-onez		MS: 527 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.30 (s, 1H), 8.26 (s, 1H), 7.50 (s, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 6.85 (s, 1H), 4.43 (d, J = 13.8 Hz, 1H), 4.31 (d, J = 13.9 Hz, 1H), 4.13 (s, 1H), 3.28- 3.21 (m, 1H), 3.20-3.01 (m, 3H), 2.60 (s, 3H), 1.94-1.74 (m, 4H), 1.45- 1.36 (s, 9H).
21	(S)-1′-(5-((3-chloro- 2-(isopropylamino) pyridin-4-yl)thio) pyrazin-2-yl)-6-(methyl- sulfonyl)-1,3-di- hydrospiro[indene- 2,4′-piperidin]-1- amine		MS: 559 [M + 1]+. 1HNMR (400 MHz, methanol-d4) δ 8.37 (s, 1H), 8.31 (s, 1H), 8.02 (s, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.81-7.74 (m, 1H), 7.71 (d, J = 5.5 Hz, 1H), 7.65 (d, J = 5.7 Hz, 1H), 7.54 (d, J = 7.9 Hz, 1H), 5.91 (d, J = 5.5 Hz, 1H), 4.28-4.18 (m, 1H), 4.13 (s, 1H), 3.66-3.56 (m, 5H), 3.40-
			3.37 (m, 1H), 3.15 (s, 3H), 1.88-1.82
			(m, 2H), 1.72-1.67 (m, 2H), 1.27 (d,
			J = 6.5 Hz, 6H).
22	(S)-1′-(5-((2-amino- 3-chloropyridin-4- yl)thio)pyrazin-2-yl)- 5,7-dihydrospiro [cyclopenta[b]pyri- dine-6,4′-piperidin]- 7,7-d2-5-amine		MS: 442 [M + 1]+. 1HNMR (400 MHz, DMSO-d6) δ 8.49 (s, 1H), 8.35 (d, 1H), 8.29 (s, 1H), 7.70 (d, 1H), 7.67 (d, 1H), 7.20 (dd, 1H), 6.34 (s, 2H), 5.83 (d, 1H), 4.31 (d, 2H), 3.98 (s, 1H), 3.30-3.20 (m, 2H), 3.15 (s, 2H), 1.85-1.67 (m, 2H), 1.57 (d, 1H), 1.22 (d, 1H).

Example 23

To a 0° C. solution of example 1 (132 mg, 0.26 mmol) in THF (8 mL) under nitrogen atmosphere was added LiBH₄ (2M/THF, 0.30 mL, 0.60 mmol). The resulting mixture was stirred for 16 h at 70° C. After cooling to RT, the reaction mixture was quenched with brine (50 mL), extracted with EA (3×40 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:16, v/v) to give example 23 (11 mg). MS: 469 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ7.63 (dd, J=7.9, 1.3 Hz, 1H), 7.50-7.39 (m, 2H), 7.37-7.24 (m, 4H), 4.69 (s, 2H), 4.29 (s, 1H), 3.80-3.58 (m, 2H), 3.26-2.96 (m, 4H), 2.26 (s, 3H), 3.01-1.89 (m, 2H), 1.74-1.59 (m, 2H).

The following example was synthesized using the above procedure or modified procedure with the corresponding starting materials.

EX No	Chemical Name	Structure	MS & 1HNMR
24	(S)-(3-(1-amino-1,3- dihydrospiro[indene-2,4′- piperidin]-1′-yl)-6-((2- amino-3-chloropyridin-4-yl) thio)-5-methylpyrazin-2- yl)methanol		MS: 483 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 7.62 (d, J = 5.5 Hz, 1H), 7.54- 7.50 (m, 1H), 7.39-7.36 (m, 3H), 5.93 (d, J = 5.5 Hz, 1H), 4.68 (s, 2H), 4.38 (s, 1H), 4.14- 3.85 (m, 4H), 3.21-3.14 (m, 2H), 2.51 (s, 3H), 1.76-1.72 (m, 2H), 1.64-1.57 (m, 2H).

Example 25

To a 0° C. solution of example 2 (0.57 g, 1.29 mmol) in DCM (20 mL) was added NBS (0.35 g, 1.97 mmol). The resulting mixture was stirred for 4 h at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:30, v/v) to give example 25 (451 mg). MS: 518 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.34 (d, J=4.5 Hz, 1H), 7.84 (d, J=7.6 Hz, 1H), 7.65 (dd, J=8.0, 1.5 Hz, 1H), 7.42 (t, J=7.8 Hz, 1H), 7.36-7.32 (m, 1H), 7.29-7.25 (m, 1H), 4.09-4.07 (m, 1H), 3.97-3.92 (m, 2H), 3.25-3.16 (m, 3H), 2.95-2.89 (m, 1H), 2.68 (s, 3H), 2.03-1.99 (m, 2H), 1.70-1.65 (m, 1H), 1.51-1.47 (m, 1H).

Example 26 & Example 27

A mixture of example 25 (155 mg, 0.30 mmol), K₄Fe(CN)₆.3H₂O (156 mg, 0.37 mmol), DBU (242 mg, 1.59 mmol) and Pd(PPh₃)₄ (39 mg, 0.034 mmol) in t-BuOH/H₂O (6 mL/6 mL) was stirred for 3.5 h at 100° C. under nitrogen atmosphere. After cooling to RT, the resulting mixture was quenched with brine (50 mL) and extracted with EA (2×30 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:8, v/v) to give example 26 (19 mg) and example 27 (25 mg).

Example 26: MS: 465 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.39 (d, J=4.7 Hz, 1H), 7.87 (d, J=7.6 Hz, 1H), 7.66 (dd, J=8.0, 1.4 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H), 7.35 (dd, J=7.6, 1.4 Hz, 1H), 7.32-7.28 (m, 1H), 4.55-4.49 (m, 2H), 4.18 (s, 1H), 3.52-3.43 (m, 2H), 3.26-3.24 (m, 1H), 3.04-2.99 (m, 1H), 2.29 (s, 3H), 2.03-1.91 (m, 2H), 1.76-1.66 (m, 1H), 1.60-1.54 (m, 1H).

Example 27: MS: 483 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.42 (d, J=4.5 Hz, 1H), 7.89 (d, J=7.6 Hz, 1H), 7.62 (dd, J=7.3, 2.3 Hz, 1H), 7.47-7.37 (m, 2H), 7.32 (dd, J=7.5, 5.2 Hz, 1H), 4.24 (s, 1H), 4.13-3.97 (m, 2H), 3.39-3.33 (m, 1H), 3.29-3.20 (m, 2H), 3.09-2.99 (m, 1H), 2.26 (s, 3H), 2.02-1.87 (m, 2H), 1.66-1.50 (m, 2H).

Example 28

A mixture of example 25 (64 mg, 0.12 mmol) and HCl/EA (4 M, 4 mL) was stirred for 1 h at RT. The reaction mixture was filtered followed by EA wash. The solid was dissolved in EA (20 mL) and washed with NH₃H₂O (10%, 20 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure and dried under high vacuum for 2 h to give example 28 (17 mg) as a yellow solid. MS: 456 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.37 (d, J=4.7 Hz, 1H), 7.87 (d, J=7.5 Hz, 1H), 7.67 (dd, J=8.0, 1.4 Hz, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.38-7.34 (m, 1H), 7.32-7.28 (m, 1H), 4.11 (s, 1H), 4.04-3.99 (m, 2H), 3.28-3.21 (m, 3H),2.98-2.93 (m, 1H) , 2.27 (s, 3H), 2.10-1.98 (m, 2H), 1.73-1.67(d, J=11.9 Hz, 2H).

Example 29 & Example 30 & Example 31

A mixture of 1,2-dichloro-3-iodobenzene (575 mg, 3.13 mmol), sodium 3-amino-5-chloropyrazine-2-thiolate (813 mg, 2.98 mmol), Pd₂(dba)₃ (134 mg, 0.15 mmol), XantPhos (176 mg, 0.30 mmol) and DIPEA (1.41 g, 10.92 mmol) in 1,4-dioxane (20 mL) was stirred for 3 h at 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:10, v/v) to give compound 29-1 (0.41 g). MS: 306 [M+1]⁺.

To a 0° C. solution of compound 29-1 (0.40 g, 1.31 mmol) in DCM (20 mL) was added NBS (0.32 g, 1.80 mmol). The resulting mixture was stirred for 17 h at RT. The reaction mixture was diluted with EA (50 mL) and brine (100 mL). The aqueous layer was separated, extracted with EA (1×50 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 29-2 (0.43 g) as a brown solid.

A mixture of compound 29-2 (0.43 g, 1.11 mmol), intermediate C2 (0.43 g, 1.38 mmol) and K₂CO₃ (1.60 g, 11.58 mmol) in CH₃CN (20 mL) was stirred for 5 h at 100° C. After cooling to RT, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:20, v/v) to give example 29 (191 mg) an a brown solid. MS: 551 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.35 (d, J=4.6 Hz, 1H), 7.85 (d, J=7.5 Hz, 1H), 7.35 (dd, J=8.0, 1.2 Hz, 1H), 7.28 (dd, J=7.5, 5.2 Hz, 1H), 7.17 (t, J=8.0 Hz, 1H), 6.77 (dd, J=8.0, 1.2 Hz, 1H), 4.14-3.95 (m, 3H), 3.28-3.12 (m, 3H), 2.91 (d, J=16.5 Hz, 1H), 2.08-1.93 (m, 2H), 1.70-1.59 (m, 1H), 1.50-1.42 (m, 1H).

A mixture of example 29 (173 mg, 0.31 mmol), K₄Fe(CN)₆.3H₂O (168 mg, 0.40 mmol), DBU (240 mg, 1.58 mmol) and Pd(PPh₃)₄ (35 mg, 0.030 mmol) in t-BuOH/H₂O (1/1, 16 mL) was stirred for 16 h at 100° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with water (50 mL) and extracted with EA (2×50 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:12, v/v) to give example 30 (117 mg) as a yellow solid. MS: 498 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.37 (d, J=4.9 Hz, 1H), 7.85 (d, J=7.5 Hz, 1H), 7.42-7.38 (m, 1H), 7.34-7.27 (m, 1H), 7.23-7.11 (m, 1H), 6.89-6.86, 6.68-6.65 (m, 1H), 4.55-4.43 (m, 1H), 4.38-4.26 (m, 1H), 4.15-3.99 (m, 1H), 3.65 (t, J=6.9 Hz, 1H), 3.25-3.12 (m, 2H), 3.02-2.91 (m, 1H), 2.13-1.81 (m, 2H), 1.65-1.59 (m, 1H), 1.50-1.42 (m, 1H).

A mixture of example 30 (105 mg, 0.21 mmol) in sulfuric acid (98%, 5 mL) was stirred for 16 h at 80° C. After cooling to RT, the reaction mixture was poured into water and the pH value was taken to 10 with NH₃H₂O (25%). The resulting mixture was extracted with EA (2×50 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:8, v/v) to give example 31 (30 mg). MS: 516 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.36 (d, J=4.6 Hz, 1H), 7.85 (d, J=7.5 Hz, 1H), 7.36 (dd, J=8.0, 1.1 Hz, 1H), 7.29 (dd, J=7.5, 5.2 Hz, 1H), 7.17 (t, J=8.0 Hz, 1H), 6.81 (dd, J=8.0, 1.1 Hz, 1H), 4.07 (s, 1H), 3.99 (d, J=13.7 Hz, 2H), 3.30-3.17 (m, 3H), 2.93 (d, J=16.5 Hz, 1H), 2.03-1.86 (m, 2H), 1.64-1.55 (m, 1H), 1.46-1.40 (m, 1H).

Example 32

Compound 32-1 was synthesized in the manner of compound 5-1, except compound 1-3 was replaced with 6-chloro-3-iodopyridin-2-amine.

A mixture of compound C2-6 (351 mg, 0.86 mmol) and TFA (1 mL) in DCM (20 mL) was stirred for 30 min at RT. The resulting mixture was concentrated under reduced pressure. Compound 32-1 (200 mg, 0.70 mmol), Pd(OAc)₂ (33 mg, 0.15 mmol), DavePhos (65 mg, 0.17 mmol), t-BuOK (1.21 g, 10.78 mmol) and toluene (30 mL) was added. The resulting mixture was stirred for 18 h at 100° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with water (100 mL) and extracted with EA (2×50 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 32-2 (0.37 g) as a brown solid. MS: 558 [M+1]⁺.

A mixture of compound 32-2 (0.37 g, 0.66 mmol) and HCl/EA (4 M, 3.00 mL, 12.00 mmol) in DCM (20 mL) was stirred for 30 min at RT. The resulting mixture was diluted with water (50 mL) and the pH value was adjusted to 9 with NH₃H₂O (25%). The resulting mixture was extracted with DCM (1×50 mL), the organic layer dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:8, v/v) to give example 32 (10 mg). MS: 454 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.43 (dd, J=13.1, 4.3 Hz, 1H), 7.96-7.88 (m, 1H), 7.60 (d, J=5.2 Hz, 1H), 7.43-7.29 (m, 2H), 6.24 (d, J=8.5 Hz, 1H), 6.01 (d, J=5.2 Hz, 1H), 4.42-4.15 (m, 3H), 3.26-3.08 (m, 4H), 1.86-1.77 (m, 2H), 1.59-1.43 (m, 2H).

Example 33

A mixture of compound C2-6 (552 mg, 1.35 mmol) and TFA (2.50 mL) in DCM (30 mL) was stirred for 1 h at RT. The resulting mixture was concentrated under reduced pressure. 2-Bromo-5-iodopyridine (354 mg, 1.25 mmol), Pd₂(dba)₃ (66 mg, 0.072 mmol), BINAP (86 mg, 0.14 mmol), t-BuOK (3204 mg, 28.55 mmol) and toluene (20 mL) was added. The resulting mixture was stirred for 21 h at 100° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with EA (50 mL) and filtered through Celite. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:20, v/v) to give compound 33-1 (392 mg) as a yellow solid. MS: 463 [M+1]⁺.

A mixture of compound 33-1 (184 mg, 0.40 mmol), intermediate Al (80 mg, 0.44 mmol), Pd₂(dba)₃ (41 mg, 0.045 mmol), XantPhos (55 mg, 0.095 mmol) and DIPEA (193 mg, 1.49 mmol) in 1,4-dioxane (20 mL) was stirred for 16 h at 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:12, v/v) to give compound 33-2 (127 mg). MS: 543 [M+1]⁺.

A mixture of compound 33-2 (127 mg, 0.23 mmol) and HCl/EA (4 M, 3.00 mL, 12.00 mmol) in DCM (20 mL) was stirred for 1.5 h at RT. The reaction mixture was diluted with water (50 mL) and the pH value was adjusted to 9 with NH₃H₂O (25%). The resulting mixture was extracted with DCM (2×50 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:8, v/v) to give example 33 (28 mg). MS: 439 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.45-8.34 (m, 2H), 7.87 (d, J=7.5 Hz, 1H), 7.67-7.54 (m, 2H), 7.53-7.44 (m, 1H), 7.37-7.25 (m, 1H), 5.95 (d, J=5.5 Hz, 1H), 4.11 (s, 1H), 3.93-3.75 (m, 2H), 3.28-3.10 (m, 3H), 3.01-2.83 (m, 1H), 2.07-1.84 (m, 2H), 1.76-1.66 (m, 1H), 1.57-1.45 (m, 1H).

Example 34

1-Bromo-4-fluorobenzene (3.69 g, 21.09 mmol), intermediate C2 (0.95 g, 3.04 mmol), K₂CO₃ (5.21 g, 37.70 mmol) and NMP (6 mL) was added to a 15 mL sealed tube. The resulting mixture was stirred for 6.5 h at 140° C. An additional batch of 1-bromo-4-fluorobenzene (1.22 g, 6.97 mmol) was added and the resulting mixture was stirred for 18 h at 160° C. After cooling to RT, the reaction mixture was poured into water (50 mL) and extracted with EA (2×50 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:15, v/v) to give compound 34-1 (249 mg) as a brown oil. MS: 358 [M+1]⁺.

A mixture of compound 34-1 (120 mg, 0.33 mmol), intermediate Al (65 mg, 0.36 mmol), Pd₂(dba)₃ (61 mg, 0.067 mmol), XantPhos (83 mg, 0.14 mmol) and DIPEA (303 mg, 2.34 mmol) in 1,4-dioxane (10 mL) was stirred for 18 h at 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:20, v/v) to give example 34 (47 mg). MS: 438 [M+1]⁺.¹HNMR (400 MHz, methanol-d₄) δ8.47 (d, J=4.6 Hz, 1H), 7.93 (d, J=7.5 Hz, 1H), 7.56 (d, J=5.5 Hz, 1H), 7.43 (d, J=8.7 Hz, 2H), 7.39-7.33 (m, 1H), 7.13 (d, J=8.7 Hz, 2H), 5.88 (d, J=5.5 Hz, 1H), 4.31 (s, 1H), 3.87-3.74 (m, 2H), 3.27-3.02 (m, 4H), 2.02-1.91 (m, 2H), 1.73-1.60 (m, 2H).

The following example was synthesized using the above procedure or modified procedure with the corresponding starting materials.

EX
No	Chemical Name	Structure	MS & 1HNMR
35	(S)-1′-(4-((2-amino- 3-chloropyridin-4- yl)thio)isoquinolin-1- yl)-1,3-dihydrospiro [indene- 2,4′-piperidin]-1-amine		MS: 488 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 8.38 (s, 1H), 8.25 (d, J = 8.2 Hz, 1H), 8.06 (d, J = 8.2 Hz, 1H), 7.76 (t, J = 7.2 Hz, 1H), 7.67 (t, J = 7.2 Hz, 1H), 7.55 (d, J = 7.4 Hz, 1H), 7.47-7.32 (m, 5H), 5.63 (d, J = 5.6 Hz, 1H), 4.48 (s, 1H), 4.06-3.87
			(m, 2H), 3.52-3.37 (m, 2H), 3.21 (d,
			J = 7.5 Hz, 1H), 2.25-2.06 (m, 2H),
			1.89-1.83 (m, 1H), 1.79-1.72 (m, 1H).

Example 36

To a solution of 6-chloro-3-methylpyrimidine-2,4(1H,3H)-dione (10.00 g, 62.28 mmol) in EtOH (200 mL) was added hydrazine hydrate (80%, 52.00 mL) at RT. The resulting mixture was stirred for 4 h at 80° C. After cooling to RT, the reaction mixture was concentrated to about 100 mL under reduced pressure and filtered. The filtered cake was washed with EtOH (2×50 mL). The filtered cake was collected and dried in a high vacuum oven to give compound 36-1 (5.56 g) as a light yellow solid. MS: 157 [M+1]⁺.

A mixture of compound 36-1 (5.56 g, 35.61 mmol) and 4-methoxybenzaldehyde (7.02 g, 51.56 mmol) in MeOH was stirred for 6 h at 70° C. After cooling to RT, the reaction mixture was filtered and the filtered cake was washed with MeOH. The filtered cake was collected and dried under high vacuum to give compound 36-2 (5.78 g) as a yellow solid. MS: 275 [M+1]⁺.

A mixture of compound 36-2 (2.03 g, 7.40 mmol), 2,3-dichlorobenzaldehyde (1.36 g, 7.77 mmol) and piperidine (0.77 g, 9.04 mmol) in DMF/iPrOH (20 mL/10 mL) was stirred for 18 h at 85° C. After cooling to RT, the reaction mixture was diluted with EA (200 mL) and washed with brine (2×50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:2, v/v) to give compound 36-3 (2.40 g) as a light yellow solid. MS: 431 [M+1]⁺.

A mixture of compound 36-3 (197 mg, 0.46 mmol) and BOP (649 mg, 1.47 mmol) in DMF (17 mL) was stirred for 10 min at RT. Then DBU (748 mg, 4.91 mmol) and C2 (229 mg, 0.73 mmol) was added and stirred for 20 h at RT. The reaction mixture was diluted with EA (100 mL) wad washed with brine (3×100 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:8, v/v) to give compound 36-4 (210 mg). MS: 615 [M+1]⁺.

A mixture of compound 36-4 (210 mg, 0.34 mmol) and TFA (15 mL) was stirred for 1.5 h at 100° C. The reaction mixture was diluted with water (100 mL) and the pH value was taken to 10 with NH₃H₂O (25%). The resulting mixture was extracted with DCM (2×50 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:8, v/v) to give example 36 (21 mg). MS: 496 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.38 (d, J=4.7 Hz, 1H), 7.87 (d, J=7.5 Hz, 1H), 7.65 (dd, J=7.9, 1.5 Hz, 1H), 7.46 (dd, J=7.6, 1.5 Hz, 1H), 7.39 (t, J=7.8 Hz, 1H), 7.31 (dd, J=7.4, 5.2 Hz, 1H), 4.14 (s, 1H), 3.68-3.58 (m, 2H), 3.55 (s, 3H), 3.29-3.12 (m, 3H), 3.01-2.90 (m, 1H), 2.15-1.96 (m, 2H), 1.74-1.65 (m, 1H), 1.57-1.45 (m, 1H).

The following example was synthesized using the above procedure or modified procedure with the corresponding starting materials.

EX
No	Chemical Name	Structure	MS & 1HNMR
37	(S)-6-(1-amino-6-fluoro- 1,3-dihydrospiro[indene- 2,4′-piperidin]- 1′-yl)-3-(2,3-dichloro phenyl)-5-methyl-1,5- dihydro-4H- pyrazolo[3,4- d]pyrimidin-4-one		MS: 513 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 7.65 (dd, J = 7.9, 1.7 Hz, 1H), 7.45 (dd, J = 7.6, 1.7 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.26 (dd, J = 8.2, 5.1 Hz, 1H), 7.16 (dd, J = 8.8, 2.0 Hz, 1H), 7.03-6.93 (m, 1H), 4.10 (s, 1H), 3.63-3.55 (m, 2H), 3.54 (s, 3H),
			3.25-3.09 (m, 3H), 2.88-2.79 (m,
			1H), 2.10-1.95 (m, 2H), 1.72-
			1.65 (m, 1H), 1.57-1.49 (m, 1H).
38	(S)-6-(1-amino-5,6,7- trifluoro-1,3- dihydrospiro[indene- 2,4′-piperidin]-1′-yl)-5- methyl-3-(5- methylthiophen- 2-yl)-1,5-dihydro-4H- pyrazolo[3,4-d] pyrimidin-4-one		MS: 501 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 8.22 (d, J = 3.6 Hz, 1H), 7.10-6.99 (m, 1H), 6.81 (d, J = 3.5 Hz, 1H), 4.28 (s, 1H), 3.59 (s, 3H), 3.57-3.43 (m, 2H), 3.26-3.15 (m, 4H), 2.54 (s, 3H), 1.92-1.76 (m, 4H).

Example 39

A mixture of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (2.53 g, 13.46 mmol), (4-methoxyphenyl)methanol (2.00 mL) and t-BuOK/THF (1 M, 53.00 mL, 53.00 mmol) in 1,4-dioxane (20 mL) was stirred for 2 h at RT. The reaction mixture was quenched with sat.aq.NH₄Cl and extracted with EA (2×100 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 39-1 (4.22 g) as a light yellow solid which was used in next step without further purification. MS: 290 [M+1]⁺.

A mixture of compound 39-1 (4.22 g, 14.57 mmol) and NBS (2.96 g, 16.63 mmol) in DMF (35 mL) was stirred for 20 min at RT. The reaction mixture was diluted with sat.aq.Na₂SO₃ (200 mL), extracted with EA (2×100 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 39-2 (4.76 g) as a brown solid which was used in next step without further purification. MS: 368 [M+1]⁺.

A mixture of compound 39-2 (4.76 g, 12.91 mmol), (Boc)₂O (2.97 g, 13.61 mmol), DIPEA (5.05 g, 39.07 mmol) in DMF (40 mL) was stirred for 16 h at RT. To the mixture was added DMAP (52 mg, 0.43 mmol) and stirred for another 1 h at 40° C. The reaction mixture purified by silica gel chromatography (eluting with EA:Hex=1:30, v/v) to give compound 39-3 (2.82 g) as a white solid. MS: 468 [M+1]⁺.

A mixture of compound 39-3 (500 mg, 1.07 mmol), (2,3-dichlorophenyl)boronic acid (215 mg, 1.13 mmol), K₂CO₃ (606 mg, 4.38 mmol) and Pd(dppf)C₂ (102 mg, 0.14 mmol) in THF/H₂O (5.0 mL/0.5 mL) was stirred for 3 h at 90° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with brine (50 mL), extracted with EA (2×50 mL). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:10, v/v) to give compound 39-4 (380 mg). MS: 534 [M+1]⁺.

A mixture of compound 39-4 (241 mg, 0.56 mmol), C2 (210 mg, 0.67 mmol) and K₂CO₃ (1903 mg, 13.77 mmol) in NMP (15 mL) was stirred for 23 h at 140° C. After cooling to RT, the reaction mixture was diluted with EA (100 mL) and washed with brine (3×50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:10, v/v) to give compound 39-5 (39 mg) as a brown solid. MS: 601 [M+1]⁺.

A mixture of compound 39-5 (38 mg, 0.063 mmol) and TFA (2 mL) in DCM (10 mL) was stirred for 1 h at RT. The reaction mixture was diluted with brine (50 mL) and the pH value was taken to 10 with NH₃H₂O (25%). The resulting mixture was extracted with DCM (2×30 mL), the organic layers combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:6, v/v) to give example 39 (12 mg). MS: 481 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.43 (d, J=4.7 Hz, 1H), 7.90 (d, J=7.5 Hz, 1H), 7.42 (dd, J=7.8, 1.5 Hz, 2H), 7.33 (dd, J=7.5, 5.2 Hz, 1H), 7.28-7.21 (m, 1H), 6.87 (s, 1H), 4.28-4.18 (m, 2H), 4.16 (s, 1H), 3.31-3.20 (m, 3H), 3.05-2.94 (m, 1H), 1.98-1.82 (m, 2H), 1.65-1.58 (m, 1H), 1.51-1.45 (m, 1H).

Example 40

A mixture of 6-amino-3-methylpyrimidine-2,4(1H,3H)-dione (0.50 g, 3.54 mmol) and PyBOP (5.62 g, 10.80 mmol) in DMF (15 mL) was stirred for 10 min at RT. Then DBU (5.62 g, 36.92 mmol) and Cl (1.39 g, 5.05 mmol) was added and stirred for 3 h at RT. The reaction mixture was diluted with EA (100 mL) wad washed with brine (3×100 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:5, v/v) to give compound 40-1 (1135 mg) as a yellow oil. MS: 326 [M+1]⁺.

A mixture of compound 40-1 (1.13 g, 3.47 mmol) and NIS (859 mg, 3.82 mmol) in DMF (10 mL) was stirred for 17 h at RT. The reaction mixture was diluted with EA (200 mL) and washed sat.aq.Na₂SO₃ with EA (2×80 mL) and sat.aq.NH₄Cl (1×80 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:8, v/v) to give compound 40-2 (828 mg). MS: 452 [M+1]⁺.

A mixture of compound 40-2 (103 mg, 0.23 mmol), intermediate Al (48 mg, 0.26 mmol), Pd₂(dba)₃ (21 mg, 0.023 mmol), XantPhos (25 mg, 0.043 mmol) and DIPEA (103 mg, 0.80 mmol) in 1,4-dioxane (10 mL) was stirred for 15 h at 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was filtered through Kieselguhr and the filtrate was concentrated under reduced pressure. The residue was purified by Prep—TLC (eluting with MeOH:DCM=1:10, v/v) to give example 40 (12 mg). MS: 484 [M+1]⁺.¹HNMR (400 MHz, methanol-d₄) δ7.62 (d, J=5.5 Hz, 1H), 7.53 (d, J=7.3 Hz, 1H), 7.45-7.32 (m, 3H), 6.19 (d, J=5.5 Hz, 1H), 4.42 (s, 1H), 3.80-3.63 (m, 2H), 3.47 (s, 3H), 3.30-3.09 (m, 4H), 2.11-1.89 (m, 2H), 1.75 (d, J=12.9 Hz, 1H), 1.66 (d, J=13.2 Hz, 1H).

Example 41

A mixture of 2,4-dichlorothiazole (1.54 g, 10.00 mmol), sodium 3-amino-5-chloropyrazine-2-thiolate -(2.77 g, 15.10 mmol) and K₂CO₃ (2.92 g, 21.10 mmol) in DMF (15 mL) was stirred for 3 h at 75° C. After cooling to RT, the reaction mixture was diluted with EA (50 mL) and water (50 mL). The organic layer was separated, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:5, v/v) to give compound 41-1 (281 mg) as a yellow solid. MS: 279 [M+1]⁺.

To a solution of intermediate C3 (288 mg, 0.70 mmol) in DCM (17 mL) was added TFA (2 mL), and stirred for 1.5 h at RT. The resulting mixture was concentrated under reduced pressure. The residue was dissolved in NMP (5 mL), 41-1 (232 mg, 1.19 mmol) and K₂CO₃ (1.18 g, 8.52 mmol) was added. The resulting mixture was stirred for 16 h at 95° C. After cooling to RT, the reaction mixture was diluted with water (30 mL) and EA (30 mL). The aqueous layer was separated and extracted with EA (2×20 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 41-2 (272 mg) as a red oil. MS: 556 [M+1-1]⁺.

A mixture of compound 41-2 (254 mg, 0.43 mmol) and HC1/1, 4-dioxane (4M, 1 mL) in DCM was stirred for 30 min at RT. The reaction mixture was concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:8, v/v) to give 41 (34 mg) as a yellow solid. MS: 452 [M+1-1]⁺.¹HNMR (400 MHz, methanol-d₄) δ9.01 (s, 1H), 7.63 (s, 1H), 7.26 (s, 1H), 4.50-4.28 (m, 3H), 3.46-3.35 (m, 1H), 3.31-3.21 (m, 2H), 3.19-3.09 (m, 1H), 2.00-1.76 (m, 4H).

Example 42

A mixture of compound B2-1 (192 mg, 1.34 mmol), (S)-1-amino-1,3-dihydrospiro [indene-2,4′-piperidine]-6-carbonitrile dihydrochloride (406 mg, 1.35 mmol), K₂CO₃ (2132 mg, 15.43 mmol) and NMP (8 mL) was stirred for 1.5 h at 140° C. After cooling to RT, the reaction mixture was diluted with water (20 mL) and extracted with EA (2 A 50 mL). The combined organic layers were washed with brine (1 b 100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:10, v/v) to give compound 42-1 (202 mg) as a brown oil. MS: 335 [M+1]⁺.

A mixture of compound 42-1 (202 mg, 0.60 mmol), NIS (167 mg, 0.74 mmol) and THF (8 mL) was stirred for 19 h at RT. The reaction mixture was diluted with brine (50 mL) and extracted with EA (2 2 50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:20, v/v) to give compound 42-2 (79 mg) as a yellow solid. MS: 461 [M+1]⁺.

A mixture of compound 42-2 (79 mg, 0.17 mmol), sodium 4-amino-5-bromopyrimidine-2-thiol (57 mg, 0.25 mmol), Pd₂(dba)₃ (15 mg, 0.016 mmol), XantPhos (21 mg, 0.036 mmol) and DIPEA (75 mg, 0.58 mmol) in 1,4-dioxane (8 mL) was stirred for 2 h at 90° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:10, v/v) to give example 42 (15 mg) as a yellow solid. MS: 538 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.02 (s, 1H), 7.93 7.76 (m, 2H), 7.70 7.64 (m, 1H), 7.50 (d, J=7.5 Hz, 1H), 6.18 (d, J=8.0 Hz, 1H), 4.29 (s, 1H), 3.62 (s, 3H), 3.46 3.36 (m, 2H), 3.30 3.15 (m, 4H), 2.06 1.90 (m, 2H), 1.77 1.67 (m, 2H).

The following compound was synthesized in the similar manner of example 42.

EX No	Chemical Name	Structure	MS & 1HNMR
43	(S)-6-(1-amino-6- bromo-1,3-dihydrospiro [indene-2,4′-piperidin]-1′- yl)-3-((3-chloro-2- methoxypyridin- 4-yl)thio)-1- methylpyridin-		MS: 561 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 7.93 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 5.5 Hz, 1H), 7.69 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 6.35 (d, J = 5.5 Hz, 1H), 6.24 (d, J = 8.0 Hz, 1H), 4.39 (s, 1H), 3.98
	2(1H)-one		(s, 3H), 3.62 (s, 3H), 3.21-2.90
			(m, 6H), 2.10-1.95 (m, 2H), 1.79-
			1.64 (m, 2H).

Example 44

Solution of 2,4-dibromothiazole (202 mg, 0.83 mmol), (S)-1-amino-1,3-dihydrospiro[indene-2,4′-piperidine]-6-carbonitrile dihydrochloride (382 mg, 1.27 mmol) and TEA (1609 mg, 15.90 mmol) in DMF (8 mL) was stirred for 30 h at 90° C. The reaction mixture was diluted with water (50 mL) and extracted with EA (2×50 mL). The combined organic layers were combined, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 44-1 (243 mg) as a light yellow solid. MS: 389 [M+1]⁺.

A mixture of intermediate A2 (420 mg, 1.67 mmol), compound 44-1 (135 mg, 0.53 mmol), Pd(PPh₃)₄ (127 mg, 0.11 mmol), Na₂CO₃ (1120 mg, 10.57 mmol), THF (20 mL) and H₂O (2 mL) was stirred for 16 h at 90° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with brine (100 mL) and extracted with EA (2×50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:50, v/v) to give the crude product and was further purified by Prep—TLC (MeOH:DCM=1:40, v/v) to give example 44 (20 mg) as an off-white solid. MS: 515 [M+1]⁺.¹HNMR (400 MHz, methanol-d₄) δ8.36 (s, 1H), 7.91 7.79 (m, 4H), 7.72 7.68 (m, 1H), 7.60 7.45 (m, 3H), 7.21 7.13 (m, 1H), 4.31 (s, 1H), 4.20 3.94 (m, 3H), 3.47 3.36 (m, 2H), 3.08 (m, 1H), 1.94 1.81 (m, 2H), 1.75 1.63 (m, 2H).

Example 45

A mixture of 1-bromo-2-chloro-3-methylbenzene (2.89 g, 14.06 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (5.43 g, 21.38 mmol), Pd(dppf)C₂CH₂C₂ (1.21 g, 1.65 mmol), Na₂CO₃ (5.56 g, 52.46 mmol) in 1,4-dioxane (30 mL) was stirred for 22 hat 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with EA and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:4, v/v) to give the compound 45-1 (2.17 g).

A mixture of compound 45-1 (1.00 g, 3.96 mmol), 3-bromo-6-chloropyrazin-2-amine (1.03 g, 4.94 mmol), Pd(dppf)C₂CH₂Cl₂ (0.84 g, 1.15 mmol), K₂CO₃ (2.37 g, 17.15 mmol), CH₃CN (40 mL) and H₂O (4 mL) was stirred for 2 h at 110° C. under nitrogen atmosphere. After cooling to RT, the reaction mixture was diluted with EA and filtered through a pad of Celite. The filtrate was washed with brine, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:15, v/v) to give the compound 45-2 (2.17 g). MS: 254 [M+1]⁺.

A mixture of compound 45-2 (102 mg, 0.40 mmol), (S)-6-bromo-1,3-dihydrospiro[indene-2,4′-piperidin]-1-amine dihydrochloride (205 mg, 0.42 mmol), K₂CO₃ (1562 mg, 11.30 mmol) and CH₃CN (20 mL) was stirred for 16 h at 100° C. After cooling to RT, the reaction mixture was diluted with EA (50 mL) filtered. The filtrate was concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:12, v/v) to give example 45 (89 mg) as a yellow solid. MS: 498 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ7.61 (s, 1H), 7.49-7.43 (m, 2H), 7.38 (d, J=7.0 Hz, 1H), 7.31 (t, J=7.5 Hz, 1H), 7.23 (dd, J=10.8, 7.9 Hz, 2H), 4.24 (t, J=13.6 Hz, 2H), 4.17 (s, 1H), 3.25-3.10 (m, 3H), 2.92 (d, J=16.2 Hz, 1H), 2.46 (s, 3H), 1.92-1.74 (m, 2H), 1.65-1.47 (m, 2H).

The following examples were synthesized in the similar manner of example 45.

EX
No	Chemical Name	Structure	MS & 1HNMR
46	(S)-1′-(5-(3-amino-2- (trifluoromethyl)phenyl) pyrimidin-2-yl)-1,3- dihydrospiro[indene-2,4′- piperidine]-1,6-diamine		MS: 455 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 8.63 (s, 1H), 8.33 (s, 1H), 8.22 (s, 1H) 7.12 (d, J = 8.0 Hz, 2H), 6.89-6.72 (m, 3H), 4.68-4.53 (m, 2H), 4.23 (s, 1H), 3.44-3.37 (m, 2H), 3.09-3.03 (m, 2H), 1.76-1.61
			(m, 4H).
47	(S)-1′-(6-amino-5-(2- chloro-3-methylphenyl) pyrazin-2-yl)-1,3- dihydrospiro[indene-2,4′- piperidine]-1,6-diamine		MS: 435 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 7.46 (s, 1H), 7.38 (d, J = 6.8 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.24-7.18 (m, 1H), 7.08 (d, J = 8.1 Hz, 1H), 6.82 (d, J = 1.7 Hz, 1H), 6.74 (dd, J = 8.0, 2.0 Hz, 1H), 4.35- 4.07 (m, 3H), 3.28-3.09 (m, 2H),
			3.07-2.90 (m, 2H), 2.45 (s, 3H), 1.88-
			1.73 (m, 2H), 1.70-1.56 (m, 2H).
48	(S)-1′-(6-(5- chlorothiophen- 2-yl)pyridazin-3-yl)-5- methyl-1,3-dihydrospiro [indene-2,4′- piperidin]-1-amine		MS: 411 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 7.83 (d, J = 9.7 Hz, 1H), 7.42-7.31 (m, 3H), 7.21 (s, 1H), 7.16 (d, J = 7.8 Hz, 1H), 7.01 (d, J = 4.0 Hz, 1H), 4.45-4.36 (m, 1H), 4.33 (s, 1H), 4.26-4.15 (m, 1H), 3.45-
			3.34 (m, 2H), 3.17 (s, 2H), 2.38 (s,
			3H), 1.95-1.84 (m, 1H), 1.83-1.70
			(m, 2H), 1.68-1.56 (m, 1H).
49	(S)-1′-(6′-chloro-[3,3′- bipyridazin]-6-yl)-5- methyl-1,3-dihydrospiro [indene-2,4′- piperidin]-1-amine		MS: 407 [M + 1]+. 1HNMR (400 MHz, methanol - d4) δ 8.63 (d, J = 9.1 Hz, 1H), 8.43 (d, J = 9.7 Hz, 1H), 7.92 (d, J = 9.1 Hz, 1H), 7.46 (d, J = 9.7 Hz, 1H), 7.19 (s, 1H), 7.18-7.11 (m, 2H), 4.50 (d, J = 13.8 Hz, 1H), 4.40-4.35
			(m, 1H), 4.28-4.25 (m, 1H), 3.48-
			3.43 (m, 2H), 3.18-3.11 (m, 2H),
			2.37 (s, 3H), 1.94-1.78 (m, 4H).

Example 50

A solution of compound C1-4 (1.90 g, 4.67 mmol) and TFA (6.00 mL) in DCM (20 mL) was stirred for 1 h at RT. The resulting mixture was concentrated under reduced pressure. 3,5-Dichloropyrazine-2-carbonitrile (818 mg, 4.70 mmol), DMSO (8 mL) and DIPEA (6.56 g, 50.76 mmol) was added and stirred for 1 h at 70° C. The reaction mixture was diluted with water (50 mL) and extracted with EA (2×50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:2, v/v) to give compound 50-1 (1.81 g). MS: 444 [M+1]⁺.

A mixture of compound 50-1 (1.81 g, 4.08 mmol), (4-methoxybenzyl)hydrazine hydrochloride (0.94 g, 4.98 mmol), TEA (4.60 g, 45.46 mmol) and EtOH (20 mL) was stirred for 18 h at 90° C. The reaction mixture was concentrated under reduced pressure. The residue was diluted with EA (100 mL), washed with sat.aq.NH₄Cl (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under high vacuum to give compound 50-2 (2.19 g) as a yellow solid. MS: 560 [M+1]⁺.

A solution of compound 50-2 (1.58 g, 2.82 mmol), tert-butyl nitrite (0.36 g, 3.49 mmol) and CH₂I₂ (1.60 g, 5.97 mmol) in CH₃CN (30 mL) was stirred for 1.5 h at 90° C. The reaction mixture was diluted with brine (150 mL), MeOH (20 mL) and extracted with EA (2×100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. To the obtained red solid was added EA (20 mL), filtered and the filter cake was collected. The crude 50-3 (1.02 g) was used in next step without further purification. MS: 567 [M+1]⁺.

A mixture of compound 50-3 (236 mg, 0.42 mmol), 1,2,3,4-tetrahydro-1,5-naphthyridine (62 mg, 0.46 mmol), Pd2(dba)3 (77 mg, 0.084 mmol), BINAP (59 mg, 0.094 mmol) and t-BuONa (121 mg, 1.26 mmol) in toluene (10 mL) was stirred for 16 h at 90° C. under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with MeOH:DCM=1:20, v/v) to give the crude product and was further purified by Prep TLC (MeOH:DCM=1:20, v/v) to give compound 50-4 (45 mg) as a yellow solid. MS: 573 [M+1]⁺.

A mixture of compound 50-4 (34 mg, 0.059 mmol), TFA (3.0 mL), H₂SO₄ (98%, 0.2 mL) and anisole (0.5 mL) was stirred for 4 h at 90° C. The pH value of the reaction mixture was adjusted to 9 with sat.aq.Na₂CO₃. The resulting mixture was extracted with EA (2×20 mL), the organic layers combined, dried over anhydrous Na₂SO₄ and concentrated reduced pressure. The residue was purified by Prep TLC (MeOH:DCM=1:10, v/v) to give example 50 (3 mg) as a light yellow solid. MS: 453 [M+1]⁺.

Example 51

A mixture of 1-bromo-3-chloro-5-methoxybenzene (2.05 g, 9.26 mmol), 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione (733 mg, 2.27 mmol) and DMF (15 mL) was stirred for 18 h at 50° C. The reaction mixture was quenched with water (15 mL) and extracted with EA (3×15 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 51-1 (2.60 g) as a white solid.

A mixture of 5-bromo-2-chloropyridine (100 mg, 0.52 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (145 mg, 0.57 mmol), Pd(dppf)C₂ (19 mg, 0.026 mmol) and CH₃COOK (153 mg, 1.56 mmol) in 1,4-dioxane (10 mL) was stirred for 2.5 h at 90° C. under nitrogen atmosphere. To the resulting mixture was added compound 51-1 (148 mg, 0.58 mmol), Pd(dppf)C₂ (21 mg, 0.029 mmol), CH₃COOK (154 mg, 1.57 mmol). The resulting mixture was stirred for 16 h at 70° C. After cooling to RT, the reaction mixture was diluted with water (20 mL) and extracted with EA (2×15 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (eluting with EA:Hex=1:10, v/v) to give the compound 51-2 (28 mg). MS: 288 [M+1]⁺.

Example 51 was synthesized in the similar manner of example 1, except compound 1-4 was replaced with compound 51-2. MS: 454 [M+1]⁺.¹HNMR (400 MHz, methanol-d₄) δ8.16 (d, J=2.3 Hz, 1H), 7.68 (dd, J=8.9, 2.5 Hz, 1H), 7.48 (d, J=7.2 Hz, 1H), 7.43-7.29 (m, 3H), 7.14 (d, J=2.9 Hz, 1H), 6.97 (d, J=8.9 Hz, 1H), 6.89 (d, J=2.9 Hz, 1H), 4.59 (s, 1H), 4.47-4.33 (m, 2H), 3.86 (s, J=7.9 Hz, 3H), 3.26-3.06 (m, 3H), 3.00-2.89 (m, 1H), 1.93-1.72 (m, 4H).

Example 52 & Example 53

Example 52 was prepared following procedures of example 51 from intermediate B2. MS: 442 [M+1]⁺.¹HNMR (400 MHz, methanol-d₄) δ8.64 (dd, J=4.7, 1.4 Hz, 1H), 8.04 (dd, J=8.1, 1.5 Hz, 1H), 7.79-7.66 (m, 2H), 7.28 (t, J=7.9 Hz, 1H), 7.06 (d, J=7.5 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 6.28 (d, J=7.9 Hz, 1H), 4.20 (s, 1H), 3.85 (s, 3H), 3.68 (s, 3H), 3.58 (t, J=6.0 Hz, 1H), 3.28-3.22 (m, 1H), 3.13-2.99 (m, 3H), 2.93-2.84 (m, 1H), 2.10-1.96 (m, 2H), 1.75-1.64 (m, 2H).

A solution of example 52 (10 mg, 0.023 mmol), KOH (40 mg, 0.71 mmol) in MeOH (2 mL) and H₂O (2 mL) was stirred for 4 h at 100° C. The reaction mixture was diluted with water (5 mL), extracted with EA (2×5 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give the example 53 (7 mg) as a yellow solid. MS: 460 [M+1]⁺. ¹HNMR (400 MHz, methanol-d₄) δ8.57 (d, J=4.7 Hz, 1H), 7.78 (d, J=7.8 Hz, 1H), 7.75-7.68 (m, 1H), 7.66-7.54 (m, 2H), 7.47 (d, J=7.6 Hz, 1H), 7.33-7.26 (m, 1H), 7.08 (d, J=7.5 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 6.19 (d, J=7.7 Hz, 1H), 4.27 (s, 1H), 3.86 (s, 3H), 3.60 (s, 3H), 3.27-3.17 (m, 2H), 3.07-2.93 (m, 4H), 1.81-1.63 (m, 4H).

Example 54

To a −80° C. solution of 1-bromo-3-chloro-5-methoxybenzene (2.24 g, 10.11 mmol) in THF (50 mL) under nitrogen atmosphere was added n-BuLi (2.5 M, 7.40 mL, 18.50 mmol) dropwise. The resulting mixture was stirred for 40 min at −80° C. Then 1,4-dioxaspiro[4.5]decan-8-one (dissolved in 9 mL THF, 1.62 g, 10.37 mmol) was added dropwise and the resulting mixture was stirred for 40 min. The reaction mixture was quenched with brine (10 mL), diluted with water (100 mL) and extracted with EA (2×50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 54-1 (3.73 g) as a yellow oil.

A suspension of compound 54-1 (3.72 g, 13.25 mmol), Pd/C (Pd 10%, H₂O 54.55%, 6.07 g) in MeOH (50 mL) was stirred for 2 h at RT under hydrogen atmosphere. The reaction mixture was filtered through a Celite. The filtrate was concentrated under reduced pressure. The residue was dissolved in acetone (60 mL) and HCl (aq, 2M, 20 mL) was added. The resulting mixture was stirred for 1 h at 60° C. The reaction mixture was diluted with water (50 mL) and extracted with EA (2×50 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound 54-2 (1.82 g) as a white solid. ¹H NMR (400 MHz, d-DMSO) 6 7.17 (t, J=8.1 Hz, 1H), 6.86-6.79 (m, 2H), 6.76-6.69 (m, 1H), 3.70 (s, 3H), 3.04-2.89 (m, 1H), 2.57-2.44 (m, 2H), 2.29-2.19 (m, 2H), 2.06-1.97 (m, 2H), 1.89-1.74 (m, 2H).

A solution of intermediate C2-6 (115 mg, 0.28 mmol), TFA (2 mL) and DCM (10 mL) was stirred for 1 h at RT. To the resulting mixture was added compound 54-2 (57 mg, 0.28 mmol), TsOH (5 mg) and NaBH(OAc)₃ (120 mg, 0.57 mmol). The resulting mixture was stirred for 3 days at RT. The reaction mixture was diluted with brine (30 mL) and extracted with DCM (2×30 mL), the organic layers combined, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep—TLC (MeOH:DCM=1:15, v/v) to give compound 54-3 (30 mg) as a white solid. MS: 496 [M+1]⁺.

A mixture of compound 54-3 (30 mg, 0.061 mmol) and HCl/EA (4 M, 1.00 mL, 4.00 mmol) in EA (10 mL) was stirred for 2.0 h at RT. The reaction mixture was diluted with water (20 mL) and the pH value was taken to 9 with NH₃H₂O (25%). The resulting mixture was extracted with EA (2×20 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give example 54 (8 mg) as a brown solid. MS: 392 [M+1]⁺.

The following compounds were synthesized using the above procedure or modified procedure with the corresponding starting materials.

			MS:
EX	Chemical Name	Structure	[M + 1]+
55	(S)-1-amino-1′-(6-((3-amino-2-chloro phenyl)thio)-1,2,4-triazin-3-yl)-1,3- dihydrospiro[indene-2,4′-piperidine]-6- carbonitrile		464
56	1-(5-((5-((1S)-1-amino-6-(methylsulfinyl)- 1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)pyrazin-2-yl)thio)-2- chlorophenyl)ethan-1-one		527
57	(S)-1′-(5-(pyrimidin-2-ylthio) pyrazin-2-yl)-6-(trifluoromethyl)- 1,3-dihydrospiro[indene-2,4′-piperidin]- 1-amine		459
58	(S)-6-bromo-5-fluoro-1′-(5-(quinolin- 4-ylthio)pyrazin-2-yl)-1,3- dihydrospiro[indene-2,4′- piperidin]-1-amine		536
59	(S)-6-(4-amino-4,6-dihydrospiro [cyclopenta[b]thiophene-5,4′-piperidin]- 1′-yl)-3-(3-(trifluoromethyl)pyridin- 4-yl)-1,5-dihydro-4H-pyrazol[3,4- d]pyrimidin-4-one		488
60	(S)-2-(1-amino-6-chloro-5-methoxy- 1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-5-(3,5- dichloropyridin-4-yl)-3-methyl- 3,7-dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one		559
61	(S)-1′-(7-(5-chloropyridin-2-yl)-5H- pyrrolo[2,3-b]pyrazin-3-yl)-1,3- dihydrospiro[cyclopenta] naphthalene-2,4′-piperidin]- 3-amine		481
62	(S)-1′-(7-(3-chloropyridin-2-yl)-5H- pyrrolo[2,3-b]pyrazin-3-yl)-1H,3H- spiro[phenalene-2,4′-piperidin]- 1-amine		481
63	(R)-1′-(3-(2-methylpyridin-3-yl)-1H- pyrazolo[3,4-b]pyrazin-6-yl)-3,4- dihydro-1H-spiro[naphthalene-2,4′- piperidin]-3-amine		426
64	(S)-6-amino-2-(1-amino-7-bromo-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-3-methyl-5-phenylpyrimidin- 4(3H)-one		480
65	(S)-1-amino-1′-(4-amino-6-oxo-5- (pyridazin-3-ylthio)-1,6- dihydropyrimidin- 2-yl)-1,3-dihydrospiro[indene-2,4′- piperidine]-7-carbonitrile		447
66	(S)-1-amino-1′-(1-methyl-6-oxo-5- (pyrazin-2-yl)-1,6-dihydropyrimidin- 2-yl)-1,3-dihydrospiro[indene- 2,4′-piperidine]-7-carbonitrile		414
67	(S)-2-(1-amino-6-chloro-5-methoxy- 1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-5-((4- isopropylphenyl)thio) pyrimidin-4(3H)-one		511
68	(S)-4-amino-6-(1-amino-6-bromo-5- fluoro-1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-3-(2-chloro- 3-methylphenyl)-1-methylpyridin- 2(1H)-one		545
69	(S)-6-(4-acetyl-1-amino-1,3-dihydrospiro [indene-2,4′-piperidin]-1′- yl)-4-amino-3-(4-(trifluoromethyl) phenyl)pyridin-2(1H)-one		497
70	(S)-6′-(1-amino-4-hydroxy-1,3- dihydrospiro[indene-2,4′- piperidin]-1′-yl)-2′-oxo- 1′,2′-dihydro-[3,3′- bipyridine]-2-carbonitrile		414
71	(S)-1′-(3-bromo-5-(1H-indol-6-yl)-6- methylpyrazin-2-yl)-4,6-dihydrospiro [cyclopenta[d]thiazole-5,4′- piperidin]-4-amine		495
72	(S)-3-(4-amino-4,6-dihydrospiro [cyclopenta[d]thiazole-5,4′- piperidin]-1′-yl)-5-methyl-6- (2-oxoindolin-7-yl)pyrazine-2- carbonitrile		458
73	(S)-1′-(5-amino-6-((2-amino-3-chloro pyridin-4-yl)thio)-1,2,4-triazin-3-yl)- 5,7-dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-5-amine		456
74	(S)-1′-(5-amino-6-((2-amino-3-chloro pyridin-4-yl)thio)pyridin-3-yl)-6- chloro-1,3-dihydrospiro[indene- 2,4′-piperidin]-1-amine		487
75	(S)-1′-(4-amino-5-((2-amino-3-chloro pyridin-4-yl)thio)pyridin-2-yl)-5,7- dihydrospiro[cyclopena[b] pyridine-6,4′-piperidin]-5-amine		454
76	(S)-1′-(5-((2,3-dichlorophenyl)thio) thiazol-2-yl)-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-7-amine		463
77	(R)-1′-(4-((3-chloropyridin-4-yl)thio) thiazol-2-yl)spiro[indoline-2,4′- piperidin]-3-amine		430
78	(R)-1′-(2-(7-chloro-1H-indol-1-yl) thiazol-4-yl)-2,3-dihydrospiro [indene-1,4′-piperidin]- 2-amine		435
79	(R)-1′-(2-((2-(trifluoromethyl) phenyl)thio)thiazol-5-yl)-3H- spiro[benzofuran-2,4′- piperidin]-3-amine		464
80	(S)-(5-(1-amino-1,3-dihydrospiro [indene-2,4′-piperidin]-1′- yl)pyrazin-2-yl)(2,3- dichlorophenyl)methanone		453
81	(S)-2-(1-amino-6-fluoro-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-5-(indolin-1-yl)-3- methyl-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one		485
82	(S)-1′-(5-((1,2,3,4-tetrahydroquinolin- 8-yl)thio)pyrazin-2-yl)-1,3- dihydrospiro[cyclopenta[b] naphthalene-2,4′- piperidin]-1-amine		494
83	(S)-1′-(5-((2-amino-3-chloropyridin- 4-yl)thio)pyrazin-2-yl)-1,3- dihydrospiro[cyclopenta[a] naphthalene-2,4′-piperidin]-1- amine		489
84	1′-(5-((3-amino-2-chlorophenyl)thio)- 6-methylpyrazin-2-yl)-1-methyl-1,3- dihydrospiro[indene-2,4′- piperidin]-1-amine		466
85	(R)-1′-(7-((2-amino-3-chloropyridin- 4-yl)thio)-1H-indol-4-yl)-3H-spiro [benzofuran-2,4′-piperidin]-3- amine		478
86	(S)-1′-(7-((2-amino-3-chloropyridin- 4-yl)thio)isoquinolin-3-yl)-5,6- dibromo-1,3-dihydrospiro[indene- 2,4′-piperidin]-1-amine		644
87	(S)-4-((5-(5-acetyl-1-amino-1,3- dihydrospiro[indene-2,4′- piperidin]-1′-yl)-3- aminopyrazin-2-yl)thio)-3-chloro- 1-methylpyridin-2(1H)-one		511
88	(S)-5-(1-amino-6-bromo-1,3-dihydro spiro[indene-2,4′- piperidin]-1′-yl)-2-(2,3- dichlorophenyl)thio)-6-(hydroxy methyl)pyridin-3-ol		480
89	(S)-6-bromo-1′-(5-(2,3-dichlorophenyl)- 6-methylimidazo[1,5-a]pyrazin-8- yl)-1,3-dihydrospiro[indene- 2,4′-piperidin]-1-amine		556
90	(S)-1′-(7-((2-amino-3-chloropyridin- 4-yl)thio)-[1,2,5]thiadiazolo[3,4-c] pyridin-4-yl)-6-bromo-1,3-dihydrospiro [indene-2,4′-piperidin]-1-amine		574
91	(S)-1′-(8-((2-amino-3-chloropyridin- 4-yl)thio)pyrido[4,3-d]pyrimidin-5-yl)- 6-bromo-1,3-dihydrospiro[indene- 2,4′-piperidin]-1-amine		568
92	(S)-3-(5-(1-amino-6-methoxy-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)pyridin-2-yl)-4,5-dichlorophenol		470
93	(S)-1-amino-1′-(5-(5-methylthiophen- 2-yl)pyrazin-2-yl)-1,3-dihydrospiro [indene-2,4′-piperidin]-6-ol		393
94	(S)-1′-(5-(1H-indol-7-yl)pyrazin-2-yl)- 5-ethyl-1,3-dihydrospiro[indene- 2,4′-piperidin]-1-amine		424
95	(S)-1′-(5-(cyclohex-1-en-1-yl)pyrazin- 2-yl)-5-isopropyl-1,3-dihydrospiro [indene-2,4′-piperidin]-1- amine		403
96	(S)-N-(1-amino-1′-(5-(2- (trifluoromethyl)phenyl)pyrimidin- 2-yl)-1,3-dihydrospiro[indene- 2,4′-piperidin]-6-yl) methanesulfonamide		518
97	(S)-1′-(5-((4-(trifluoromethyl) pyrimidin- 5-yl)thio)pyrazin-2-yl)-5,7- dihydrospiro[cyclopenta[c] pyridine-6,4′-piperidin]-7-amine		460
98	(S)-1′-(5-((2-chloropyridin-3-yl)thio) pyrazin-2-yl)-5,7-dihydrospiro[cyclo penta[c]pyridine-6,4′-piperidin]-5- amine		425
99	(S)-4-((5-(5-amino-5,7-dihydrospiro [cyclopenta[d]pyrimidine-6,4′- piperidin]-1′-yl)pyrazin-2-yl)thio)- 3-chlorobenzoic acid		469
100	(S)-1′-(5-((3-(trifluoromethyl)pyrazin- 2-yl)thio)pyrazin-2-yl)-5,7- dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-7-amine		460
101	(S)-1′-(5-((3-chloropyridazin-4-yl)thio) pyrazin-2-yl)-5,7-dihydrospiro [cyclopenta[d]pyrimidine-6,4′- piperidin]-7-amine		427
102	(S)-4-((5-(5-amino-5,7-dihydrospiro [cyclopenta[b]pyrazine-6,4′- piperidin]-1′-yl)pyrazin-2-yl)thio)- 3-chlorobenzamide		468
103	(S)-(1-amino-1′-(5-((3-chloro-2- (methylamino)pyridin-4-yl)thio)pyrazin-2- yl)-1,3-dihydrospiro[indene-2,4′- piperidin]-6-yl)dimethylphosphine oxide		529
104	(S)-1-amino-1′-(6-amino-5-((3-chloro- 2-(dimethylamino)pyridin-4-yl)thio) pyrazin-2-yl)-1,3-dihydrospiro[indene- 2,4′-piperidine]-5-carboxylic acid		526
105	ethyl (S)-1-amino-1′-(5-((3-chloro-2- (methylamino)pyridin-4-yl)thio)pyrazin-2- yl)-1,3-dihydrospiro[indene-2,4′- piperidine]-5-carboxylate		525
106	(S)-1′-(5-((3-(morpholinomethyl) phenyl)thio)pyrazin-2-yl)-6- (trifluoromethyl)-1,3-dihydrospiro [indene-2,4′-piperidin]-1-amine		556
107	(S)-6-bromo-5-fluoro-1′-(5-((3-(penta fluoro-16-sulfanyl)phenyl)thio)pyrazin- 2-yl)-1,3-dihydrospiro[indene-2,4′- piperidin]-1-amine		611
108	(S)-N-(3-((5-(1-amino-6-(methylthio)- 1,3-dihydrospiro[indene-2,4′-piperidin]- 1′-yl)pyrazin-2-yl)thio)phenyl) cyclopropanecarboxamide		518
109	(S)-6-(6-amino-1-bromo-4H,6H-spiro [cyclopenta[c]thiophene-5,4′- piperidin]-1′-yl)-3-(m-tolyl)-1,5- dihydro-4H-pyrazolo[3,4-d] pyrimidin-4-one		511
110	(S)-2-(1-amino-5,6,7-trifluoro-1,3- dihydrospiro[indene-2,4′-piperidin]-1′- yl)-5-(3-ethylphenyl)-3-methyl-3,7- dihydro-4H-pyrrolo[2,3-d] pyrimidin-4-one		508
111	(R)-1′-(3-(3-(tert-butyl)phenyl)-1H- pyrazolo[3,4-b]pyrazin-6-yl)-3,4- dihydro-1H-spiro[naphthalene-2,4′- piperidin]-3-amine		467
112	(S)-2-(3-amino-1,3-dihydrospiro [cyclopenta[a]naphthalene-2,4′- piperidin]-1′-yl)-5-(3- isopropylphenyl)-3,7-dihydro-4H- pyrrolo[2,3-d]pyrimidin-4-one		504
113	(S)-1-amino-1′-(3-(3-chloro-2- morpholinopyridin-4-yl)-4-oxo-4,5- dihydro-1H-pyrrolo[3,2-c]pyridin-6- yl)-5-fluoro-1,3-dihydrospiro [indene-2,4′-piperidine]- 6-carbonitrile		574
114	(S)-1′-(7-(3-chloro-2-(cyclobutylamino) pyridin-4-yl)-5H-pyrrolo[2,3-b]pyrazin-3- yl)-1,3-dihydrospiro[cyclopenta [a]naphthalene-2,4′-piperidin]- 3-amine		550
115	(S)-1′-(3-(3-chloro-2-(cyclopropylamino) pyridin-4-yl)-1H-pyrazolo[3,4-b] pyrazin-6-yl)-N6-methyl-1,3-dihydrospiro [indene-2,4′-piperidine]-1,6- diamine		516
116	(S)-5-amino-1′-(3-(3-chloro-2- (pyrrolidin-1-yl)pyridin-4-yl)-1H-pyrazolo [3,4-b]pyrazin-6-yl)-2-fluoro-5,7- dihydrospiro[cyclopenta[b]pyridine- 6,4′-piperidine]-3-carboxamide		563
117	1-(4-(6-((S)-4-amino-2-chloro-4,6- dihydrospiro[cyclopenta[d]thiazole-5,4′- piperidin]-1′-yl)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-3-chloropyridin-2-yl) pyrrolidin-3-ol		558
118	(S)-1′-(3-(3-chloro-2-((cyclopropyl- methyl)amino)pyridin-4-yl)-1H-pyrazolo [3,4-b]pyrazin-6-yl)-N6,N6- dimethyl-1,3-dihydrospiro[indene- 2,4′-piperidine]-1,6-diamine		544
119	(S)-1′-(3-(2-amino-6-chloropyridin- 4-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)- 2-(tert-butyl)-4,6-dihydrospiro [cyclopenta[b]thiophene-5,4′- piperidin]-4-amine		509
120	(S)-2-chloro-1′-(3-(1,3-dihydroiso- benzofuran-5-yl)-1H-pyrazolo[3,4-b] pyrazin-6-yl)-4,6-dihydrospiro [cyclopenta[d]thiazole-5,4′- piperidin]-6-amine		480
121	(S)-3-chloro-1′-(3-((2-chlorophenyl) thio)-1H-pyrazolo[3,4-b]pyrazin-6-yl)- 5,7-dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-5-amine		498
122	(S)-1′-(3-(3-chloro-2-(ethylamino)pyridin- 4-yl)-1H-pyrazolo[3,4-b]pyrazin- 6-yl)-4,6-dihydrospiro[cyclopenta [b]thiophene-5,4′-piperidin]-4-amine		481
123	(R)-1′-(7-(methyl(pyridin-4-yl)amino)- 5H-pyrrolo[2,3-b]pyrazin-3-yl)-3H- spiro[furo[2,3-b]pyridine-2,4′- pipendin]-3-amine		429
124	(R)-1′-(3-((3-chloropyridin-4-yl) amino)-1H-pyrazolo[3,4-b]pyrazin-6-yl)- 6,7-dihydrospiro[cyclopenta[b] pyridine-5,4′-piperidin]-6-amine		448
125	(S)-2-methoxy-1′-(3-(1-phenylvinyl)- 1H-pyrazolo[3,4-b]pyrazin-6-yl)-4,6- dihydrospiro[cyclopenta[d]thiazole- 5,4′-piperidin]-4-amine		460
126	(R)-1-(3-benzyl-1H-pyrazolo[3,4-b] pyrazin-6-yl)-1′,3′-dihydrospiro [piperidine-4,2′-pyrrolo[2,3-b] pyridin]-3′-amine		413
127	(S)-(6-(6-amino-4,6-dihydrospiro [cyclopenta[d]thiazole-5,4′-piperidin]- 1′-yl)-1H-pyrazolo[3,4-b]pyrazin-3- yl)(phenyl)methanone		432
128	(4S)-1′-(3-(1-phenylethyl)-1H-pyrazolo [3,4-b]pyrazin-6-yl)-4,6-dihydrospiro [cyclopenta[d]thiazole-5,4′- piperidin]-4-amine		432
129	1-(6-((S)-5-amino-2-methoxy-5,7- dihydrospiro[cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-1H-pyrazolo[3,4- b]pyrazin-3-yl)-1-phenylethan-1-ol		472
130	(S)-1′-(3-((2,3-dichloropyridin-4-yl) oxy)-1H-pyrazolo[3,4-b]pyrazin-6-yl)- 5,7-dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-5-amine		483
131	(S)-6-bromo-1′-(3-(5-(3,4-difluorophenyl)- 3,4-dihydroquinolin-1(2H)-yl)- 1H-pyrazolo[3,4-b]pyrazin-6-yl)-1,3- dihydrospiro[indene-2,4′- piperidin]-1-amine		642
132	(S)-6-amino-2-(1-amino-6-bromo-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-5-(4-cyclopropoxyphenyl)-3- methylpyrimidin-4(3H)-one		536
133	(S)-N-(1-amino-1′-(4-amino-5-((4- (methylthio)phenyl)thio)-6-oxo-1,6- dihydropyrimidin-2-yl)-1,3-dihydrospiro [indene-2,4′-piperidin]-6-yl)acetamide		523
134	(S)-2-(1-amino-6-(methylamino)-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-5-(4-(benzyloxy)phenyl)-3- methylpyrimidin-4(3H)-one		522
135	(S)-2-(7-acetyl-1-amino-1,3-dihydrospiro [indene-2,4′-piperidin]-1′-yl)-5- (benzo[d][1,3]dioxol-4-ylthio) pyrimidin-4(3H)-one		491
136	4-amino-6-((1S)-1-amino-7-(1- hydroxyethyl)-1,3-dihydrospiro[indene- 2,4′-piperidin]-1′-yl)-3-(4- (difluoromethoxy)phenyl)-1- methylpyridin-2(1H)-one		511
137	(S)-1-amino-1′-(4-amino-6-oxo-5-(4- phenoxyphenyl)-1,6-dihydropyridin- 2-yl)-1,3-dihydrospiro[indene-2,4′- piperidine]-4-carbonitrile		504
138	(S)-6-(1-amino-4-hydroxy-1,3-dihydrospiro [indene-2,4′-piperidin]-1′-yl)-3- (4-cyclohexylphenyl)-1-methylpyridin- 2(1H)-one		484
139	(S)-3-([1,1′-biphenyl]-4-yl)-6-(1- amino-4-methoxy-1,3-dihydrospiro [indene-2,4′-piperidin]-1′-yl) pyridin-2(1H)-one		478
140	(S)-6-amino-2-(1-amino-6-(2-oxopiperidin- 1-yl)-1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-3-methyl-5-(4- (trifluoromethoxy)phenyl)pyrimidin- 4(3H)-one		583
141	(S)-1-(1-amino-1′-(4-amino-5-((4- cyanophenyl)thio)-1-methyl-6-oxo-1,6- dihydropyrimidin-2-yl)-1,3-dihydrospiro [indene-2,4′-piperidin]-6-yl)urea		517
142	(S)-4-amino-6-(1-amino-6-chloro-5- fluoro-1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-1-methyl-3-(4- (tetrahydro-2H-pyran-4-yl)phenyl)pyridin- 2(1H)-one		537
143	(S)-6-(1-amino-6-(trifluoromethyl)-1,3- dihydrospiro[indene-2,4′-piperidin]-1′- yl)-3-(4-(2-methoxyethoxy)phenyl)-1- methylpyridin-2(1H)-one		528
144	(S)-6-amino-2-(1-amino-6-(piperidine-1- carbonyl)-1,3-dihydrospiro[indene- 2,4′-piperidin]-1′-yl)-3-methyl-5- (quinolin-8-ylthio)pyrimidin-4(3H)-one		596
145	(S)-6-amino-2-(1-amino-6-morpholino- 1,3-dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-3-methyl-5-((4-nitrophenyl)thio) pyrimidin-4(3H)-one		564
146	(S)-6-amino-2-(5-amino-3-nitro-5,7- dihydrospiro[cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-3-methyl-5-(quinolin-8- ylthio)pyrimidin-4(3H)-one		531
147	(S)-6-(5-amino-3-(4-methylpiperazin-1- yl)-5,7-dihydrospiro[cyclopenta[b] pyridine-6,4′-piperidin]-1′-yl)-1- methyl-3-(naphthalen-1-ylthio) pyridin-2(1H)-one		567
148	(S)-2-(1-amino-6-(1H-pyrrol-1-yl)-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-5-((2,2-difluorobenzo[d][1,3] dioxol-4-yl)thio)pyrimidin-4(3H)-one		550
149	(S)-7-(5-(1-amino-6-(1H-imidazol-1- yl)-1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-6-(hydroxymethyl)-3- methylpyrazin-2-yl)isoindolin-1-one		522
150	(S)-3-(1-amino-6-(ethylamino)-1,3- dihydrospiro[indene-2,4′-piperidin]-1′- yl)-6-(1H-indol-5-yl)-5-methylpyrazine-2- carboxamide		496
151	(S)-N-(1-amino-1′-(3-bromo-5-(1H- indol-6-yl)-6-methylpyrazin-2-yl)-1,3- dihydrospiro[indene-2,4′-piperidin]- 6-yl)cyclopropanecarboxamide		571
152	(S)-4-(6-amino-5-(1-amino-4-methoxy- 1,3-dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-3-methylpyrazin-2-yl)-1,3- dihydro-2H-benzo[d]imidazol-2-one		472
153	(S)-3-(1-amino-5-methoxy-1,3- dihydrospiro [indene-2,4′-piperidin]-1′-yl)- 5-methyl-6-(2-oxoindolin-7-yl)pyrazine- 2-carbonitrile		481
154	(S)-N-(5-(1-amino-7-methoxy-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-6-((2-hydroxyethyl)amino)-3- methylpyrazin-2-yl)benzenesulfonamide		539
155	(S)-1′-(6-methyl-3-(1H-pyrazol-5-yl)- 5-(1H-pyrrolo[2,3-b]pyridin-4-yl) pyrazin-2-yl)-5,7-dihydrospiro[cyclopenta [b]pyridine-6,4′-piperidin]-5-amine		478
156	(S)-2-(3-(5-amino-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′-piperidin]- 1′-yl)-6-(8-chlorochroman-7-yl)-5- methylpyrazin-2-yl)propan-2-ol		520
157	(S)-6-chloro-1′-(5-(7-chloro-2,3- dihydrobenzofuran-6-yl)pyrazin-2-yl)-1,3- dihydrospiro[indene-2,4′-piperidin]- 1-amine		467
158	(S)-4-bromo-1′-(5-(3-(1-methyl-1H- pyrazol-5-yl)phenyl)pyrazin-2-yl)-1,3- dihydrospiro[indene-2,4′-piperidin]- 1-amine		515
159	(S)-1-amino-1′-(6-cyano-5-(1H-indazol- 7-yl)pyrazin-2-yl)-5-fluoro-1,3- dihydrospiro [indene-2,4′-piperidine]-6- carboxamide		483
160	(S)-1′-(5-(1H-indol-3-yl)-6-iodopyrazin- 2-yl)-5,7-dihydrospiro[cyclopenta [b]pyridine-6,4′-piperidin]-5-amine		523
161	(R)-6-(5-(7′-amino-7′,8′-dihydro-5′H- spiro[piperidine-4,6′-quinolin]-1-yl)- 3-vinylpyrazin-2-yl)isoindolin-1-one		453
162	(R)-1-(4-(5-(6-amino-6,7-dihydrospiro [cyclopenta[b]pyridine-5,4′-piperidin]- 1′-yl)-3-ethylpyrazin-2-yl)-3,3- difluoroindolin-1-yl)ethan-1-one		505
163	(S)-1′-(5-(3-methyl-1H-indazol-6-yl)- 6-phenylpyrazin-2-yl)-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-5-amine		488
164	(S)-1′-(5-(1H-benzo[d][1,2,3]triazol- 6-yl)-6-cyclopropylpyrazin-2-yl)-6- ((tetrahydro-2H-pyran-4-yl)oxy)-1,3- dihydrospiro[indene-2,4′- piperidin]-1-amine		538
165	(S)-1-amino-1′-(3-((l-methyl-1H- imidazol-2-yl)thio)-1H-pyrazolo[3,4-b] pyrazin-6-yl)-1,3-dihydrospiro[indene- 2,4′-piperidine]-6-carbonitrile		458
166	(S)-1′-(3-(1H-benzo[d]imidazol-1-yl)- 1H-pyrazolo[3,4-b]pyrazin-6-yl)-6- bromo-1,3-dihydrospiro[indene-2,4′- piperidin]-1-amine		515
167	(S)-1-(6-(1-amino-5-chloro-6-methoxy- 1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-3,4-dihydro-1,5- naphthyridin-2(1H)-one		531
168	(1-(6-((S)-1-amino-6-(methylthio)-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-1,2,3,4-tetrahydro-1,5- naphthyridin-4-yl)methanol		529
169	1-(6-((1S)-1-amino-6-(methylsulfinyl)-1,3- dihydrospiro[indene-2,4′- piperidin]-1′-yl)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-5- fluoro-1,2,3,4-tetrahydroquinoline- 6-carbonitrile		557
170	(S)-6-chloro-1′-(3-(2,3-dihydro-1H- pyrrolo[3,2-b]pyridin-1-yl)-1H-pyrazolo [3,4-b]pyrazin-6-yl)-5-methyl-1,3- dihydrospiro[indene-2,4′-piperidin]- 1-amine		487
171	(S)-5-(6-(1-amino-4-methoxy-1,3- dihydrospiro[indene-2,4′-piperidin]- 1′-yl)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-N- (2-methoxyethyl)-5,6,7,8-tetrahydro-1,5- naphthyridine-2-carboxamide		584
172	(S)-1-amino-5-fluoro-1′-(3-(6-(piperazin- 1-yl)-3,4-dihydro-1,5-naphthyridin- 1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin- 6-yl)-1,3-dihydrospiro[indene- 2,4′-piperidine]-6-carbonitrile		580
173	(S)-2-(1-(6-(1-amino-6-(methylthio)- 1,3-dihydrospiro[indene-2,4′- piperidin]-1′-yl)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-1,2,3,4-tetrahydroquinolin- 5-yl)thiazole-4-carboxylic acid		625
174	(S)-1′-(6-(aminomethyl)-5-(2,3- dichloropyridin-4-yl)pyrazin-2-yl)-6- (1H-imidazol-1-yl)-1,3-dihydrospiro [indene-2,4′-piperidin]-1-amine		521
175	(1S)-1-amino-1′-(5-(2,3-dichloropyridin- 4-yl)-3-(2-(hydroxymethyl)pyrrolidine- 1-carbonyl)-6-methylpyrazin-2-yl)-N,N- dimethyl-1,3-dihydrospiro[indene- 2,4′-piperidine]-6-carboxamide		638
176	(S)-1′-(8-(2-amino-3-chloropyridin-4- yl)-7-methylimidazo[1,2-c]pyrimidin- 5-yl)-5-fluoro-1,3-dihydrospiro[indene- 2,4′-piperidin]-1-amine		478
177	(S)-1′-(5-(1-methyl-1H-indol-2-yl) pyrazin-2-yl)-1,3-dihydrospiro [indene-2,4′-piperidin]-3,3-d2-1- amine		410
178	(S)-1-(6-(5-amino-5,7-dihydrospiro [cyclopenta[b]pyridine-6,4′- piperidin]-1′-yl)-1H-pyrazolo [3,4-b]pyrazin-3-yl)-1,2,3,4- tetrahydro-6H-pyrido[1,2-a] pyrimidin-6-one		470
179	(S)-1′-(3-(2,3,4,5-tetrahydro-1H- benzo[b]azepin-1-yl)-1H-pyrazolo [3,4-b]pyrazin-6-yl)-5,7- dihydrospiro[cyclo penta[c]pyridine-6,4′-piperidin]-5- amine		467
180	(3-((S)-1-amino-6-fluoro-1,3-dihydro spiro[indene-2,4′-piperidin]-1′-yl)-6- ((R)-1-methylisoindolin-2-yl) pyrazin-2-yl)methanol		460
181	(S)-1′-(3-(6,7-dihydropyrazolo[1,5- a]pyrimidin-4(5H)-yl)-1H-pyrazolo [3,4-b]pyrazin-6-yl)-5,7-dihydrospiro [cyclopenta[c]pyridine-6,4′- piperidin]-5,5-d2-7-amine		443
182	(S)-4-(difluoromethyl)-1′-(5-methyl- 6-((R)-2-methyl-3,4-dihydro-1,5- naphthyridin- 1(2H)-yl)pyridin-3-yl)-1,3-dihydrospiro [indene-2,4′-piperidin]-1-amine		470
183	(S)-1′-(8-(2-chloro-3-(isopropyl(methyl) amino)phenyl)-[1,2,4]triazolo[4,3-c] pyrimidin-5-yl)-2,3,6,8-tetrahydrospiro [indeno[5,6-b][1,4]dioxine- 7,4′-piperidin]-6-amine		561
184	(S)-1-(5-amino-1′-(8-((5-chloro-1- methylindolin-6-yl)thio)imidazo[1,5- a]pyridin-5-yl)-2,3,5,7-tetrahydro-1H- spiro[cyclopenta[b]pyrrolo[3,2-e] pyridine-6,4′-piperidin]-1-yl) ethan-1-one		601

Example A.

Phosphatase Assay (Single Dose Inhibition)

Assay Protocol:

For single dose inhibition assays using 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) as a substrate, SHP2 samples (diluted to 0.5 nM in reaction buffer) were incubated with dPEG8 peptide for 30 min in reaction buffer[60 mM 3,3-dimethyl glutarate (pH7.2), 75 mM NaCl, 75 mM KCl, and 1 mM EDTA, 0.05% Tween 20, 2mM dithiothreitol (DTT) ] to active the PTP. DMSO [0.5% (v/v)] or compounds (20nM) were added to the mixture and incubated for 30 min at room temperature. Reactions were initiated by the addition of DiFMUP (12 μM; total reaction volume of 100 μL), and the fluorescence (excitation at 340 nm, emission at 450 nm) of the resulting solutions was measured on a 2104-0020 EnVision Xcite Multilabel Reader (PerkinElmer) after 30min. The experiment is carried out in triplicate. The value for the control sample (DMSO) was set to 100%, and the values for the compound-treated samples were expressed as activity relative to the control sample. The inhibition of SHP2 by compounds of the invention were shown in table 1.

Example    SHP2 inhibition(%)
1@0.02 μM  82
2@0.02 μM  80
3@0.02 μM  81
4@0.02 μM  89
5@0.02 μM  84
6@0.02 μM  89
8@0.02 μM  68
15@0.02 μM 64
19@0.02 μM 61
21@0.02 μM 68
23@0.02 μM 85
24@0.02 μM 87
25@0.02 μM 78
26@0.02 μM 67
27@0.02 μM 79
28@0.02 μM 74
29@0.02 μM 68
30@0.02 μM 80
31@0.02 μM 82
32@0.02 μM 75
33@0.02 μM 70
36@0.02 μM 88
37@0.02 μM 68
38@0.02 μM 53
39@0.02 μM 78
40@0.02 μM 68
45@0.02 μM 78
47@0.02 μM 56
50@0.02 μM 86

Claims

1. A compound of formula I or a pharmaceutically acceptable salt thereof:

2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein ring A is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

3. The compound or pharmaceutically acceptable salt thereof of claim 1 or claim 2, wherein ring A is a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

4. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-3, wherein ring A is a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

5. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-4, wherein ring A is

6. The compound or pharmaceutically acceptable salt thereof of claim 5, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

7. The compound or pharmaceutically acceptable salt thereof of claim 5 or claim 6, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

8. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-7, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

9. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-8, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

10. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-9, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

11. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-10, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —CO—C1-6alkyl, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —SF5, —NHCO—C3-8cycloalkyl, —NH—C3-8cycloalkyl, —C1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C1-6alkylene-C3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

12. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-11, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —CO—C1-6alkyl, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —SF5, —NHCO—C3-8cycloalkyl, —NH—C3-8cycloalkyl, —C1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C1-6alkylene-C3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

13. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-12, wherein X2 is N, S, NRX2, C(RX2)2,CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-4alkyl, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl or 3-6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

14. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-13, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

15. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-14, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene—C3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

16. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-15, wherein RX1 and RX2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

17. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-16, wherein RX1 and RX2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

18. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-17, wherein RX1 and RX2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

19. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-18, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-6alkyl, —C1-6alkoxy, C3-8cycloalkyl, C5-8aryl, —S—C1-6alkyl, 3-12 membered heterocyclyl, —O—C3-8cycloalkyl, —O—C1-6alkylene-C1-6alkoxy, —O—C5-8aryl or —O—C1-6alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

20. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-19, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-6alkyl, —C1-6alkoxy, C3-8cycloalkyl, C5-8aryl, —S—C1-6alkyl, 3-12 membered heterocyclyl, —O—C3-8cycloalkyl,—O—C1-6alkylene-C1-6alkyl, —O—C5-8aryl or —O—C1-6alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

21. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-20, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-3alkyl, —C1-3alkoxy, C3-6cycloalkyl, C5-8aryl, —S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl, —O—C1-3alkylene-C1-3alkyl, —O—C5-6aryl or —O—C1-3alkylene-C5-6aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

22. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-21, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C3-6cycloalkyl, C5-8aryl, —S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl, —O—C1-3alkylene-C1-3alkyl, —O—C5-6aryl or —O—C1-3alkylene-C5-6aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

23. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-22, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C3-6cycloalkyl, C5-8aryl, -S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl, —O—C1-3alkylene—C1-3alkyl, —O—C5-6aryl or —O—C1-3alkylene-C5-6aryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

24. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-23, wherein RX2 and RX3 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

25. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-24, wherein RX2 and RX3 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

26. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-25, wherein RX2 and RX3 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, an 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

27. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-26, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl, —C1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

28. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-27, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl, —C1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

29. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-28, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-3alkyl, —C1-3alkoxy, —NHCO-(5-10 membered heterocyclyl) or 5-10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

30. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-29, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

31. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-30, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

32. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-31, wherein RX3 and RX4 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

33. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-32, wherein RX3 and RX4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

34. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-33, wherein RX3 and RX4 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

35. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-34, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

36. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-35, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or -C1-3alkoxy.

37. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-36, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

38. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-37, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

39. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-38, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

40. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-39, wherein RX4 and RX5together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

41. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-40, wherein RX4 and RX5together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

42. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-41, wherein RX4 and RX5 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

43. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-42, wherein X6 is O, S, CO or NRX6, or C(RX6)2; each of RX6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

44. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-43, wherein X6 is O, S, CO or NRX6, or C(RX6)2; each of RX6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

45. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-44, wherein X6 is O, S, CO or NRX6, or C(RX6)2; each of RX6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

46. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-45, wherein X6 is O, S, CO or NRX6, or C(RX6)2; each of RX6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

47. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-46, wherein X6 is O, S, CO or NRX6, or C(RX6)2; each of RX6 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

48. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-47, wherein RX5 and RX6 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

49. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-48, wherein RX5 and RX6 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

50. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-49, wherein RX5 and RX6 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

51. The compound or pharmaceutically acceptable salt thereof of any one of claims 5-50, wherein ring A is selected from

52. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-51,

53. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-52, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—, —NRG—SO2—,

54. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-53, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—, —NRG—SO2—,

55. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-54, wherein ring B is a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring, a 3-10 membered carbocyclic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2,3, 4, 5 or 6 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2, 3, 4, 5 or 6heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

56. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-55, wherein ring B is a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring, a 3-10 membered carbocyclic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2,3, 4, 5 or 6 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

57. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-56, wherein ring B is a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, a 7 membered carbocyclic ring, a 8 membered carbocyclic ring, a 9 membered carbocyclic ring, a 10 membered carbocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, a 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2, 3 or 4 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2, 3 or 4 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

58. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-57,

59. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-58, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH2, —OH, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

60. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-59, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH2, —OH, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6alkenyl, —C3-8cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

61. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-60, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH2, —OH, —CN, —C1-3alkyl, —C1-3alkoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

62. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-61, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, I, —NH2, —OH, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

63. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-62, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6 alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

64. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-63, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6 alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

65. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-64, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl, —C1-3alkoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

66. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-65, wherein Y2 is N or CRY2; Rye is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

67. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-66, wherein RY1 and RY2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

68. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-67, wherein RY1 and RY2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

69. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-68, wherein RY1and RY2together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

70. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-69, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, carboxyl, —COO—C1-6alkyl, —NH—C1-6alkylene—OH, —C1-6alkylene—OH, —CO—C3-8heterocyclic ring, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl, —C1-6alkyl substituted with —OH or —C1-6alkoxy.

71. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-70, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, carboxyl, —COO—C1-6alkyl, —NH—C1-6alkylene—OH, —C1-6alkylene—OH, —CO—C3-8heterocyclic ring, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl, —C1-3alkyl substituted with —OH or —C1-3alkoxy.

72. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-71, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-3alkyl, carboxyl, —COO—C1-3alkyl, —NH—C1-3alkylene—OH, —C1-3alkylene—OH, —CO—C3-8heterocyclic ring, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl, —C1-3alkyl substituted with —OH or —C1-3alkoxy.

73. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-72, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, methyl, ethyl, propyl, isopropyl, carboxyl, —COO—C1-3alkyl, —NH—C1-3alkylene—OH, —C1-3alkylene—OH, —CO—C3-8heterocyclic ring, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, ethyl substituted with —OH, methoxy, ethoxy, propoxy or isopropoxy.

74. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-73, wherein RY3 and RY4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

75. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-74, wherein RY3 and RY4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

76. The compound or pharmaceutically acceptable salt there of any one of claims 1-75, wherein RY3 and RY4together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

77. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-75, wherein ring B is selected from

78. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-77, wherein each of R1 and R2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-6alkyl, —N(C1-6alkyl)2, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

79. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-78, wherein each of R1 and R2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-3alkyl, —N(C1-3alkyl)2, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

80. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-79, wherein each of R1 and R2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

81. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-80, wherein each of R1 and R2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

82. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-81, wherein R1 and R2 together with the carbon atom to which they are both attached form CO or C═NR5.

83. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-82, wherein R1 and R2 together with the carbon atom to which they are both attached form CO.

84. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-83, wherein R1 and R2 together with the carbon atom to which they are both attached form C═NR5.

85. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-84, wherein each of R3 and R4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-6alkyl, —N(C1-6alkyl)2, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

86. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-85, wherein each of R3 and R4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-3alkyl, —N(C1-3alkyl)2, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

87. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-86, wherein each of R3 and R4 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

88. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-87, wherein each of R3 and R4 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

89. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-88, wherein R3 and R4 together with the carbon atom to which they are both attached form 3-12 membered heterocyclic ring or 5-12 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

90. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-89, wherein R3 and R4 together with the carbon atom to which they are both attached form 3-10 membered heterocyclic ring or 5-10 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

91. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-90, wherein R3 and R4 together with the carbon atom to which they are both attached form 3 membered heterocyclic ring, 4 membered heterocyclic ring, 5 membered heterocyclic ring, 6 membered heterocyclic ring, 7 membered heterocyclic ring, 8 membered heterocyclic ring, 9 membered heterocyclic ring, 10 membered heterocyclic ring, 5 membered heteroaromatic ring, 6 membered heteroaromatic ring, 7 membered heteroaromatic ring, 8 membered heteroaromatic ring, 9 membered heteroaromatic ring, 10 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

92. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-91, wherein each of R5 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl or —C1-6alkoxy.

93. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-92, wherein each of R5 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-3alkyl or —C1-3alkoxy.

94. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-93, wherein each of R5 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy

95. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-94, wherein W is absent, —O, —S or —C(RW)2-; and each of RW is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —CO—C1-6alkyl, —CO—OC1-6alkyl, —C1-6alkylene-O—C1-6alkoxy, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

96. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-95, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —CO—C1-3alkyl, —CO—OC1-3alkyl, —C1-3alkylene-O—C1-3alkoxy, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

97. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-96, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkylene-O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

98. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-97, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkylene-O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

99. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-98, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkylene-O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

100. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-99, wherein ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

101. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-100, wherein ring C is absent, a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

102. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-101, wherein ring C is absent, a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

103. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-102, wherein ring C is selected from

104. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-103, wherein each of R5a and R5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

105. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-104, wherein each of R5a and R5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

106. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-105, wherein each of R5a and R5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

107. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-106, wherein each of R5a and R5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

108. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-107, wherein each of RY6, and R6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

109. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-108, wherein each of R6a and R6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

110. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-109, wherein each of R6a and R6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

111. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-110, wherein each of Rha and R6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

112. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-111, wherein each of Ra is independently hydrogen, deuterium, F, Cl, Br, —NRa1Ra2, —CN, —OH, —NO2, oxo, ═O, carboxyl, —C1-3alkoxy,—C1-4alkyl, —C3-6cycloalkyl, —C1-3alkylene—NRa1Ra2, —C1-3alkylene-O—C1-6alkyl, —C1-3alkylene-(3-8 membered heterocyclic), —C1-3alkylene-(5-8 membered heteroaryl), —C1-3alkylene—CO—NRa1Ra2, —C1-3alkylene—NRa1—CO—NRa1Ra2, —C1-3alkylene—NRa1—CO—C1-3alkyl, —CO—NRa1Ra2, —CO—CO—NRa1Ra2, —C3-8carbocyclic, −5-8 membered heteroaryl, −3-8 membered heterocyclic, —CO—C1-3alkyl, —COO—C1-3alkyl, —CO—C1-3alkylene—NRa1Ra2, —CO—NR-(3-8 membered heterocyclic), —CO—NR-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C1-3alkylene—CO—ORa1, —O—C1-3alkylene—CO—NRa1Ra2, —O—C1-3alkylene—NRa1Ra2, —O—C3-8carbocyclic, —O-(3-8 membered heterocyclic), —NRa1—CO—C1-3alkyl, —NRa1—CO—NRa1Ra2, —NRa1—CO-(5-8 membered heteroaryl), —NRa1—CO—C3-6cycloalkyl,—NRa1—C1-3alkylene—NRa1Ra2, —NRa1—C1-3alkylene-(3-8 membered heterocyclic), —NRa1—C1-3alkylene-(5-8 membered heteroaryl), —NRa1—SO2C1-3alkyl, —S—C1-3alkyl, —SONRa1Ra2, —SO2NRa1Ra2, —SO—C1-3alkyl, —SO2—C1-3alkyl, —PO(C1-3alkyl)2, —PO(C1-3alkoxy)2, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

113. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-112, wherein each of Ra is independently hydrogen, deuterium, F, Cl, Br, —NRa1Ra2, —CN, —OH, —NO2, oxo, ═O, carboxyl, methoxy, ethoxy, propoxy, isopropoxy methyl, ethyl, propyl, isopropyl, butyl, isobutyl, —C3-6cycloalkyl,-C1-3alkylene—NRa1Ra2, —C1-3alkylene-O—C1-6alkyl, —C1-3alkylene—CO—ORa1, —C1-3alkylene-(3-8 membered heterocyclic), —C1-3alkylene-(5-8 membered heteroaryl), —C1-3alkylene—CO—NRa1Ra2, —C1-3alkylene—NRa1—CO—NRa1Ra2, —CO—NRa1Ra2, —CO—CO—NRa1Ra2, —C3-8carbocyclic, −5-8 membered heteroaryl, −3-8 membered heterocyclic, —CO—C1-3alkyl, —COO—C1-3alkyl, —CO—C1-3alkylene—NRa1Ra2, —CO—NR-(3-8 membered heterocyclic), —CO—NR-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C1-3alkylene—CO—ORa1, —O—C1-3alkylene—CO—NRa1Ra2, —O—C1-3alkylene-NRa1Ra2, —O—C3-8carbocyclic, —O-(3-8 membered heterocyclic), —NRa1—CO—C1-3alkyl, -NL1—CO—NRa1Ra2, -NL1—CO-(5-8 membered heteroaryl), -NLI—CO—C3-6cycloalkyl,—NRa1—C1-3alkylene—NRa1Ra2, —NRa1—C1-3alkylene-(3-8 membered heterocyclic), —NRa1—C1-3alkylene-(5-8 membered heteroaryl), —NRa1—SO2C1-3alkyl, —S—C1-3alkyl, —SONRa1Ra2, —SO2NRa1Ra2, —SO—C1-3alkyl, −502—C1-3alkyl, —PO(C1-3alkyl)2, —PO(C1-3alkoxy)2, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

114. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-113, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, halogen, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

115. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-114, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

116. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-115, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 3 membered carbocyclic ring, a 4 membered carbocyclic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, wherein each of the heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

117. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-116, Ra and Rw with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, halogen, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

118. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-117, Ra and Rw with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, -C1-3alkyl or —C1-3alkoxy.

119. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-118, Ra and Rw with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

120. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-116, Ra and Rw with the atom to which they are both attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 5 membered heteroaryl ring, a 6 membered heteroaryl ring, a 5 membered heterocyclic ring or a 6 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

121. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-120, wherein each of Ra1and Ra2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted -C1-6alkyl.

122. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-121, wherein each of Ra1and Ra2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

123. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-122, wherein each of Ra1and Ra2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

124. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-123, wherein each of Ra1and Ra2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

125. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-124, wherein the compound is of Formula II:

126. The compound or pharmaceutically acceptable salt thereof of claim 125, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

127. The compound or pharmaceutically acceptable salt thereof of claim 122 or claim 126, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

128. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-127, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

129. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-128, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

130. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-129, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

131. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-130, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —CO—C1-6alkyl, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —SFS, —NHCO—C3-8cycloalkyl, —NH—C3-8cycloalkyl, —C1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C1-6alkylene-C3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

132. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-131, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —CO—C1-6alkyl, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —SF5, —NHCO—C3-8cycloalkyl, —NH—C3-8cycloalkyl, —C1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C1-6alkylene-C3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

133. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-132, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl, —C1-3alkoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene—C3-6cycloalkyl or 3-6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

134. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-133, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

135. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-134, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

136. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-135, wherein RX1 and RX2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

137. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-137, wherein RX1 and RX2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

138. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-137, wherein RX1 and RX2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

139. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-138, wherein X3 is N, S, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-6alkyl, —C1-6alkoxy, C3-8cycloalkyl, C5-8aryl, —S—C1-6alkyl, 3-12 membered heterocyclyl, —O—C3-8cycloalkyl,—O—C1-6alkylene-C1-6alkoxy, —O—C5-8aryl or —O—C1-6alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

140. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-139, wherein X3 is N, S, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-6alkyl, —C1-6alkoxy, C3-8cycloalkyl, C5-8aryl, —S—C1-6alkyl, 3-12 membered heterocyclyl, —O—C3-8cycloalkyl, —O—C1-6alkylene-C1-6alkoxy, —O—C5-8aryl or —O—C1-6alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

141. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-140, wherein X3 is N, S, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-3alkyl, —C1-3alkoxy, C3-6cycloalkyl, C5-8aryl, —S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl, —O—C1-3alkylene-C1-3alkoxy, —O—C5-8aryl or —O—C1-6alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

142. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-141, wherein X3 is N, S, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C3-6cycloalkyl, C5-8aryl, -S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl or —O—C1-3alkylene—C1-3alkoxy, −0—C5-8aryl or —O—C1-3alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

143. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-142, wherein X3 is N, S, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C3-6cycloalkyl, C5-8aryl, -S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl or —O—C1-3alkylene-C1-3alkoxy, —O—C5-8aryl or —O—C1-3alkylene-C5-8aryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

144. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-143, wherein RX2 and RX3 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

145. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-144, wherein RX2 and RX3 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

146. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-145, wherein RX2 and RX3 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

147. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-146, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl, —C1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

148. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-147, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl, —C1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

149. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-148, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-3alkyl, —C1-3alkoxy, —NHCO-(5-10 membered heterocyclyl) or 5-10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

150. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-149, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

151. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-150, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

152. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-151, wherein RX3 and RX4 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

153. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-152, wherein RX3 and RX4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

154. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-153, wherein RX3 and RX4 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

155. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-154, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

156. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-155, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

157. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-156, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

158. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-157, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

159. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-158, wherein X5 is N, S, NRX5, C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

160. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-159, wherein RX4 and RX5 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

161. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-160, wherein RX4 and RX5 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

162. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-161, wherein RX4 and RX5 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

163. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-162, wherein ring A is selected from

164. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-163, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—,

165. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-164, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—, —NRG—SO2—,

166. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-165, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—, —NRG—SO2—,

167. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-166, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, —C1-6alkoxy, —N—(C1-6alkyl)2, —C1-6alkenyl, —C3-8cycloalkyl or —Cs-maryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

168. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-167, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6alkenyl, —C3-8cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

169. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-168, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-3alkyl, —C1-3alkoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

170. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-169, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

171. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-170, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6 alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

172. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-171, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6 alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

173. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-172, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl, —C1-3alkoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

174. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-173, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

175. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-174, RY1 and RY2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

176. The compound or pharmaceutically acceptable salt thereof of any one of claims 122-172, RY1 and RY2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

177. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-176, RY1 and RY2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

178. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-177, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, carboxyl, —COO—C1-6alkyl, —NH—C1-6alkylene—OH, —C1-6alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

179. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-178, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, carboxyl, —COO—C1-6alkyl, —NH—C1-6alkylene—OH, —C1-6alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

180. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-179, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-3alkyl, carboxyl, —COO—C1-3alkyl, —NH—C1-3alkylene—OH, —C1-3alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

181. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-180, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, methyl, ethyl, propyl, isopropyl, carboxyl, —COO—C1-3alkyl, —NH—C1-3alkylene—OH, —C1-3alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

182. The compound or pharmaceutically acceptable salt thereof of any one claims 125-181, wherein RY3 and RY4together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

183. The compound or pharmaceutically acceptable salt thereof of any one claims 125-182, wherein RY3 and RY4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

184. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-183, wherein RY3 and RY4together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

185. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-184, wherein ring B is selected from

186. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-185, wherein each of R1 and R2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-6alkyl, —N(C1-6alkyl)2, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

187. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-186, wherein each of R1 and R2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-3alkyl, —N(C1-3alkyl)2, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

188. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-187, wherein each of R1 and R2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

189. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-188, wherein each of R1 and R2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

190. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-189, wherein R1 and R2 together with the carbon atom to which they are both attached form CO or C═NR5.

191. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-190, wherein R1 and R2 together with the carbon atom to which they are both attached form CO.

192. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-191, wherein R1 and R2 together with the carbon atom to which they are both attached form C═NR5.

193. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-192, wherein each of R3 and R4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-6alkyl, —N(C1-6alkyl)2, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

194. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-193, wherein each of R3 and R4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-3alkyl, —N(C1-3alkyl)2, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

195. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-194, wherein each of R3 and R4 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

196. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-195, wherein each of R3 and R4 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

197. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-196, wherein R3 and R4 together with the carbon atom to which they are both attached form a 3-12 membered heterocyclic ring or a 5-12 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

198. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-197, wherein R3 and R4 together with the carbon atom to which they are both attached form a 3-10 membered heterocyclic ring or a 5-10 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

199. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-198, wherein R3 and R4 together with the carbon atom to which they are both attached form a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

200. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-199, wherein each of R5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl or —C1-6alkoxy.

201. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-200, wherein each of R5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-3alkyl or —C1-3alkoxy.

202. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-201, wherein each of R5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy

203. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-202, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —CO—C1-6alkyl, —CO—OC1-6alkyl, —C1-6alkyl-O—C1-6alkoxy, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

204. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-203, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —CO—C1-3alkyl, —CO—OC1-3alkyl, —C1-3alkyl—O—C1-3alkoxy, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

205. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-204, wherein W is absent, —O, —S or —C(RW)2-; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkyl—O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

206. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-205, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkyl—O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

207. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-206, wherein W is absent, —O, —S or —C(RW)2-; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkyl—O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

208. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-207, wherein ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

209. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-208, wherein ring C is absent, a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

210. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-209, wherein ring C is absent, a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, a 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

211. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-210, wherein ring C is selected from

212. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-211, wherein each of R5a and R5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

213. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-212, wherein each of R5a and R5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

214. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-213, wherein each of R5a and R5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

215. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-214, wherein each of Rsa and R5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

216. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-215, wherein each of R6a and R6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

217. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-216, wherein each of R6a and R6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

218. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-217, wherein each of R6a and R6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

219. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-218, wherein each of R6a and R6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

220. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-219, wherein each of Ra is independently selected from hydrogen, deuterium, F, Cl, Br, —NRa1Ra2, —CN, —OH, —NO2, oxo, ═O, carboxyl, —C1-3alkoxy, —C1-3alkyl, —C3-6cycloalkyl, —C1-3alkylene—NRa1Ra2, —C1-3alkylene-O—C1-6alkyl, —C1-3alkylene—CO—ORa1, —C1-3alkylene-(3-8 membered heterocyclic), —C1-3alkylene-(5-8 membered heteroaryl), —C1-3alkylene—CO—NRa1Ra2, —C1-3alkylene-NRa1—CO—C1-3alkyl, —CO—NRa1Ra2, —CO—CO—NRa1Ra2, —C3-8carbocyclic, −5-10 membered heteroaryl, −3-8 membered heterocyclic, —CO—C1-3alkyl, —COO—C1-3alkyl, —CO—C1-3alkylene-NRa1Ra2, —CO—NRa1-(3-8 membered heterocyclic), —CO—NRa1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C1-3alkylene-CO—ORa1, —O—C1-3alkylene-CO—NRa1Ra2, —O—C1-3alkylene-NRa1Ra2, —O—C3-8carbocyclic, −0-(3-8 membered heterocyclic), —NRa1—CO—C1-3alkyl, —NRa1—CO—NRa1Ra2, —NRa1—CO-(5-8 membered heteroaryl), —NRa1—CO—C3-6cycloalkyl, —NRa1—C1-3alkylene—NRa1Ra2, —NRa1—C1-3alkylene-(3-8 membered heterocyclic), —NRa1—C1-3alkylene-(5-8 membered heteroaryl), —NRa1—SO2 C1-3alkyl, —S—C1-3alkyl, —SO2NRa1Ra2, —SO2NRa1Ra2, —SO—C1-3alkyl, —SO2C1-3alkyl, —PO(C1-3alkyl)2, —PO(C1-3alkoxy)2, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

221. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-220, wherein each of Ra is independently selected from hydrogen, deuterium, F, Cl, Br, —NRa1Ra2, —CN, —OH, —NO2, oxo, ═O, carboxyl, methoxy, ethoxy, propoxy, isopropoxy methyl, ethyl, propyl, isopropyl, —C3-6cycloalkyl, —C1-3alkylene-NRa2, —C1-3alkylene-O—C1-6alkyl, —C1-3alkylene-CO—ORa1, —C1-3alkylene-(3-8 membered heterocyclic), —C1-3alkylene-(5-8 membered heteroaryl), —C1-3alkylene—NRa1—C—NRa1Ra2, —CO—NRa1Ra2, —C3-8carbocyclic, −3-8 membered heterocyclic, —CO—C1-3alkyl, —COO—C1-3alkyl, —CO—C1-3alkylene-NRa1Ra2, —CO—NRa1-(3-8 membered heterocyclic), —CO-NRa1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C1-3alkylene-CO—ORa1, —O—C1-3alkylene-CO—NRa1Ra2, —O—C1-3alkylene-NRa1Ra2, —O—C3-8carbocyclic, −O-(3-8 membered heterocyclic), —NRa1—CO—C1-3alkyl, -NIU-00-(5-8 membered heteroaryl), —NRa1—CO—C3-6cycloalkyl,—NRa1—C1-3alkylene—NRa1Ra2, —NRa1—C1-3alkylene-(3-8 membered heterocyclic), —NRa1—C1-3alkylene-(5-8 membered heteroaryl), —NRa1—SO2C1-3alkyl, —S—C1-3alkyl, —SO2NRa1Ra2, —SO—C1-3alkyl, —SO2C1-3alkyl, —PO(C1-3alkyl)2, —PO(C1-3alkoxy)2, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

222. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-221, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, halogen, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

223. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-222, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

224. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-223, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 3 membered carbocyclic ring, a 4 membered carbocyclic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, wherein each of the heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

225. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-224, wherein each of Ra1 and Ra2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted -C1-6alkyl.

226. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-225, wherein each of Ra1 and Ra2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

227. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-226, wherein each of Ra1and Ra2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl;—C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

228. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-227, wherein each of Ra1and Ra2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

229. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-228, wherein the compound is of Formula II-a:

230. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-229, wherein the compound is of Formula II-b

231. The compound or pharmaceutically acceptable salt thereof of any one of claims 125-230, wherein the compound is of Formula II-c

232. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-124, wherein the compound is of Formula III:

233. The compound or pharmaceutically acceptable salt thereof of claim 232, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

234. The compound or pharmaceutically acceptable salt thereof of claim 232 or claim 233, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

235. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-234, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

236. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-235, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

237. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-236, wherein X1 is N, S, NRX1, C(RX1)2, or CRX1; each of RX1 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CONH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

238. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-237, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —CO—C1-6alkyl, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —SF5, —NHCO—C3-8cycloalkyl, —NH—C3-8cycloalkyl, —C1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C1-6alkylene-C3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

239. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-238 wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —CO—C1-6alkyl, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —SF5, —NHCO—C3-8cycloalkyl, —NH—C3-8cycloalkyl, —C1-6alkylene-(3-8 membered heterocyclyl), —NHCO-(5-12 membered heterocyclyl), —NH—C1-6alkylene—C3-8cycloalkyl or 3-8 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

240. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-239, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-4alkyl, —C1-3alkoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl or 3-6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

241. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-240, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

242. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-241, wherein X2 is N, S, NRX2, C(RX2)2, CRX2 or CO; each of RX2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, —CO—C1-3alkyl, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —SF5, —NHCO—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —C1-3alkylene-(3-6 membered heterocyclyl), —NHCO-(5-10 membered heterocyclyl), —NH—C1-3alkylene-C3-6cycloalkyl, 3 membered heterocyclic, 4 membered heterocyclic, 5 membered heterocyclic or 6 membered heterocyclic, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, -oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

243. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-242, wherein RX1 and RX2 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

244. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-243, wherein RX1 and RX2 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

245. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-244, wherein RX1 and RX2 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

246. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-245, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-6alkyl, —C1-6alkoxy, C3-8cycloalkyl, C5-8aryl, —S—C1-6alkyl, 3-12 membered heterocyclyl, —O—C3-8cycloalkyl or —O—C1-6alkylene-C1-6alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

247. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-246, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-6alkyl, —C1-6alkoxy, C3-8cycloalkyl, C5-8aryl, —S—C1-6alkyl, 3-12 membered heterocyclyl, —O—C3-8cycloalkyl or —O—C1-6alkylene-C1-6alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

248. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-247, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, —C1-3alkyl,—C1-3alkoxy, C3-6cycloalkyl, C5-8aryl, -S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl or —O—C1-3alkylene—C1-3alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

249. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-248, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C3-6cycloalkyl, C5-8aryl, —S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl or —O—C1-3alkylene-C1-3alkyl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

250. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-249, wherein X3 is N, S, O, NRX3, C(RX3)2 or CRX3; each of RX3 is independently selected from hydrogen, deuterium, F, Cl, Br, carboxyl, —NO2, —NH2, —CN, —CONH2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, C3-6cycloalkyl, C5-8aryl, —S—C1-3alkyl, 3-10 membered heterocyclyl, —O—C3-6cycloalkyl or —O—C1-3alkylene —C1-3alkyl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

251. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-250, wherein RX2 and RX3 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

252. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-251, wherein RX2 and RX3 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

253. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-252, wherein RX2 and RX3 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N or O, and each of the ring systems is independently optionally substituted or unsubstituted.

254. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-253, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

255. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-254, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NHCO-(5-12 membered heterocyclyl) or 5-12 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

256. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-255, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl,—C1-3alkoxy, —NHCO-(5-10 membered heterocyclyl) or 5-10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

257. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-256, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

258. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-257, wherein X4 is N, S, NRX4, C(RX4)2 or CRX4; each of RX4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NHCO-(5-10 membered heterocyclyl), 5 membered heteroaryl, 6 membered heteroaryl, 7 membered heteroaryl, 8 membered heteroaryl, 9 membered heteroaryl or 10 membered heteroaryl, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, oxo, ═O, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

259. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-258, wherein RX3 and RX4 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

260. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-259, wherein RX3 and RX4 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

261. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-260, wherein RX3 and RX4 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

262. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-261, wherein X5 is N, S, NRX5 C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

263. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-262, wherein X5 is N, S, NRX5 C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl or —C1-6alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

264. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-263, wherein X5 is N, S, NRX5 C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl or —C1-3alkoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

265. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-264, wherein X5 is N, S, NRX5 C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

266. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-265, wherein X5 is N, S, NRX5C(RX5)2 or CRX5; each of RX5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy, and each of which is independently optionally substituted with 1, 2 or 3 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

267. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-266, wherein RX4 and RX5 together with the ring to which they are attached form a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

268. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-267, wherein RX4 and RX5 together with the ring to which they are attached form a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

269. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-268, wherein RX4 and RX5 together with the ring to which they are attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring or a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

270. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-269, wherein ring A is selected from

271. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-270, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—,

272. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-271, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—,

273. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-272, wherein G is selected from absent, S, —SO—, —SO2—, O, —CO—, —NRG—,

274. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-273, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, -C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, -C1-6alkyl or —C1-6alkoxy.

275. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-274, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6alkenyl, —C3-8cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

276. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-275, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl, —C1-3alkoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

277. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-276, wherein Y1 is N or CRY1; RY1 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

278. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-277, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6 alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

279. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-278, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-6alkyl, —C1-6alkoxy, —NH—C1-6alkyl, —N—(C1-6alkyl)2, —C1-6 alkenyl, —C3-8cycloalkyl or —C5-10aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

280. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-279, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —C1-3alkyl, —C1-3alkoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

281. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-280, wherein Y2 is N or CRY2; RY2 is selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, —NH—C1-3alkyl, —N—(C1-3alkyl)2, —C1-3alkenyl, —C3-6cycloalkyl or —C5-8aryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

282. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-281, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, carboxyl, —COO—C1-6alkyl, —NH—C1-6alkylene—OH , —C1-6alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

283. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-282, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-6alkyl, carboxyl, —COO—C1-6alkyl, —NH—C1-6alkylene—OH ,-C1-6alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

284. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-283, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, —C1-3alkyl, carboxyl, —COO—C1-3alkyl, —NH—C1-3alkylene—OH ,—C1-3alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

285. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-284, wherein RY3 and RY4 are independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —OH, —CN, methyl, ethyl, propyl, isopropyl, carboxyl, —COO—C1-3alkyl, —NH—C1-3alkylene—OH ,—C1-3alkylene—OH, —CONH2 or −5-8 membered heteroaryl, and each of which is independently optionally substituted with 1, 2, 3, 4, 5, or 6 substituents, and the said each substituents is independently selected from deuterium, F, Cl, Br, I, —NH2, —CN, —OH, —NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

286. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-285, wherein ring B is selected from

287. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-286, wherein each of R1 and R2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-6alkyl, —N(C1-6alkyl)2, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

288. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-287, wherein each of R1 and R2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-3alkyl, —N(C1-3alkyl)2, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

289. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-288 wherein each of R1 and R2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

290. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-289, wherein each of R1 and R2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

291. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-290, wherein R1 and R2 together with the carbon atom to which they are both attached form CO or C═NR5.

292. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-291, wherein R1 and R2 together with the carbon atom to which they are both attached form CO.

293. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-292, wherein R1 and R2 together with the carbon atom to which they are both attached form C═NR5.

294. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-293, wherein each of R3 and R4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-6alkyl, —N(C1-6alkyl)2, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

295. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-294, wherein each of R3 and R4 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —NH—C1-3alkyl, —N(C1-3alkyl)2, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted

296. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-295 wherein each of R3 and R4 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

297. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-296, wherein each of R3 and R4 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; —NH—C1-3alkyl; —N(C1-3alkyl)2; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

298. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-297, wherein R3 and R4 together with the carbon atom to which they are both attached form 3-12 membered heterocyclic ring or 5-12 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

299. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-298, wherein R3 and R4 together with the carbon atom to which they are both attached form 3-10 membered heterocyclic ring or 5-10 membered heteroaromatic ring or C═NR5; and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

300. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-299, wherein R3 and R4 together with the carbon atom to which they are both attached form 3 membered heterocyclic ring, 4 membered heterocyclic ring, 5 membered heterocyclic ring, 6 membered heterocyclic ring, 7 membered heterocyclic ring, 8 membered heterocyclic ring, 9 membered heterocyclic ring, 10 membered heterocyclic ring, 5 membered heteroaromatic ring, 6 membered heteroaromatic ring, 7 membered heteroaromatic ring, 8 membered heteroaromatic ring, 9 membered heteroaromatic ring, 10 membered heteroaromatic ring or C═NR5, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

301. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-300, wherein each of R5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-6alkyl or —C1-6alkoxy.

302. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-301, wherein each of R5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —C1-3alkyl or —C1-3alkoxy.

303. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-302, wherein each of R5 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

304. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-303, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —CO—C1-6alkyl, —CO—OC1-6alkyl, —C1-6alkyl-O—C1-6alkoxy, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

305. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-304, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —CO—C1-3alkyl, —CO—OC1-3alkyl, —C1-3alkyl—O—C1-3alkoxy, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl

306. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-305, wherein W is absent, —O, —S or —C(RW)2-; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkyl—O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

307. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-306, wherein W is absent, —O, —S or —C(RW)2—; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkyl—O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

308. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-307, wherein W is absent, —O, —S or —C(RW)2-; and each of RW is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN;—OH; —NO2; carboxyl; —CO—C1-3alkyl; —CO—OC1-3alkyl; —C1-3alkyl—O—C1-3alkoxy; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

309. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-308, wherein ring C is absent, a 5-12 membered aromatic ring, a 5-12 membered heteroaromatic ring or a 5-12 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

310. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-309, wherein ring C is absent, a 5-10 membered aromatic ring, a 5-10 membered heteroaromatic ring or a 5-10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

311. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-310, wherein ring C is absent, a 5 membered aromatic ring, a 6 membered aromatic ring, a 7 membered aromatic ring, an 8 membered aromatic ring, a 9 membered aromatic ring, a 10 membered aromatic ring, a 5 membered heteroaromatic ring, a 6 membered heteroaromatic ring, a 7 membered heteroaromatic ring, an 8 membered heteroaromatic ring, a 9 membered heteroaromatic ring, a 10 membered heteroaromatic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 7 membered heterocyclic ring, an 8 membered heterocyclic ring, a 9 membered heterocyclic ring, a 10 membered heterocyclic ring, and each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the ring systems is independently optionally substituted or unsubstituted.

312. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-311, wherein ring C is selected from

313. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-312, wherein each of R5a and R5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

314. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-313, wherein each of R5a and R5b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

315. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-314, wherein each of R5a and R5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

316. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-315, wherein each of RYa and R5b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

317. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-316, wherein each of R6a and R6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted —C1-6alkyl.

318. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-317, wherein each of R6a and R6b is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

319. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-318, wherein each of R6a and R6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

320. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-319, wherein each of R6a and R6b is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

321. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-320, wherein each of Ra is independently selected from hydrogen, deuterium, F, Cl, Br, —NRa1Ra2, —CN, —OH, —NO2, oxo, ═O, carboxyl, —C1-3alkoxy,—C1-4alkyl, —C3-6cycloalkyl, —C1-3alkylene—NRa1Ra2, —C1-3alkylene-O—C1-6alkyl, —C1-3alkylene—CO—ORa1, —C1-3alkylene-(3-8 membered heterocyclic), —C1-3alkylene-(5-8 membered heteroaryl), —C1-3alkylene—CO—NRa1Ra2, —C1-3alkylene—NRa1—CO—NRa1Ra2, —C1-3alkylene—NRa1—CO—C1-3alkyl, —CO—NRa1Ra2, —CO—CO—NRa1Ra2, —C3-8carbocyclic, −3-8 membered heterocyclic, —CO—C1-3alkyl, —COO—C1-3alkyl, —CO—C1-3alkylene—NRa1Ra2, —CO—NRa1-(3-8 membered heterocyclic), —CO—NRa1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C1-3alkylene-CO—ORa1, —O—C1-3alkylene-CO—NRa1Ra2, -0 -C1-3alkylene-NRa1Ra2, —O—C3-8carbocyclic, —O-(3-8 membered heterocyclic), —NRa1—CO—C1-3alkyl, —NRa1—CO—NRa1Ra2, —NRa1—CO-(5-8 membered heteroaryl), —NRa1—CO—C3-6cycloalkyl,—NRa1—C1-3alkylene—NRa1Ra2, —NRa1—C1-3alkylene-(3-8 membered heterocyclic), —NRa1—C1-3alkylene-(5-8 membered heteroaryl), —NRa1—SO2C1-3alkyl, —SONRa1Ra2, —SO2NRa1Ra2, —SO—C1-3alkyl, —SO2C1-3alkyl, —PO(C1-3alkyl)2, —PO(C1-3alkoxy)2, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

322. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-321, wherein each of Ra is independently selected from hydrogen, deuterium, F, Cl, Br, —NRa1R.2, —CN, —OH, —NO2, oxo, ═O, carboxyl, methoxy, ethoxy, propoxy, isopropoxy methyl, ethyl, propyl, isopropyl, butyl, isobutyl, —C3-6cycloalkyl,-C1-3alkylene-NRa1Ra2, —C1-3alkylene-(3-8 membered heterocyclic), —C1-3alkylene-(5-8 membered heteroaryl), -3alkylene-CO-NRa1Ra2, -3alkylene-NRa1-CO-NRa1Ra2, —CO—NRa1Ra2, —CO—CO—NRa1Ra2, —C3-8carbocyclic, −3-8 membered heterocyclic, —CO—C1-3alkyl, —CO—C1-3alkylene—NRa1Ra2, —CO—NR.1-(3-8 membered heterocyclic), —CO—NRa1-(3-8 membered heterocyclic), —CO-(3-8 membered heterocyclic), —O—C1-3alkylene-CO—ORa1, —O—C1-3alkylene—CO—NRa1Ra2, —O—C1-3alkylene-NRa1Ra2, —O—C3-8carbocyclic, —O-(3-8 membered heterocyclic), —NRa1—CO—C1-3alkyl, —NRa1—CO-(5-8 membered heteroaryl), —NRa1—CO—C3-6cycloalkyl,—NRa1—C1-3alkylene—NRa1Ra2, —NRa1—C1-3alkylene-(3-8 membered heterocyclic), —NRa1—C1-3alkylene-(5-8 membered heteroaryl), —NRa1—SO2C1-3alkyl, —SONRa1Ra2, —SO2NRa1Ra2, —SO2C1-3alkyl, —PO(C1-3alkyl)2, —PO(C1-3alkoxy)2, −3-8 membered heterocyclic or −5-8 membered heteroaryl; each of which is independently optionally substituted; and n is 0, 1, 2, 3, 4, 5 or 6.

323. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-322, wherein each of Ra1and Rae is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-6alkoxy, or substituted or unsubstituted

324. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-323, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, halogen, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

325. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-324, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3-6 membered heterocyclic ring or a 3-6 membered carbocyclic ring, wherein each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

326. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-325, wherein two adjacent Ra can be joined together to form a 6-membered aromatic ring, a 5-membered heteroaromatic ring, a 6-membered heteroaromatic ring, a 3 membered heterocyclic ring, a 4 membered heterocyclic ring, a 5 membered heterocyclic ring, a 6 membered heterocyclic ring, a 3 membered carbocyclic ring, a 4 membered carbocyclic ring, a 5 membered carbocyclic ring, a 6 membered carbocyclic ring, wherein each of the heteroaryl contains 1, 2 or 3 heteroatoms selected from N, O or S, and each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S, each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

327. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-326, Ra and Rw with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, halogen, —NH2, —CN, —OH, —NO2, carboxyl, —C1-6alkyl or —C1-6alkoxy.

328. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-327, Ra and Rw with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

329. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-328, Ra and Rw with the atom to which they are both attached form a 3-10 membered aromatic ring, a 3-10 membered heteroaromatic ring or a 3-10 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

330. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-329, Ra and Rw with the atom to which they are both attached form a 5 membered aromatic ring, a 6 membered aromatic ring, a 5 membered heteroaryl ring, a 6 membered heteroaryl ring, a 5 membered heterocyclic ring or a 6 membered heterocyclic ring; each of the heteroaromatic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; each of the heterocyclic ring contains 1, 2 or 3 heteroatoms selected from N, O or S; and each of the ring systems is independently optionally substituted with deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, —C1-3alkyl or —C1-3alkoxy.

331. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-330, wherein each of Ra1 and Ra2 is independently selected from hydrogen, deuterium, F, Cl, Br, —NH2, —CN, —OH, —NO2, carboxyl, substituted or unsubstituted —C1-3alkoxy, or substituted or unsubstituted —C1-3alkyl.

332. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-331, wherein each of Ra1and Ra2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with halogen, NH2, CN, OH, NO2, carboxyl, C1-3alkyl or C1-3alkoxy.

333. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-332, wherein each of Ra1and Ra2 is independently selected from hydrogen; deuterium; F; Cl; Br; —NH2; —CN; —OH; —NO2; carboxyl; methoxy; ethoxy; propoxy; isopropoxy; —C1-3alkoxy substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy; methyl; ethyl; propyl; isopropyl; —C1-3alkyl substituted with F, Cl, Br, NH2, CN, OH, NO2, carboxyl, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy or isopropoxy.

334. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-333, wherein the compound is of Formula III-a:

335. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-334, wherein the compound is of Formula III-b:

336. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-335, wherein the compound is of Formula III-c:

337. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-336, wherein the compound is of Formula III-d:

338. The compound or pharmaceutically acceptable salt thereof of any one of claims 232-337, wherein the compound is of Formula III-e:

339. The compound or pharmaceutically acceptable salt thereof of any one of claims 1-338, wherein the compound is selected from

340. A pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt thereof as defined in any one of claims 1-339 and at least one pharmaceutically acceptable excipient.

341. The pharmaceutical composition of claim 340, wherein, the compound in a weight ratio to the said excipient within the range from about 0.0001 to about 10.

342. A combination pharmaceutical product comprising the compound or a pharmaceutically acceptable salt thereof of any of claims 1-339, together with one or more other therapeutically active agents.

343. Use of the compound or a pharmaceutically acceptable salt thereof of any one of claim 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 342 for the preparation of a medicament.

344. The use of claim 343, wherein the medicament is used for the treatment or prevention of cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.

345. Use, in the manufacture of a medicament for use as an inhibitor of SHP2, of at least one compound or a pharmaceutically acceptable salt thereof any one of claims 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 342.

346. Use of the compound or a pharmaceutically acceptable salt thereof of any one of claims 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 342 for the preparation of a medicament in the treatment of diseases or conditions mediated by the activity of SHP2.

347. The use of claim 346, wherein the diseases or conditions mediated by the activity of SHP2 is cancer.

348. The use of claim 346, wherein the diseases or conditions mediated by the activity of SHP2 is selected from Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.

349. A method for preventing or treating a disease, lessening a disease symptoms, delaying the progression or onset of a disease, comprising administering to the patient in need thereof a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof of any one of claims 1-339, the pharmaceutical composition of claims 340 or 341, or the combination pharmaceutical product of claim 342, wherein the disease is cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.

350. A method for inhibiting the activity of SHP2 level, comprising administering to the patient in need thereof a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof of any one of claims 1-339, or the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 342.

351. A method for preventing or treating a disease, lessening a disease symptoms, delaying the progression or onset of a disease, comprising administering to the patient in need thereof a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof of any one of claims 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 342, wherein the disease is mediated by the activity of SHP2.

352. The method of claim 351, wherein the disease mediated by the activity of SHP2 is cancer.

353. The method of claim 351, wherein the disease mediated by the activity of SHP2 is selected from Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.

354. The compound or the pharmaceutically acceptable salt thereof of any one of claims 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 342 for use in preventing or treating a disease, lessening a disease symptom, delaying the progression or onset of a disease, wherein the disease is cancer, cancer metastasis, cardiovascular disease, an immunological disorder or an ocular disorder.

355. The compound or the pharmaceutically acceptable slat thereof any one of claims 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 339, for use in inhibiting the activity of SHP2.

356. The compound or the pharmaceutically acceptable salt thereof of any one of claims 1-339, the pharmaceutical composition of claim 340 or 341, or the combination pharmaceutical product of claim 339 for use in preventing or treating a disease, lessening a disease symptom, delaying the progression or onset of a disease, wherein the disease is mediated by the activity of SHP2.

357. The compound or the pharmaceutically acceptable salt thereof, the pharmaceutical composition, or the combination pharmaceutical product of claim 356, wherein the disease mediated by the activity of SHP2 is cancer.

358. The compound or the pharmaceutically acceptable salt thereof, the pharmaceutical composition, or the combination pharmaceutical product of claim 356, wherein the disease mediated by the activity of SHP2 is selected from Noonan syndrome, leopard syndrome, juvenile myelomonocytic leukemias, liver cancer, neuroblastoma, melanoma, squamous-cell carcinoma of the head and neck, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, gastric carcinoma, neuroblastoma, anaplastic large-cell lymphoma and glioblastoma.